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SUMMARY 
P2X4 and P2X7 receptors have gained increasing significance as drug targets for 
their involvement in neurotransmission, pain, cancer, inflammation and immunity. 
To date, numerous P2X7 antagonists have been developed, yet relatively few P2X4 
antagonists have been reported, and no data is available regarding their binding 
sites on the receptor. Using in silico techniques, we attempted to identify novel 
P2X4 and P2X7 modulators, and combined experimental and structural data to 
explore allosteric pockets with future potential for drug design. Two virtual 
screenings of commercially available drug-like compounds performed in the 
human P2X4 homology model led to the selection, purchase and biological 
evaluation via calcium influx assay of 42 compounds. While no compound with 
significant antagonist activity at human P2X4 was found, multiple compounds 
abolished ATP-induced YO-PRO dye uptake at human P2X7, including Compound 25 
(IC50 value of 8 µM). Further 27 structural analogues to Compound 25 were 
purchased and assayed, expanding the number of active antagonists and offering 
an insight in the structure-activity relationship. In parallel, a mutagenesis study of 
human and rat P2X4 receptors based on (i) species-specific pharmacology and (ii) 
the recently published panda P2X7 crystal structures led us to identify the 
allosteric binding site for the P2X4-selective antagonist BX-430. The pocket was 
then used to perform a new virtual screen, identifying 20 potential ‘hit’ 
candidates for future biological evaluation. Finally, we performed docking 
simulations of the positive P2X4 allosteric modulator ivermectin and the partially 
selective P2X7 agonist 2’(3’)-4-O-benzoylbenzoyl ATP (BzATP), with good 
correlation between binding conformations and previously published 
pharmacological data. In conclusion, although no novel human P2X4 antagonist has 
been identified, this work led to (i) the discovery of an allosteric site not 
previously described in human P2X4, (ii) the identification of a novel P2X7 
antagonist with micromolar potency and (iii) and increased understanding of the 
molecular basis for subtype-specific modulator potency at P2X4 and P2X7 
receptors. 
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fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-
[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone  
JNJ-
64413739 
(S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(6-methyl-1-
(pyrimidin-2-yl)-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-
c]pyridin-5-yl)methanone 
JNK-1/2 c-Jun N-terminal kinases 1/2 
K+ Potassium ions 
KCC2 Chloride channel  
KO Knock out 
LPS Lipopolysaccharide  
MAPK Mitogen-activated protein kinases 
max. Maximal 
MM Molecular Mechanics  
 XIX 
mRNA Messenger RNA 
n. c. No convergence 
n. d.  Not determined 
Na+ Sodium ions 
nACh  Nicotinic acetylcholine receptor 
NC 2600 P2X4 allosteric modulator (undisclosed structure) 
nfP2X7 Non-pore functional P2X7 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NF023 8,8’-[Carbonyl-bis(imino-3,1-phen-ylenecarbonylimino)]bis-
1,3,5- naphthalene-trisulfonic acid  
NF279  8,8’-[Carbonyl-bis(imino-4,1-phenylenecarbonylimino-4,1- 
pheylene-carbonyl-imino)]bis-1,3,5-naphthalene trisulfonic 
acid  
NHS  National Health Service 
NLR NOD-like receptor  
NLRP3  inflammasome 
NMDA  N-methyl-D-aspartate 
NMDAR N-methyl-D-aspartate receptor 
NMR Nuclear magnetic resonance  
NO Nitric oxide  
NOS Nitric Oxide Synthase  
NP-1815-PX (5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-
naphtho[1, 2-b][1,4]diazepine-2,4(3H,5H)-dione) 
NRTI Nucleotiside Reverse Transcriptase Inhibitor  
NRTI Nucleoside reverse transcriptase inhibitors 
NSAID  Non-steroidal anti-inflammatory drug 
p Probability value 
P2K1 kinase-like purinergic receptor found in green plants (also 
refered as DORN1) 
 XX 
P2RX1  Gene coding for P2X1 
P2RX2 Gene coding for P2X2 
P2RX3 Gene coding for P2X3 
P2RX4 Gene coding for P2X4 
P2RX7 Gene coding for P2X7 
p38  P38 mitogen-activated protein kinases 
PCP Phencyclidine  
PDB Protein Data Bank  
pEC50  Negative decadic logarithm of EC50 value 
PET Positron emission tomography 
pH Negative decadic logarithm of H+ concentration 
pIC50  Negative decadic logarithm of IC50 value 
PLIF Protein-Ligand Interaction Fingerprint 
PNP Purine nucleoside phosphorylase  
PPADS  Pyridoxalphosphate-6-azophenyl-2‘-4‘-disulfonic acid 
PPARα  Peroxisome proliferator-activated receptor α 
PSB-12054  N-(benzyloxycarbonyl)phenoxazine  
PSB-12062 N-(p-methylphenylsulfonyl)phenoxazine  
QM Quantum Mechanics  
RB-2  Reactive Blue-2 
RMSD  Root Mean Square Deviation 
RNA  Ribonucleic acid 
ROS Reactive oxygen species 
rP2X4 Rat (Rattus norvegicus) P2X4 
rP2X7 Rat (Rattus norvegicus) P2X7 
RPE Retinal pigment epithelial cells  
rs208294  Polymorphism responsible for gain-of-function mutation 
 XXI 
(Y155H) in human P2X7 
rs25644 Missense single nucleotide polymorphism responsible for the 
S242G mutation in human P2X4 
rs3751143  Polymorphism responsible for loss-of-function mutation 
(E496A) in human P2X7 
rs7958311  Polymorphism responsible for hypo-function mutation (R270H) 
in human P2X7 
RT  Room temperature 
SchP2X Schistosoma mansoni P2X receptor 
SDH Spinal dorsal horn 
SEM Standard error of the mean 
SH3 Src homology 3 
siRNA Small (or short) interfering RNA 
SNP Single nucleotide polymorphism  
SP Standard Precision 
STAT3  Signal transducer and activator of transcription 3 
T Thymine 
TCA Tricyclic antidepressant 
THDOC Tetrahydrodeoxycorticosterone; 3α,21-dihydroxy-5α-pregnan-
20-one 
TLR Toll-like receptors 
TM Transmembrane domain 
TNFR Tumor necrosis factor receptor 
TNFR1 tumor necrosis factor receptor 1  
TNFα Tumor necrosis factor alpha 
TNP-ATP  2‘-3‘-O-(2, 4,6-Trinitrophenyl)adenosine-5‘-triphosphate  
TRIS  Tris(hydroxymethyl)aminomethane 
TrkB Tropomyosin receptor kinase B 
UDP  Uridine 5‘-diphosphate 
 XXII 
UTP  Uridine 5‘-triphosphate 
VEGF Vascular endothelial growth factor 
WB34 Cell line expressing human P2X4 (also named G34) 
XP Extra precision 
zfP2X4  Zebrafish P2X4 receptor 
α,β-MeATP  α,β-Methylene-adenosine 5‘-triphosphate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XXIII 
AMINO ACID ABBREVIATIONS  
Ala (A)  Alanine  
Asn (N)  Asparagine  
Asp (D)  Aspartic acid  
Arg (R)  Arginine  
Cys (C)  Cysteine  
Glu (E)  Glutamic acid  
Gln (Q) Glutamine  
Gly (G)  Glycine  
His (H)   Histidine  
Ile (I)   Isoleucine  
Leu (L)   Leucine  
Lys (K)  Lysine  
Met (M)  Methionine  
Phe (F)  Phenylalanine  
Pro (P)  Proline  
Ser (S)  Serine  
Thr (T)  Threonine  
Trp (W)  Tryptophan  
Tyr (Y)  Tyrosine  
Val (V)  Valine 
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1 INTRODUCTION 
Intracellular adenosine triphosphate (ATP) is important as an energy source and 
second messenger in signal transduction. In the extracellular compartment − 
where the concentration of purines and pyrimidines is usually several fold lower 
(around nanomolar concentration) (Di Virgilio 2012; Gorodeski 2012) − ATP plays a 
pivotal role in the purinergic signalling system. Following cell damage, release 
through hemichannels or from presynaptic neurons, ATP binds both metabotropic 
(P2Y) and ionotropic (P2X) purinergic receptors (North 2002). While P2X receptors 
display a strong selectivity to ATP, P2Y is activated also by uridine triphosphate 
(UTP), uridine diphosphate and adenosine diphosphate (ADP); the latter is a 
product of degradation of ATP by ectonucleotidases, which are capable of 
catalysing the breakage of the phosphoesteric bond (Abbracchio et al. 2009). 
Further degradation leads to adenosine and adenine, also involved in intercellular 
signalling (Thimm et al. 2015) (Figure 1-1) 
	  
Figure 1-1: Extracellular purines involved in purinergic signalling. ATP is 
released in the extracellular compartment through hemichannels (pannexins 
and connexins), from synapsis or after cell damage and where it interacts 
with P2X and P2Y receptors. ATP is also readily converted in ADP, adenosine 
and Adenine through the action of ectonucleotidases such as ectonucleoside 
triphosphate diphosphohydrolases (E-NTPDases; i), ecto-5’-nucleotidase (ii) 
and purine nucleoside phosphorylase (PNP; iii). 
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1.1  The P2X receptor family 
1.1.1 Phylogeny	  of	  P2X	  receptors	  
ATP signalling via ionotropic receptors is thought to have been one of the first 
intercellular systems to develop and is widely present in eukaryotes. P2X 
receptors have been experimentally identified in numerous invertebrates and 
primitive organisms such as basal fungi (Cai 2012), trematodes (Schistosoma 
mansoni, SchP2X) (Agboh et al. 2004), amoebas (Dictyostelium discoideum, 
DdP2XA-E) (Fountain et al. 2007), algae (Ostreococcus tauri) (Fountain et al. 
2008), choanoflagellates (Monosiga brevicollis) (Cai 2006), tardigrades (Hypsibius 
dujardini, HdP2X) (Bavan et al. 2009), molluscs (e.g. Lymnea stagnalis) (Bavan et 
al. 2012) and arthropods (Boophilus microplus) and the Gulf Coast tick 
Ambylomma maculatum) (Bavan et al. 2011; Kasuya et al. 2016). Interestingly 
some model organisms such as C. elegans and Drosophila melanogaster and green 
plants do not show evidence for the presence of P2X receptors in their genomes, 
suggesting that the gene was lost in some major lineages; nevertheless there is no 
doubt that ATP maintains an important signalling role in those organisms (e.g. the 
DORN1 kinase-type receptor in Arabidopsis thaliana and Camelina sativa, named 
P2K1) (Cao et al. 2014; Cho et al. 2017; Li et al. 2016). The increasing availability 
of genome data is a source for further future identification of P2X receptor 
homologues in other organisms aiming at a more comprehensive understanding of 
structure and function of P2X receptors. 
1.1.2 General	  structure	  of	  P2X	  receptors	  
1.1.2.1 Main	  conserved	  features	  
P2X receptors are a family of ATP-gated trimeric cation channels. Each subunit 
comprises an intracellular N- and C-terminal cytoplasmic domain connected to an 
approximately 280-amino-acid extracellular domain through two transmembrane 
α-helices (TM). Trimers contain three ATP-binding sites, each located at the 
extracellular interface of two adjacent subunits and the residues directly 
interacting with the ATP are highly conserved (Jiang et al. 2000b; Newbolt et al. 
1998; Roberts and Evans 2004; Young 2010). The orthosteric pocket will be 
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described in greater details in Section 1.5.3.1. The extracellular domain also 
bears the interacting sites for ions (Acuña‐Castillo et al. 2007; Liu et al. 2008) 
and at least one allosteric binding site as shown by crystal structure data (see 
Section 1.5.3.2). The receptors undergo post-translational modifications that 
include the formation of disulfide bonds and N-glycosylation. All the subtypes bear 
10 cysteine residues in the extracellular domain (also conserved across different 
species), which greatly contribute to the tertiary structure by pairing into 5 
disulfide bonds (Clyne et al. 2002; Ennion and Evans 2002). N-glycosylation at the 
consensus sequence Asn-X-Ser/Thr in the extracellular domain is critical in 
receptor trafficking and cell surface expression. Although glycosylation sites varies 
from 2 to 6 across subtypes, receptors that present at least two or three 
glycosylated sites are expressed on the plasma membrane and appear to be 
functional whereas, receptors that were treated with tunicamycin or bear 
mutations leaving one or no glycosylated site are not functional (Newbolt et al. 
1998; Torres et al. 1998). In contrast, the cytoplasmic C-terminal domains of the 
receptors show little conservation among different subtypes and significantly vary 
in length ranging from 29 residues in human P2X4 to 240 residues in human P2X7 
(North 2002). 
1.1.2.2 Trimeric	  assembly:	  homotrimers	  and	  heterotrimers	  
Physiologically relevant receptors may be formed by three identical subunits – 
therefore called homo-trimers – or by different subunits (hetero-trimers) (Antonio 
et al. 2014; Guo et al. 2007; Lewis et al. 1995). The possible organization and 
combinations are widely reviewed in (Saul et al. 2013) and shown in Table 1.1. 
The first identified and most largely characterized heterotrimer was P2X2/3, 
initially identified through co-immunoprecipitation after co-expression in a insect 
cell host expression system (Radford et al. 1997) and subsequently confirmed for 
human receptors (Hausmann et al. 2012). A later study showed that engineered 
cysteine residues in P2X3 and P2X2 were able to form functional receptors that 
showed intermediate functional characteristics between P2X2 and P2X3 (Jiang et 
al. 2003). Furthermore, the same study demonstrated the stoichiometry of the 
functional unit (P2X2/3(2)) by taking advantage of cysteine mutagenesis and 
subtype-specific pharmacological properties of the competitive P2X3 and P2X2/3 
agonist αβ-meATP. In native tissues the P2X2/3 assembly is found in rodents in 
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sensory and autonomic ganglia neurons, in the nerve fibers of the bladder and in 
taste buds (Cockayne et al. 2005) (Bo et al. 1999). The applicability of this data to 
humans is not clear, as human dorsal root ganglia neurons do not express P2X2 
transcripts (Serrano et al. 2012). The formation of heterotrimers between P2X4 
and P2X7 subtypes had been cause of debate. An initial report showed the 
presence of natively co-expressed P2X4/7 heterotrimers in numerous epithelial 
and immune cell types (Guo et al. 2007). Subsequent works in mouse lung 
epithelial cells (Weinhold et al. 2010) and when P2X4 and P2X7 were co-expressed 
in oocytes suggested an interaction between homomers rather than the presence 
of an heterotrimeric receptor type with a distinct electrophysiological or 
pharmacological phenotype (Schneider et al. 2017). 
	  
	   P2X1	   P2X2	   P2X3	   P2X4	   P2X5	   P2X6	   P2X7	  
Functional	  
hetero-­‐
trimers	  
P2X2a	  
P2X4b	  
P2X5c	  
P2X1a	  
P2X3d	  
P2X4f 
P2X5e	  
P2X6f	  
P2X2d	  
P2X1b	  
P2X2f	  
P2X5g	  
P2X6f	  
P2X7h	  
P2X1c	  
P2X2e	  
P2X4g	  
P2X2f	  
P2X4f	  
P2X4h	  
a(Brown,	   Townsend-­‐Nicholson,	   Jacobson,	   Burnstock,	   &	   King,	   2002);	   b(Nicke,	  
Kerschensteiner,	   &	   Soto,	   2005);	   c(Annmarie	   Surprenant,	   Schneider,	   Wilson,	   Galligan,	   &	  
North,	  2000);	  d(Radford	  et	  al.,	  1997)	  (Hausmann	  et	  al.,	  2012)	  (Jiang	  et	  al.,	  2003);	  e(Compan	  
et	   al.,	   2012);	   f(Ligia	   S	   Antonio	   et	   al.,	   2014);	   g(Torres,	   Egan,	   &	   Voigt,	   1999);	   h(Guo	   et	   al.,	  
2007). 
Table 1.1: List of proposed heterotrimeric P2X receptor assemblies. 
1.1.3 Receptor	  activation	  
In functional trimers, the binding of ATP causes receptor activation and the 
opening of the pore resulting in non-selective cation flux (Ca2+, Na+ influx and K+ 
efflux). This leads to depolarisation and consequent activation of signalling 
pathways. Concentration-response curved derived from the measurement of ion 
current recordings following receptor activation usually show a Hill Coefficient 
greater than 1, implying a cooperative effect of ATP binding. According to the 
mathematical models of Yan et al. and Kandra et al., the binding of one molecule 
of ATP to P2X7 is not sufficient to activate the receptor but it is necessary for the 
receptor to be more susceptible to the binding of a second molecule of ATP in the 
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adjacent subunit, which is then sufficient to cause receptor activation (Khadra et 
al. 2013; Yan et al. 2010). Channel gating may be described in 3 phases: 
activation, desensitization and deactivation (North 2002). A rapid increase in ion 
currents is observed after activation by ATP. Desensitization happens with current 
decay when the agonist is still bound, and this is followed by deactivation when 
the current rapidly stops after the ATP leaves the binding site. Different receptor 
subtypes show different desensitization kinetics. P2X1 and P2X3 show fast 
desensitization kinetics whereas P2X2 and P2X4 show slow desensitization after 
application of ATP (North 2002). The gating of the receptor has been studied 
through biophysical-mathematical models (Khadra et al. 2013) and recently has 
been captured through a series of crystal structures of human P2X3 (Mansoor et al. 
2016) that will be further described in Section 1.5.3.1. 
1.1.4 P2X	   receptor	   involvement	   in	   physiological	   and	  
patho-­‐physiological	  processes	  
There are 7 subtypes of P2X receptors in humans, widely distributed in many 
different tissues, which play roles in inflammation (Lister et al. 2007), neuronal 
modulation (North 2002), immune system activation (Trautmann 2009) and smooth 
muscle and cardiac contraction (Yamamoto et al. 2006). Due to the recent 
growing interest in P2X receptors for their involvement in diseases, numerous 
experiments have been carried out using knock-out mice, as well as extensive 
analysis of receptor polymorphisms in humans (Roberts et al. 2006a) (see Table 
1.2 and Table 1.3). P2X1 knock-out mice reveal roles for P2X1 in male infertility 
(Mulryan et al. 2000), kidney function (Inscho et al. 2004) and arterial 
thrombosisis (Hechler et al. 2003). In humans, a 3-nucleotide in-frame deletion in 
the P2RX1 gene (corresponding to Leu-351, Leu-352 or Leu-353) is associated with 
deficiency in platelet aggregation (Oury et al. 2000). 
In the P2RX2 gene, a non-synonymous single nucleotide polymorphism (SNP) 
results in the expression of a loss-of-function mutant (V60L) in humans linked to 
hereditary hearing loss in Chinese individuals characterised by noise-induced 
progressive loss of sensitivity (Yan et al. 2013). A different polymorphism 
(1057G>C) responsible for the expression of G353R mutant has been found in 
members of an Italian family with hereditary hearing loss (Faletra et al. 2014). 
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The link between P2X2 loss-of-function mutants and hearing loss is further 
supported P2X2 knockout mice (Yan et al. 2013). Mice lacking P2X2 also show 
reduced inflammatory pain sensation, decreased bladder reflex and motility and 
reduced taste sensation (Cockayne et al. 2005). P2X2 is also involved in tuning the 
ventilatory response to hypoxia (Rong et al. 2003). P2X3 has been associated with 
decreased pain, lower bladder reflex and loss of visceral mechanosensory 
transduction (Cockayne et al. 2005) and cough reflex. Recently a P2X3 antagonist 
(AF-219) has been advanced to the phase II of clinical trial as treatment for cough 
(Abdulqawi et al. 2015). P2X2/P2X3 heterotrimers are natively expressed in 
sympathetic and sensory neurons and when generating P2X2/P2X3 double knock-
out mice by breeding single knock-outs, the majority of the double-knockout mice 
(approximately 90%) died before weaning, showing numerous phenotype 
abnormalities, while a normal phenotype was observed for the ones that reached 
adulthood, perhaps due to compensation (Cockayne et al. 2005). The P2X2 and 
P2X3 single knock out showed only modest lost of taste compared to the double 
KO - where taste sensation was completely abolished (Eddy et al. 2009; Finger and 
Kinnamon 2013) - implying that the heteromeric P2X2/3 receptor is involved in 
gustatory signaling. 
P2X4 has been primarily associated with pain signaling and hypertension while 
P2X7 is mainly expressed in immune cells and play a role in inflammation and cell 
survival (a more detailed description of P2X4 and P2X7 involvement in diseases is 
described in Section 1.2 and Section 1.4). P2X5 is mainly non-active in humans 
due to alternative splicing and only 10-15% of humans produce the full-length 
receptor (Kotnis et al. 2010). In fact, in the African American population a single 
nucleotide mutation gives rise to splice variants, which may include or exclude 
exon 10. In contrast, samples from people of American Caucasian, Chinese and 
Middle Eastern backgrounds showed only the allele that gives rise to the 
espression of P2X5 lacking exon 10, which is deprived of a portion of the ATP 
binding site and part of the transmembrane domain and is not functional (Kotnis 
et al. 2010). The function of P2X5 in individuals carrying the receptor containing 
exon 10 has not yet been elucidated. Similarly, P2X6 is widespread in many 
tissues; its role is unclear, although it appears to function only in heterotrimers 
(see Table 1.1). In fact, when expressed in oocytes P2X6 appeared to form 
oligomers - mainly tetramers - that were retained in the ER, leading to the 
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hypothesis that P2X6 is unable to homo-oligomerize to form a functional receptor 
(Aschrafi et al. 2004). 
	  
Receptor	  
Subtype	   Localization	   Main	  functions	  
P2X1	   Platelets,	  smooth	  muscle,	  CNS	  
Promoting	  platelet	  aggregation,	  involved	  
in	  kidney	  function,	  male	  fertility	  
(infertility	  in	  KO	  rodents)	  
P2X2	  
Autonomic	  ganglia,	  sensory	  
ganglia,	  smooth	  muscle,	  CNS,	  
pancreas	  
Inflammatory	  pain	  transduction,	  role	  in	  
sensory	  transduction	  (taste	  and	  hearing	  
loss	  in	  KO	  rodents)	  
P2X3	   Nociceptive	  neurons,	  sympathetic	  neurons,	  sensory	  neurons,	  CNS	  
Pain	  transduction,	  sensory	  transduction	  
(taste	  and	  temperature),	  bladder	  reflex	  
and	  intestinal	  motility	  
P2X4	   Microglia,	  endothelial	  cells,	  CNS,	  	  
Inflammatory	  and	  neuropathic	  pain	  
transduction,	  vasodilation,	  cardio-­‐
protection	  and	  increased	  heart	  function	  
P2X5	   Skeletal	  muscle,	  epithelial	  cells,	  skin	   -­‐	  
P2X6	   Peripheral	  nerves,	  CNS	   -­‐	  
P2X7	   Immune	  cells,	  macrophages,	  
microglia,	  pancreas	  
Inflammation,	  pain	  transduction,	  fluid	  
secretion,	  normal	  skeletal	  functions	  
Table 1.2: Main localization and function of P2X receptor subtypes. P2X5 is 
prominently non-functional in humans due to a splice variant polymorphism. 
P2X6 is unable to from homotrimers and is found only as subunit forming 
heterotrimers. 
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Receptor	  
subtype	  
Chromosome	  
location	  
Polymorphism,	  
mutation	  
Implicated	  condition,	  Reference	  
P2X1	   17p13.2	  
L351,	  L352	  or	  
L353	  in-­‐frame	  
deletion	  
Platelet	  aggregation	  defect	  (Oury	  et	  
al.	  2000)	  
P2X2	   12q24.33	  
178G>T;	  V60L	  
(loss-­‐of-­‐function	  
receptor)	  
Hearing	  loss	  (Yan	  et	  al.	  2013)	  
1057G>C;	  G353R	   Hearing	  loss	  (Faletra	  et	  al.	  2014)	  
P2X3	   11q12.1	   -­‐	   -­‐	  
P2X4	   12q24.32	  
1248A>G;	  T315C;	  
rs28360472	  
High	  pulse	  pressure	  (Stokes	  et	  al.	  
2011)	  age-­‐related	  macular	  
degeneration	  (Gu	  et	  al.	  2013)	  
S242G;	  rs25644	   Increased	  lumbar	  bone	  mineral	  density	  (Wesselius	  et	  al.	  2013b)	  
P2X5	   17p13.2	  
328-­‐349	  amino	  
acid	  deletion	  
(loss-­‐of-­‐function	  
receptor)	  
n/a	  (Kotnis	  et	  al.	  2010)	  
P2X6	   22q11.21	   -­‐	   -­‐	  
P2X7	   12q24.31	  
370T>V;	  A76V;	  
rs17525809	  
Multiple	  sclerosis	  (Oyanguren-­‐Desez	  
et	  al.	  2011)	  
474G>A;	  G150R;	  
rs28360447	  
Osteoporosis	  (Husted	  et	  al.	  2013;	  
Wesselius	  et	  al.	  2013a)	  
489C>T;	  H155Y;	  
rs208294	  
Multiple	  sclerosis	  (Oyanguren-­‐Desez	  
et	  al.	  2011),	  sepsis	  (Geistlinger	  et	  al.	  
2012),	  chronic	  pain	  (Sorge	  et	  al.	  
2012)	  
835G>A;	  R270H;	  
rs7958311	   Chronic	  pain	  (Sorge	  et	  al.	  2012)	  
946G>A;	  R307Q;	  
rs28360457	  
Osteoporosis	  (Gartland	  et	  al.	  2012;	  
Jørgensen	  et	  al.	  2012)	  
1068G>A;	  A348T	  
(gain	  of	  function);	  
rs1718119	  	  
Osteoporosis	  (Husted	  et	  al.	  2013;	  
Jørgensen	  et	  al.	  2012;	  Varley	  et	  al.	  
2016;	  Wesselius	  et	  al.	  2013a),	  
anxiety	  disorder	  (Erhardt	  et	  al.	  
2007),	  toxoplasmosis	  (Jamieson	  et	  
al.	  2010)	  
1096C>G;	  T357S;	  
rs2230911	   Osteoporosis	  (Gartland	  et	  al.	  2012)	  
1405A>G;	  Q460R;	  
rs2230912	  
Osteoporosis	  (Gartland	  et	  al.	  2012;	  
Husted	  et	  al.	  2013;	  Jørgensen	  et	  al.	  
2012;	  Wesselius	  et	  al.	  2013a),	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Multiple	  sclerosis,	  sepsis	  
(Geistlinger	  et	  al.	  2012),	  mood	  
disorders	  	  (Barden	  et	  al.	  2006)	  
(Hejjas	  et	  al.	  2009;	  Lucae	  et	  al.	  
2006;	  McQuillin	  et	  al.	  2009)	  but	  not	  
confirmed	  by	  (Green	  et	  al.	  2009;	  
Grigoroiu‐Serbanescu	  et	  al.	  2009)	  
1513A>C;	  E496A;	  
rs3751143	  
Osteoporosis	  (Gartland	  et	  al.	  2012;	  
Husted	  et	  al.	  2013;	  Jørgensen	  et	  al.	  
2012;	  Ohlendorff	  et	  al.	  2007;	  Varley	  
et	  al.	  2016;	  Wesselius	  et	  al.	  2013a),	  
tuberculosis	  (Fernando	  et	  al.	  2007;	  
Niño‐Moreno	  et	  al.	  2007;	  Tekin	  et	  
al.	  2010)	  but	  not	  seen	  in	  Chinese	  
population	  (Xiao	  et	  al.	  2009)	  
1729T>A;	  I568N;	  
rs1653624	  
Osteoporosis	  (Gartland	  et	  al.	  2012;	  
Jørgensen	  et	  al.	  2012;	  Ohlendorff	  et	  
al.	  2007)	  
Table 1.3: Summary of the most reported single polymorphisms and P2X 
variants and their association with pathological conditions in humans. Table 
modified from (Caseley et al. 2014). 
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1.2  P2X4 as a drug target 
1.2.1 P2X4	  distribution	  and	  main	  physiological	  functions	  
P2X4 is characterized by a wide tissue distribution being mainly expressed in the 
central nervous system, in glandular tissues, lungs, immune cells, testis and 
epithelial cells (North 2002; Suurväli et al. 2017). P2X4 was initially cloned in rat 
brain and found in rat spinal cord and non-neuronal organs (Bo et al. 1995; Buell 
et al. 1996; Soto et al. 1996) and later shown to be strongly expressed in activated 
microglial cells where it plays a pivotal role in pain neurotransmission (see 
Section 1.2.3.3). P2X4 is also expressed in salivary glands (Tenneti et al. 1998) 
and endocrine glandular tissues (Stojilkovic and Zemkova 2013) such as the 
hypothalamus (Vavra et al. 2011), adrenal glands (Tanaka et al. 1996), thymus 
(Glass et al. 2000; Tanaka et al. 1996), pancreas (Coutinho-Silva et al. 2001), 
testis (Antonio et al. 2009) and placenta (Roberts et al. 2006b) where purinergic 
signalling is involved in hormonal regulation and release (Burnstock 2014). P2X4 
receptors are present in in HUVEC (Human Umbellical Vein Endothelial Cells) 
(Yamamoto et al. 2000b) and in capillaries, in arteries and arterioles where they 
also localize at the level of the endothelium, playing a role in smooth muscle tone 
(Yamamoto et al. 2006) (see Section 1.2.3.3 for further details). Furthermore, 
P2X4 is expressed in lymphocytes (being the most abundant P2X present), 
monocytes and in CD34+ stem and progenitor cells (Wang et al. 2004) suggesting a 
role in immune system regulation. Notably, the P2X4 receptor displays a peculiar 
preferential subcellular localization at the level of early endosomes and lysosomes 
(Bobanovic et al. 2002; Qureshi et al. 2007) and undergoes fast dynamin-
dependent internalization from the membrane after activation and before being 
recycled and trafficked back to the plasma membrane (Qureshi et al. 2007). It has 
been shown that N-glycosylation confers stability to P2X4 in the proteolytic 
lysosomal enviorment, preserving its function and preventing protein degradation 
(Qureshi et al. 2007). Indeed, lysosomal P2X4 is dually regulated by intraluminal 
ATP concentration and pH, which at resting condition (lysosomal pH~4.5-5.0) 
inhibits ATP-induced Ca2+ efflux from the lysosome (Huang et al. 2014) as 
previously shown by multiple research groups who observed that P2X4 activity is  
pH-dependent (Stoop et al. 1997) (Clarke et al. 2000) and identified His-286 as the 
amino acid residue responsible for pH-sensitivity (Clarke et al. 2000). In alveolar 
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type II cells, P2X4 is located in the lamellar bodies (a cellular compartment with 
many similarities to lysosomes) and is critically important in the secretion and 
activation of the pulmonary surfactant in the alveoli by promoting fusion pore 
opening and fusion-activated Ca2+ entry (FACE) (Miklavc et al. 2011; Miklavc et al. 
2013; Thompson et al. 2013). Very recently, Fois et al. showed that the source of 
ATP required to activate the P2X4 is the lamellar bodies themselves, finely tuning 
the fusion events process and the localised increase of Ca2+ (Fois et al. 2017). The 
localised increase of Ca2+ to which P2X4 contributes stimulates the reabsorption of 
liquids from the alveolar lumen and the secretion of the lipophilic pulmonary 
surfactant at the gas-liquid interface (Figure 1-2). This process is crucial for the 
correct gas-liquid exchange in the alveoli during respiration (Fois et al. 2017). 
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Figure 1-2: P2X4 modulation of pulmonary surfactant secretion in alveolar 
type II cells. Lamellar bodies are large vacuolar intracellular organelles 
expressing P2X4 and characterized by acidic pH in the lumen in resting 
conditions. Under these conditions P2X4 is inhibited. Upon exocytosis, P2X4 
becomes part of the plasma membrane and under more alkalinized condition 
is activated by extracellular ATP resulting in localized increased of Ca2+. The 
local increase in Ca2+ around the fused vesicle promotes the fusion of the 
lamellar body. Reabsorption of fluid is also promoted assisting the release of 
surfactant. Figure adapted from (Miklavc et al. 2013). 
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1.2.2 P2X4	   isoforms,	   polymorphisms	   and	   disease	  
susceptibility	  
Three different isoforms have been identified for human P2X4 (Carpenter et al. 
1999; Dhulipala et al. 1998) and interestingly one of these shows a portion of a 
heat shock protein substituting for TM1, although it is not clear what are the 
pathophysiological implications of the expression of such isoform and no further 
study has been conducted on this P2X4 variant. Multiple naturally occurring 
variants have also been observed for P2X4, some of which are linked to medical 
conditions or pathologies (see Figure 1-3 for the location of the most common 
disease-related and non-disease related point mutations and Table 1.3), such as 
the missense single nucleotide polymorphism (SNP) responsible for the S242G 
mutation (rs25644) which has been linked to increased lumbar bone mineral 
density (Wesselius et al. 2013b). The same study identified a significant 
correlation between Y315C – of which the function is impaired – and increased risk 
of osteoporosis. Multiple studies associated the same polymorphism with increased 
risk of age-related macular degeneration (AMD) (Gu et al. 2013), increased risk of 
multiple sclerosis (Sadovnick et al. 2017), increased pulse pressure (Stokes et al. 
2011) highlighting the potential involvement of P2X4 in various and highly 
dissimilar pathologies. 
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Figure 1-3: Bubble diagram of human P2X4 sequence representing general 
receptor features and the most-studied single nucleotide polymorphisms 
(SNPs). Image created using Protter 1.0 (http://wlab.ethz.ch/protter/) 
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1.2.3 P2X4	  involvement	  in	  pathological	  conditions	  
1.2.3.1 Cardiovascular	  diseases	  
P2X4 has been found in the heart where it shows a positive cardio-protective role 
when overexpressed, while on the contrary a deletion of P2X4 in a rodent model 
of heart failure has been linked to lower myocyte contractile performance (Hu et 
al. 2002; Shen et al. 2006; Shen et al. 2009). P2X4 expression was also detected in 
smooth muscle cells of human mammary artery isolated from patients undergoing 
coronary bypass (Wang et al. 2002) although the expression was significantly lower 
than P2X1, the most abundant (Vial and Evans 2002; Wang et al. 2002). The 
highest expression of P2X4 in the circulatory system is in endothelium, the inner 
cell monolayer in direct contact with blood. The endothelial cells are capable of 
sensing the shear stress on the walls of the vessel, which is correlated to an 
increase of cytosolic Ca2+ (Ando et al. 1993). Yamamoto et al. demonstrated that 
P2X4 is responsible for the shear stress-induced Ca2+ influx, observing that the 
activation of P2X4 expressed in HUVEC cells happens in response to increased flow 
shear-stress combined with low levels of ATP (<250 nmol/L) and is sufficient to 
induce Ca2+ influx (Yamamoto et al. 2000a). The increase of cytosolic Ca2+ triggers 
the activation of the nitric oxide synthase (NOS) and the production of nitric oxide 
(NO) that has a vasodilatation action on the smooth muscles of the blood vessels 
(Bredt et al. 1992; Zhao et al. 2015) (see Figure 1-4). The discovery of Yamamoto 
et al. has important consequences for our understanding of the physiological 
mechanism of blood pressure control and was later supported by the observation 
of increased pulse pressure in humans who have the P2X4 loss-of-function 
polymorphism Y315C (Stokes et al., 2011). Increased pulse pressure is one of the 
best-known risk factors contributing in the rise of cardiovascular pathologies. 
According to the World Health Organization (WHO), approximately 17.7 million 
(31% of all the deaths) people died worldwide in 2015 due to cardiovascular 
diseases (CVDs) ranking CVDs as first cause of mortality (World Health 
Organization (WHO) 2017). If the low-functional P2X4 contributes to increased 
pulse pressure, then selective P2X4 agonists or allosteric activators might aid in 
the treatment of hypertension.  
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Figure 1-4: Mechanism of shear stress-induced smooth muscle relaxation in 
blood vessels through activation of P2X4 on endothelial cells. (A) Schematic 
representation of the layers forming blood vessels. Arterioles and arteries 
differ from veins for a thicker tunica media formed by smooth muscle cells 
and the presence of an additional elastic membrane between the tunica 
media and tunica adventitia (outer tunica), not present in veins. (B) 
Mechanism of nitric oxide production in endothelial cells. Nitric oxide is one 
of the most important physiological mechanisms that controls vasodilation 
under physiological and pathological conditions. 
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1.2.3.2 P2X4	  in	  the	  central	  nervous	  system	  
P2X4 is expressed in the central nervous system and might be involved in the 
mediation of the glutamatergic and GABAergic signalling. In P2X4 knock-out mice, 
social interactions are compromised, in addition to the mice displaying as 
enhanced perception to sensory stimuli (Wyatt et al. 2013). Furthermore, the 
function of GABAergic and glutamatergic receptor signalling is altered (Du et al. 
2012; Duncan 2005), leading to a phenotype that present similarities with rodent 
models of autism-spectrum disorder  (Wyatt et al. 2013). In studies conducted 
primarily by Professor Davies group, ethanol has shown allosteric modulation at 
P2X4 (Davies et al. 2002b) and the positive modulation of P2X4 seemed to 
counteract alcohol dependency behaviour in rodent models (Franklin et al. 2014) 
(Khoja et al. 2018). The correlation between P2X4 and alcohol dependency 
remains unproven in humans; a pilot study aiming to test the effect of ivermectin 
administration on alcohol dependency behaviour in human volunteers failed to 
show a decrease in alcohol-craving behaviour (Roche et al. 2016).  
1.2.3.3 Neuropathic	  Pain	  
P2X4 is expressed in microglial cells that are found in brain and spinal cord and 
represent the prominent form of innate immunity in the central nervous system 
(CNS). The development of neuropathic pain after nerve damage is an extremely 
complex mechanism that involves multiple pathways and is characterized by pain 
hypersensitivity and allodynia (pain caused by otherwise normally innocuous 
stimuli). After nerve damage, the proliferation of microglia cells in the spinal 
dorsal horn (SDH) has been observed (referred as microgliosis) (Gilmore and 
Skinner 1979) and the blockage of this phenomenon avoids the development of 
pain hypersensitivity (Gu et al. 2016). During microgliosis but not in inflammatory 
pain, the expression of colony stimulating factor 1 (CSF1) is rapidly increased and 
the silencing of Csf1 gene or inhibition of CSF1 receptor reduces migrogliosis and 
pain hypersensitivity (Masuda et al. 2012). CSF1 is also responsible for the up-
regulation of multiple factors and genes including the interferon regulatory factor 
8 (IRF8), which in turn induces IRF5 production and localization in the cytoplasm 
(Masuda et al. 2014; Masuda et al. 2012). Upon stimulation by fibronectin, IRF5 
translocates to the nucleus and promotes P2X4 expression (Masuda et al. 2014; 
Tsuda et al. 2008). Activation of P2X4 results in the release of brain-derived 
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neurotrophic factor (BDNF). BDNF increases Cl- levels in neurons by down-
regulating the KCC2 chloride channel via the TrkB receptor. This intracellular 
increase in intracellular Cl- strengthens glutamatergic responses (via NMDA 
receptors) (Hildebrand et al. 2016) and switches inhibitory GABAergic signalling to 
excitatory (Coull et al. 2005). This imbalance towards hyper-excitation in neurons 
is at the base of mechanical allodynia and neuropathic pain (see Figure 1-5). In a 
rodent model of neuropathic pain, P2X4 expression is up-regulated in microglia 
after peripheral nerve damage (Tsuda et al. 2003; Ulmann et al. 2008). In P2X4 
knock-out mice via siRNA-silencing, and in pharmacological P2X4 blockade, pain 
hypersensitivity to innocuous stimuli was abolished after nerve injury (Tsuda et al. 
2003). In multiple studies the administration of P2X4 antagonists decreases 
allodynia and pain hypersensitivity after nerve injury (Matsumura et al. 2016; 
Nagata et al. 2009). Furthermore the intracranial injection of activated microglial 
cells (P2X4-stimulated cultured cells) in non-injured rats was sufficient to attain 
allodyinic responses (Tsuda et al. 2003). Taken together these evidences strongly 
suggest that the development of selective and potent P2X4 antagonists could be a 
substantial step for effective treatments towards neuropathic pain treatment, 
which is still an unmet medical need. In fact, approximately 20% of people suffer 
from chronic pain worldwide (Treede et al. 2015), and 6-10% of those individuals 
suffer from neuropathic pain (Bouhassira et al. 2008; van Hecke et al. 2014), a 
disabling condition due to nerve damage that poorly responds to usual pain-killer 
treatment options (Kamerman et al. 2015).  
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Figure 1-5: Mechanism of pain transduction in individuals without nerve 
injury (A) and after peripheral nerve injury (B). 
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1.2.3.4 P2X4	  and	  airway	  diseases	  
Very recently, the role of P2X4 in alveolar type II cells has been investigated and a 
crucial role in surfactant exocytosis has been observed (see Section 1.2.1) (Fois 
et al. 2017; Miklavc et al. 2011; Miklavc et al. 2013; Thompson et al. 2013). This 
raises the prospect of targeting a deregulated surfactant secretion system to 
provide beneficial effects in multiple airway pathological conditions including 
respiratory distress syndrome in the premature infant, asthma, lung infections, 
Chronic obstructive pulmonary disease and emphysema and pneumonia (Frerking 
et al. 2001). 
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1.3  P2X4 ligands: state of the art  
1.3.1 P2X4	  antagonists	  
As yet — despite the rising interest in P2X receptors as drug targets — for most 
subtypes, relatively few agonists or antagonists have been developed (with scarce 
subtype-selectivity) and, even in the case of P2X7, where several potent and 
selective compounds have been described, none have yet successfully passed 
clinical trials (Gunosewoyo and Kassiou 2010). 	  
In the case of P2X4, few modulators have been described. TNP-ATP, Brilliant Blue 
G (BBG) and PPADS (see Table 1.4 for detailed IC50 and Figure 1-6 for chemical 
structures) are well-known and frequently used as comparative controls in activity 
assays until recently but none of them display significant subtype selectivity.  
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Figure 1-6: Structures of the first generation of unselective antagonists at 
P2X4 
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To date, the compound PSB-12054 is one of the most potent allosteric antagonists 
described in a scientific journal (IC50 of 0.189 µM, see Table 1.4 and Figure 1-7), 
with 35-fold higher selectivity at hP2X4 compared to other human P2X receptors 
(Hernandez-Olmos et al. 2012). A structurally similar compound, PSB-12062 
(discovered by the same research group), also displayed a relatively high potency 
(IC50 of 0.928–1.76 µM), but a lower species-selectivity (among rat, mouse and 
human) (Hernandez-Olmos et al. 2012). Both compounds present some structural 
similarities with tricyclic antidepressants, some of which (but not all) display 
activity at P2X receptors (Hempel et al. 2013; Nagata et al. 2009; Sim and North 
2010). Antidepressants such Paroxetine and Fluoxetine show activity at P2X4 and 
P2X7 but their mechanism of action is slightly controversial in the case of P2X4, 
where they appear to affect receptor trafficking (Toulme et al. 2010). This effect 
seems to be subtype-dependent as there is evidence for the two antidepressants 
acting directly on P2X7 activation (Dao-Ung et al. 2015). In 2014 a new group of 
compounds was developed from the scaffold of Carbamazepine, another CNS 
active molecule. Compound 34 was identified as partially selective against human 
P2X4 displaying an IC50 of 3.44 µM (Tian et al. 2014). A patented allosteric 
antagonist, 5-BDBD, was reported to have a significant potency (IC50= 0.5 µM) and 
acceptable P2X4-selectivity but the full activity profile was not described in the 
patent (Fischer et al. 2004), and later characterisation displayed inconsistent 
results with previous studies (Balázs et al. 2013). Further analogues of 5-BDBD (in 
addition to the original patent) among whose some N-methylated compounds have 
been synthesized and their activity is reported to be comparable with 5-BDBD 
(Wang et al. 2017a). A substantial advance in P2X4-selective compound 
development occurred in 2015 when a new allosteric antagonist, BX430, was 
described as potent and selective with IC50 of 0.55 µM and approximately 100-fold 
higher potency compared to human P2X7 (although the data regarding to 
selectivity were not shown in the publication (Ase et al. 2015)). Very recently the 
group led by Professor Tsuda published the structure of NP-1815-PX, a potent and 
selective allosteric modulator (IC50 of 0.26 µM) with anti-allodynic effect in a 
rodent model of herpetic pain becoming one of the first P2X4 compounds active in 
an animal model reported in literature (Matsumura et al. 2016). NP-1815-PX is 
poorly permeable to the blood brain barrier (BBB) but NC 2600, a compound 
developed by the same collaboration between Kyushu University and Nippon 
Chemipharm with better ADMET profile, has advanced to Phase I of clinical trial 
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(Inoue and Tsuda 2018). Some antagonists are only reported in patents, an 
example worth remembering is the structure herein called Compound 30 (see 
Figure 1-7 and Table 1.4), which showed a very high potency in cell based assay 
with a reported IC50 lower than 0.1 µM (Newcom and Spear 2015). 
P2X4 activation (in contrast to most of the other receptor subtypes) is sensitive to 
pH, which has important implications in physiological conditions (see Section 
1.2.1). 
Intriguingly, ethanol has been demonstrated to act as a P2X4 antagonist in rodent 
models, with an IC50 of approximately 50 mM in rat (Xiong et al. 2000). Despite a 
much lower potency compared to other antagonists, the action of ethanol on P2X4 
receptors (known to be expressed in the central nervous system) has opened a 
new perspective in the development of animal models of alcohol dependency. 
Since the inhibitory effect of ethanol is antagonized by ivermectin (Asatryan et al. 
2010), the use of ivermectin has been explored and proposed to treat alcohol 
dependency behaviour (see Section 1.2.3.2). Although, a recent pilot study in 
human volunteers failed to show a decrease in alcohol-craving behaviour (Roche 
et al. 2016). 
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Compound	   IC50	  (μM)	   Methods	   References	  
Antagonists	  and	  negative	  allosteric	  modulator	  
Suramin	   >300	  
two-­‐
electrode	  
voltage-­‐
clamp	  
(Soto	  et	  al.	  1996)	  
NF023;	  8,8'-­‐[carbonylbis(imino-­‐3,1-­‐
phenylenecarbonylimino)]bis-­‐1,3,5-­‐
naphthalene-­‐trisulphonic	  acid	  
>100	  
two-­‐
electrode	  
voltage-­‐
clamp	  
(Soto	  et	  al.	  1999)	  
PPADS;	  4-­‐[2-­‐[4-­‐formyl-­‐6-­‐methyl-­‐5-­‐oxo-­‐3-­‐
(phosphonooxymethyl)	  pyridin-­‐2-­‐ylidene]	  
hydrazinyl]	  benzene-­‐1,3-­‐disulfonic	  acid	  
>300	  
two-­‐
electrode	  
voltage-­‐
clamp	  
(Soto	  et	  al.	  1996)	  
BBG;	  Brilliant	  Blue	  G;	  sodium;3-­‐[[4-­‐[(E)-­‐
[4-­‐(4-­‐ethoxyanilino)phenyl]-­‐[4-­‐[ethyl-­‐[(3-­‐
sulfonatophenyl)methyl]azaniumylidene]-­‐
2-­‐methylcyclohexa-­‐2,5-­‐dien-­‐1-­‐
ylidene]methyl]-­‐N-­‐ethyl-­‐3-­‐
methylanilino]methyl]benzenesulfonate	  
3–100	  
whole-­‐cell	  
patch	  
clamp	  
(Jiang	  et	  al.	  
2000a)	  
TNP-­‐ATP,	  2',3'-­‐O-­‐(2,4,6-­‐Tri-­‐
nitrophenyl)adenosine-­‐5'-­‐triphosphate	   15	  
whole-­‐cell	  
patch	  
clamp	  
(Virginio	  et	  al.	  
1998)	  
5-­‐BDBD;	  5-­‐(3-­‐Bromophenyl)-­‐1,3-­‐dihydro-­‐
2H-­‐benzofuro[3,2-­‐e]-­‐1,4-­‐diazepin-­‐2-­‐one	   0.5	  
Ca2+	  influx	  
assay	  
(Fischer	  et	  al.	  
2004)	  
Paroxetin	   1.87	  
whole-­‐cell	  
patch	  
clamp;	  
Ca2+	  
imaging	  
assay	  
(Nagata	  et	  al.	  
2009)	  
Compound	  34;	  N,N-­‐diisopropyl-­‐5H-­‐
dibenz[b,f]aze-­‐	  pine-­‐5-­‐carboxamide	  	   3.44	  
Ca2+	  influx	  
assay	   (Tian	  et	  al.	  2014)	  
BX-­‐430;	  N-­‐[2,6-­‐Dibromo-­‐4-­‐(1-­‐
methylethyl)phenyl]-­‐N'-­‐(3-­‐pyridinyl)urea	   0.5	  
Ca2+	  influx	  
assay;	  
whole-­‐cell	  
patch	  
clamp	  
(Ase	  et	  al.,	  2015	  
PSB-­‐12054	   0.189	   Ca
2+	  influx	  
assay	  
(Hernandez-­‐
Olmos	  et	  al.	  
2012)	  
PSB-­‐12062	   0.9-­‐1.7	   Ca
2+	  influx	  
assay	  
(Hernandez-­‐
Olmos	  et	  al.	  
2012)	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NP-­‐1815-­‐PX;	  (5-­‐[3-­‐(5-­‐thioxo-­‐4H-­‐
[1,2,4]oxadiazol-­‐3-­‐yl)phenyl]-­‐1H-­‐
naphtho[1,	  2-­‐b][1,4]diazepine-­‐
2,4(3H,5H)-­‐dione)	  
0.26	  
Ca2+	  
imaging	  
assay;	  hot	  
plate	  and	  
tail	  flick	  in	  
mice	  
models	  
(Matsumura	  et	  
al.	  2016)	  
NC	  2600	  (unknown	  structure)	   n/a	   n/a	   (Inoue	  and	  Tsuda	  2018)	  
Compound	  30	  (WO	  2015088564	  A1);	  3-­‐
acetyl-­‐8-­‐chloro-­‐4-­‐(pyridin-­‐3-­‐yl)-­‐1,5-­‐
dihydro-­‐2H-­‐pyrido[3,2-­‐b]indol-­‐2-­‐one;	  (as	  
representative	  of	  the	  class)	  
<0.1	   Ca
2+	  influx	  
assay	  
(Newcom	  and	  
Spear	  2015)	  
H+	   pKa	  ~	  7.0	  
whole-­‐cell	  
patch	  
clamp	  
(Stoop	  et	  al.	  
1997)	  
Cu2+	   10	  
whole-­‐cell	  
patch	  
clamp	  
(Coddou	  et	  al.	  
2007)	  
Hg2+	   10	  
whole-­‐cell	  
patch	  
clamp	  
(Coddou	  et	  al.	  
2005)	  
CO	   Not	  determined	  
whole-­‐cell	  
patch	  
clamp	  
(Wilkinson	  et	  al.	  
2009)	  
CORM-­‐2	   36.6	  
whole-­‐cell	  
patch	  
clamp	  
(Wilkinson	  and	  
Kemp	  2011)	  
Ethanol	   50000-­‐60000	  
whole-­‐cell	  
patch	  
clamp	  
(Xiong	  et	  al.	  
2000;	  Davies	  et	  
al.	  2002a)	  
	  
Table 1.4: P2X4 antagonists and allosteric modulators. 
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Figure 1-7: Structures of recent P2X4 antagonists and antidepressants with 
reported activity at P2X4 or at receptor trafficking. 
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1.3.2 P2X4	  agonists	  and	  positive	  allosteric	  modulators	  
Compared to other P2X receptor subtypes, P2X4 has a distinctive sensitivity profile 
towards agonist molecules; it is only partially activated by 2meSATP and BzATP 
(EC50=10-100 µM and EC50=3-10 µM respectively, see Figure 1-8), and poorly 
activated by either αβmeATP or other ATP analogues (see Table 1.5 for a 
comprehensive list of modulators and the corresponding potencies). Figure 1-8 
and Figure 1-10 report the structures of P2X4 modulators (selection). 
	  
	  
	  
Figure 1-8: Structures of agonist and partial agonists at P2X4 receptor. 
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Ivermectin (IVM) is an anti-parasitic macrolide drug whose primary mode of action 
is the positive allosteric modulation of GluCls (glutamate-activated chloride 
channels) (Hibbs and Gouaux 2011), which causes paralysis in invertebrates. 
Ivermectin is an non-selective allosteric modulator at numerous receptors such as 
glutamate-sensitive Cl- channel, alpha-glycine receptor (Du et al. 2015; Huang et 
al. 2017; Shan et al. 2001), nicotinic acetylcholine receptor α7 (Krause et al. 
1998) and GABA receptor (Menez et al. 2012). Ivermectin also modulates P2X4 and 
has been demonstrated to both prolong and increase the ATP-response at P2X4 in 
an allosteric manner (Priel and Silberberg 2004). Although its mechanism of action 
at P2X4 has not been elucidated, mutagenesis studies (Jelínkova et al. 2008; 
Jelínková et al. 2006; Silberberg et al. 2007), biophysical-mathematical (Mackay 
et al. 2017) and molecular modelling studies (Latapiat et al. 2017; Pasqualetto et 
al. 2018) and two ivermectin-bound crystal structures of three different ionotropic 
receptors (GluCls, α1-glycine receptor and α3-glycine receptor, PDB ID entries: 
3RI5, 3JAF and 5VDH respectively. 3RI5 and 3JAF are compared in Figure 1-9) 
strongly suggest that the drug might insert at the level of the phospholipid 
bilayer, between transmembrane domains at the subunit interface, preventing 
closure of the ion channel. Ivermectin is a valid tool for the study of P2X receptor 
pharmacology but caution needs to be taken when investigating ivermectin in drug 
repurposing due the non-selective profile and its ability to interact with a great 
variety of receptors present in the nervous system.  
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Figure 1-9: Crystal structure of glutamate-sensitive Cl channel (A, PDB ID: 
3RI5) (Hibbs and Gouaux 2011) and of the alpha-glycine receptor (B, PDB ID: 
3JAF)  (Du et al. 2015) in complex with ivermectin. Structures embedded in 
the lipid bilayer were obtained from MemProtMD database 
(http://memprotmd.bioch.ox.ac.uk). 
An allosteric positive modulation in the low nanomolar range was also seen for 
group of neuroactive steroids (see Table 1.5) including alphaxalone (EC50=0.3-1 
nM (Codocedo et al. 2009)). It is unclear whether the modulatory effect is due to 
a specific binding-site interaction or to the interplay with the membrane 
surrounding the receptor: specific stereo-selective steroid effects were not 
investigated on P2X4. However, the aforementioned neurosteroids are not 
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receptor-selective, being also GABAA blockers (alphaxalone IC50=0.9 µM in the 
presence of GABA and IC50=90 µM in its absence) with general anaesthetic 
properties (alphaxalone is approved for veterinary use), therefore causing major 
and potentially dangerous side-effects. 
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Compound	   EC50	  (μM)	   Methods	   References	  
Full	  agonists	   	   	   	  
ATP;	  Adenosine	  triphosphate	  
	  
1–10	  
	  
two-­‐electrode	   (Soto	  et	  al.	  1996)	  
whole-­‐cell	  patch	  
clamp	  
(Jones	  et	  al.	  2000;	  
Stokes	  et	  al.	  2011)	  
Partial	  agonists	   	   	   	  
BzATP;	  3'-­‐O-­‐(4-­‐Benzoylbenzoyl)ATP	  
(Note:	  usually	  sold	  as	  isomer	  
mixture	  with	  2'-­‐O-­‐(4-­‐
Benzoyl)benzoyl	  ATP)	  
9.4	   whole-­‐cell	  patch	  clamp	   (Stokes	  et	  al.	  2011)	  
2-­‐meSATP	  
	  
4–300	  
two-­‐electrode	  
voltage-­‐clamp	   (Soto	  et	  al.	  1996)	  
whole-­‐cell	  
patch	  clamp	  
(Jones	  et	  al.	  2000)	  
αβ-­‐meATP	   >300-­‐	   two	  electrode	  
voltage-­‐clamp	  
(Soto	  et	  al.	  1996)	  
CTP	  
200	   two-­‐electrode	  voltage-­‐clamp	   (Soto	  et	  al.	  1996)	  
564	   two-­‐electrode	  voltage-­‐clamp	   (Kasuya	  et	  al.	  2016)	  
Ap4P;	  Diadenosine	  Tetraphosphate	   2-­‐10	  
two-­‐electrode	  
voltage-­‐clamp	  
(Wildman	  et	  al.	  
1999)	  
whole-­‐cell	  
patch	  clamp	  
(Jones	  et	  al.	  2000)	  
Positive	  Modulators	   	   	   	  
Ca2+	   1000	  
whole-­‐cell	  
patch	  clamp	  
(Khakh	  et	  al.	  1999)	  
Zn2+	   5	  
whole-­‐cell	  
patch	  clamp	  
(Soto	  et	  al.	  1996;	  
Coddou	  et	  al.	  2007)	  
Cd2+	   20	   two-­‐electrode	  voltage-­‐clamp	  
(Coddou	  et	  al.	  
2005)	  
IVM	   0.250	  
whole-­‐cell	  
patch	  clamp	  
(Khakh	  et	  al.	  1999)	  
Alfaxalone	   0.4	  
whole-­‐cell	  
patch	  clamp	  
(Codocedo	  et	  al.	  
2009)	  
ALP;	  allopregnanolone	   0.3	  
whole-­‐cell	  
patch	  clamp	  
(Codocedo	  et	  al.	  
2009)	  
THDOC;	  
Tetrahydrodeoxycorticosterone;	  
3α,21-­‐dihydroxy-­‐5α-­‐pregnan-­‐20-­‐
one	  
0.1	  
whole-­‐cell	  
patch	  clamp	  
(Codocedo	  et	  al.	  
2009)	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Cibacron	  blue	   >300	  
whole-­‐cell	  
patch	  clamp	  
(Miller	  et	  al.	  1998)	  
Propofol	   50	  
whole-­‐cell	  
patch	  clamp	  
(Tomioka	  et	  al.	  
2000)	  
Table 1.5: Potencies of P2X4 agonists and allosteric (positive) modulators. 
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Figure 1-10: Structures of P2X4 positive allosteric modulators 
In conclusion, the clear physiological significance of P2X4 receptor together with 
the lack of available well-characterised, highly potent and selective compounds 
(IC50 values in the low nanomolar range), highlights the need to develop novel 
selective and potent modulators and any class of molecule (agonist, positive 
allosteric modulator, competitive or allosteric antagonist) may be of potential 
therapeutic benefit. 
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1.4  P2X7 as a drug target 
1.4.1 P2X7	  C-­‐terminal	  domain	  
One distinctive characteristic of P2X7 is its long (240 amino-acid) intracellular C-
terminal domain (CTD), which undergoes post-translational modification 
(palmitoylation) of at least 3 groups of cysteine residues, which presumably 
anchor the C-terminal domain to the plasma membrane like molecular staples. 
Mutation of these domains (and consequent lack of palmitoylation) leads to lack of 
receptor expression and alteration of receptor function (Gonnord et al. 2009; 
Karasawa et al. 2017). A second distinctive characteristic of P2X7 is its ability to 
form a large-conductance pore permeable to fluorescent dye molecules following 
activation, which is thought to require the distal portion of the CTD (amino-acids 
582-595) (Smart et al., 2003). Recently, Karasawa et al. reconstituted a giant 
panda P2X7 construct lacking significant portions of both the N- and C-terminal 
domains into synthetic lipid vesicles, and demonstrated the ability of this 
construct to form the large-conductance pore, implying that the CTD is not 
required for pore formation. However, the authors also demonstrated that 
incorporation of cholesterol into the vesicles markedly attenuated pore formation, 
suggesting a physiological role for the CTD in binding cholesterol to counteract its 
inhibitory effect on pore formation (Karasawa et al. 2017). While the 3-
dimensional structure of the CTD is not known, multiple protein- and lipid-binding 
motifs have been identified within it (Figure 1-11), which confer exclusive 
physiological properties to the receptor including its role in inflammation and cell 
death. Among the identified motifs are the Src homology 3 (SH3) binding domain 
(441-460, rat numbering) (Denlinger et al. 2001), a tumour necrosis factor 
receptor 1 (TNFR1) homology region (436-531, rat numbering) identified as a 
death domain responsible for apoptosis (Denlinger et al. 2001), two regions usually 
found in cytoskeleton-interacting proteins (389-405; 494-508) and a 
lipopolysaccharide (LPS)-binding region (573-590) (Denlinger et al. 2001). The 
presence of multiple motifs led to the hypothesis of multiple interacting proteins 
(Kim et al. 2001), and a number of interactors have been identified, including 
cytoskeletal proteins (such as β-actin, α-actinin 4, laminin α-3) and a variety of 
cytoplasmic and membrane proteins involved in trafficking and signalling 
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(http://www.p2x7.co.uk). In the light of the recent crystal structure of human 
P2X3 (see Section 1.5.2) it might also be hypothesized that a portion of the P2X7 
CTD may form a cytoplasmic cap when binding ATP (Mansoor et al. 2016). 
	  
	  
	  
Figure 1-11: C-terminal motifs present in rat P2X7 receptor. The 
palmitoylation is depicted for all the cysteines found involved in post-
translational modification according to Gonnord et al. (groups of cysteines 
that gave approximately 50% of surface expression are also shown anchored 
to the membrane) (Gonnord et al. 2009).  
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1.4.2 P2X7	  distribution	  and	  main	  physiological	  functions	  
P2X7 is mostly expressed in osteoclasts and hematopoietic cells such as 
macrophages, monocytes, erythrocytes, eosinophils, lymphocytes, natural killer 
cells, dendritic cells and mast cells (Burnstock and Knight 2004; Gu et al. 2000; 
Kaczmarek-Hájek et al. 2012). P2X7 is also found in fibroblasts, various 
endothelial and epithelial tissues, nervous system cells such as microglia, 
oligodendrocytes, astrocytes and also peripheral nervous system cells (Burnstock 
and Knight 2004; Gorodeski 2012; Montreekachon et al. 2011; Wilson et al. 2007). 
Furthermore P2X7 is present in several different cell types in the eye (Sanderson 
et al. 2014), including the lachrymal gland where it is responsible for triggering 
protein secretion through an increase in intracellular Ca2+ (Hodges et al. 2009), 
corneal epithelium (also present as splice variant) (Mankus et al. 2011), amacrine 
cells where it may modulate GABAergic signalling and the outer plexiform layer 
where P2X7 may control photoreceptor function (Puthussery and Fletcher 2004). 
In retinal ganglion cells P2X7 stimulation leads to cell death (Hu et al. 2010) while 
in retinal pigment epithelium P2X7 activation decreases cell turnover and 
increases lipid oxidation (Guha et al. 2013). 
In several cell types (including astrocytes, macrophages and monocytes), the 
activation of P2X7 leads to activation of JNK-1/2, ERK-1/2 and p38 as part of the 
MAPK/ERK signalling cascade (Bradford and Soltoff 2002; Potucek et al. 2006). 
P2X7 activation is involved in numerous pathways; notably it is involved in the 
release of pro-inflammatory cytokines especially interleukin 1 beta (IL-1β) and 
interleukin 18 (IL-18) through NLRP3 inflammasome activation. Inflammasomes are 
cytosolic assemblies of multiple proteins that act as bio-molecular sensors. NLRP3 
in particular is formed by a NOD-like receptor (NLR), adapter protein apoptosis 
associated speck-like protein (ASC) and procaspase 1 and their oligomerization 
which in turn leads to proteolysis, caspase 1 activation and subsequent excretion 
of pro-inflammatory cytokines (Martinon et al. 2009). P2X7 activation has been 
associated with NRLP3 activation and rapid release of pro-inflammatory cytokines 
through microvescicle shedding in human THP-1 monocytes – a novel mechanism of 
secretion for secretory proteins lacking specific secretory motifs (Ferrari et al. 
1997; MacKenzie et al. 2001). The mechanism of activation of the inflammasome 
is still unclear but reactive oxygen species (ROS) production, release of oxidized 
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mitochondrial DNA (mtDNA) in the cytoplasm and potassium efflux play key roles 
in its activation, and it has been proposed that P2X7 NLRP3-activation follows a 
similar cascade of events (Figure 1-12) (Dubyak 2012; Kanneganti et al. 2007) (He 
et al. 2016). 
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Figure 1-12: Inflammasome NLRP3 activation and pro-inflammatory 
cytokines release through microvesicle shedding (He et al. 2016). NLRP3 
activation may be the results of two different signals: (i) priming (arrows 
and labels in blue) and (ii) activation (in black). (i) Pro-interleukin-1 beta 
(pro-IL β) and NLRP3 (whose levels at rest in macrophages are insufficient 
for inflammasome activation) are upregulated by exposure to microbial 
molecules and endogenous cytokines through activation of NF-kB. (ii) Stimuli 
such as toxins, ATP, K+ efflux activates Caspase-1 converts pro-IL β in IL β, 
which is secreted through microvescicle shedding. 
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1.4.3 Polymorphisms	  and	  isoforms	  
P2X7 not only has widespread tissue distribution but also a wide number of 
receptor isoforms. Ten different splice isoforms are present in humans (A-J) of 
which isoform A is the best characterized and contains 13 exons displaying the 
canonical 595 amino acids (Cheewatrakoolpong et al. 2005). Among the others, 
isoforms G and H show an additional exon (N3) giving rise to an alternative 
starting codon and a receptor which lacks the first transmembrane domain (TM1) 
(Cheewatrakoolpong et al. 2005), while more than one isoform lacks or presents a 
shorter CTD (B, E and G). Of particular interest, isoform B is expressed in multiple 
tissues (spleen, lymph node, thymus tonsil, bone marrow, lung brain, fetal liver) 
and in higher levels compared to isoform A in lymphoid tissues and lymphocytes 
(Adinolfi et al. 2010; Cheewatrakoolpong et al. 2005). It has been shown that 
isoform A and B heterotrimers form functional receptors with increased activity, 
pore formation and membrane blebbing and their activation leads to increased 
levels of extracellular ATP and intracellular Ca2+ resulting in lymphocyte 
proliferation via nuclear factor activation (Adinolfi et al. 2010; 
Cheewatrakoolpong et al. 2005). 
P2X7 displays also a high degree of polymorphism with more than 650 recorded 
single nucleotide polymorphisms (SNPs) (Bradley et al. 2011), of which most are 
intronic or synonymous. However, among the non-synonymous SNPs, some have 
been associated with higher risk for pathologies such as age-related macular 
degeneration (AMD) (together with P2X4), osteoporosis and mood disorders (see 
Table 1.3). The rs3751143 (E496A) polymorphism is a loss-of-function mutation of 
the receptor that is highly associated with tuberculosis susceptibility. A SNP 
responsible for a gain-of-function mutation is associated with increased pain 
sensitivity following mastectomy or osteoarthritis (rs208294 (Y155H)), while in 
contrast, for the hypo-functional mutation caused by SNP rs7958311 (R270H), 
lower pain susceptibility has been reported (Sorge et al. 2012). 
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Figure 1-13: Recurrent polymorphisms in human P2X7 sequence. 
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1.4.4 P2X7	  involvement	  in	  pathophysiology	  
1.4.4.1 Inflammation,	  infection	  and	  immunity	  
Extracellular ATP is a danger-signal molecule that activates inflammatory and 
immune responses.  P2X7 activation in response to ATP released from damaged or 
infected cells leads to release of pro-inflammatory cytokines, in particular 
interleukin (IL)-1β, through the NLRP3-inflamasome pathway (Giuliani et al. 2017). 
This also happens in polarized pro-inflammatory macrophages (M1) but in 
polarized anti-inflammatory macrophages (M2) the activation of the 
inflammasome and ROS production appears to be disconnected from P2X7 
activation (Pelegrin and Surprenant 2009). The role of P2X7 in innate immunity 
was further highlighted in animal models of bacterial and parasite infections 
where hypo-activation of P2X7 (or loss of receptor in knock-out animals) led to a 
reduced ability to contain the infection. In mice with viral infection, P2X7 
activation regulates the acute immune response (Corrêa et al. 2016; Graziano et 
al. 2015; Morandini et al. 2014; Swartz et al. 2015; Tewari et al. 2015). 
Inflammation plays a substantial role in many physiological and pathological 
conditions, therefore it is not a surprise that P2X7 is involved in a variety of 
diverse diseases. P2X7 involvement has been suggested in allergy, chronic 
obstructive pulmonary disease (COPD), asthma, cystic fibrosis and airway infection 
(Zheng et al. 2017), and injury (Lucattelli et al. 2011; Monçao-Ribeiro et al. 2014). 
It also plays a role in Inflammatory bowel disease (IBD) (Kurashima et al. 2015), in 
the damaging of kidney in nephritis (Zhao et al. 2013) and in inflammatory skin 
disorders such as psoriasis, chronic dermatitis as well as wound healing (Geraghty 
et al. 2016). Strong evidence from animal models implicating P2X7 in 
osteoarthritis led to the first clinical evaluations of a P2X7 antagonist in 
rheumatoid arthritis (Keystone et al. 2012b; Stock et al. 2012) and in Crohn’s 
disease (Eser et al. 2015). No efficacy was observed against rheumatoid arthritis 
(Keystone et al. 2012b; Stock et al. 2012) and in diminishing pro-inflammatory 
markers in Crohn’s diseases (although AZ9056 showed potential in reducing the 
chronic pain associated with the disease (Eser et al. 2015)) and thus the potential 
of anti-P2X7 for inflammatory diseases and at which stage of the disease P2X7-
signalling blockage is efficacious is still under debate.  
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1.4.4.2 Age	  related	  macular	  degeneration	  (AMD)	  
Age-related macular degeneration (AMD) is an incurable condition characterized 
by progressive tissue degeneration and cell death leading ultimately to loss of 
central vision. WHO (World Health Organization) reports AMD as the third 
prominent cause of blindness worldwide ranking it higher than diabetic 
retinopathy (World Health Organization (WHO) 2018). Globally, AMD is the first 
among the non-avoidable causes of visual impairment and in the United Kingdom 
there are more than 600,000 sufferers according to NHS (National Health Service 
(NHS) 2018). Two forms of AMD have been classified (wet and dry) according to 
the presence of abnormal angiogenesis under the macula and currently there are 
relatively few treatment options for the wet form, mainly surgery or intraocular 
injection of anti-VEGF antibodies (National Institute for Health and Care 
Excellence (NICE) 2018), whereas there are no treatment options for the most 
common type of AMD (the dry form) (National Institute for Health and Care 
Excellence (NICE) 2018). Disease pathogenesis is complex but the death of retinal 
pigment epithelial cells (RPE) plays a critical negative role (Datta et al. 2017). As 
in other cell types, the prolonged activation of NLRP3 inflammasome in RPE 
causes cell death (Anderson et al. 2013; Gnanaguru et al. 2016). In a DICER-
knockout mouse model, and in human subjects with AMD or with geographical 
atrophy (the advanced dry form of AMD), the dismetabolism of Alu-RNA due to 
lack or loss-of-function of DICER1 (micro-RNA processing enzyme) leading to Alu-
RNA accumulation is cytotoxic for retinal pigment epithelium cells (Kaneko et al. 
2011; Tarallo et al. 2012). Alu–RNA was demonstrated to induce NLRP3 activation 
(Tarallo et al. 2012) through a P2X7-dependent mechanism (Kerur et al. 2013). 
The combination of P2X7 activation that causes ROS, lipid oxidation (Bartlett et 
al. 2013) and lysosomal disregulation (Guha et al. 2013) triggers cell death. In 
2014 it was observed that the administration of NRTIs (see Section 1.4.5) blocked 
the activation of NLRP3 inflammasome by Alu-RNA acting as antagonists of the 
P2X7 signalling pathway, reducing RPE cell death (Fowler et al. 2014). These 
findings highlight the importance of P2X7 as target for slowing down the 
progression of age-related macular degeneration and other visual impairment 
conditions such as diabetic retinopathy where chronic inflammation leads to 
retinal degeneration. 
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1.4.4.3 Inflammatory	  pain	  and	  neuropathic	  pain	  	  
In animal models of neuropathic pain, not only P2X4, but also P2X7 plays a pivotal 
role in aberrant pain transduction. P2X7 expression is increased in microglia after 
peripheral nerve damage and in paclitaxel-treated rodents (P2X7-knockout 
rodents show decreased chronic inflammatory and neuropathic pain in neuropathic 
pain models (Alves et al. 2013; Chessell et al. 2005)). Moreover it has been shown 
that administration of P2X7 antagonists decreases pain hypersensitivity after 
peripheral nerve damage (Honore et al. 2006) and paclitaxel-induced pain 
hypersensitivity (Ochi-Ishi et al. 2014) (A740003 and A438079 respectively, see 
Section 1.4.5 for further details about antagonist potencies and structures). In 
the latter study it was proposed that activation of P2X7 results in the release of 
CCL3, but although CCL3 blockade decreases pain hypersensitivity (Matsushita et 
al. 2014), the mechanism involving CLL3 in allodynia is still not entirely clear. 
Release of pro-inflammatory cytokines after P2X7 activation is a well-studied 
pathway (in particular the release of IL-1β). As both type 1 and type 2 diabetes 
are inflammatory diseases, the consequently development of diabetic neuropathy 
and its correlation with P2X7 has been studied. Various polymorphisms are 
associated to pain sensitivity in diabetic neuropathy (Ursu et al. 2014), and a 
reduction in P2X7 expression in dorsal root ganglia by administration of long 
noncoding silencing-RNA helps reducing pain hypersensitivity and release of pro-
inflammatory factors (such as TNFα) in a type 2 diabetes rodent model (Liu et al. 
2017; Liu et al. 2016). 
1.4.4.4 Tumor	  progression	  
P2X7 is overexpressed in multiple cancer cells although the role played by P2X7 is 
contradictory. Numerous studies show an association between increased 
expression of P2X7 and reduced tumour proliferation (Park et al. 2016); in 
contrast other evidences suggested that P2X7 increased cancer cell proliferation 
(Ferrari et al. 2017). These dual conflicting effects might be linked to diverse 
levels of activation of P2X7, with basal activity leading to proliferation and 
conversely an overstimulation by extracellular ATP resulting in apoptosis and 
further activation of the anti-tumour immune system responses (Garg et al. 2017; 
Savio et al. 2018). The dual effect of P2X7 activation was also observed in mouse 
embryonic stem where exogenous millimolar concentration of ATP stimulated pro-
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apoptotic and pro-necrotic signalling leading to cell death while endogenous low 
levels of ATP promoted cell survival (Thompson et al. 2012). 
Variants of P2X7 unable to form a large pore conductance - in response of agonist 
stimulation - have also been identified in multiple cancer cells (Ghiringhelli et al. 
2009). Gilbert et al. recently showed that a molecularly distinct form of non-pore 
functional P2X7 (nfP2X7) was selectively recognised by a specific antibody (raised 
against 200-216 amino acid sequence) binding to E200 residue, which conversely is 
not accessible by the same antibody in P2X7 wild-type (Gilbert et al. 2018). 
Furthermore, Gilbert et al. demonstrated that cell exposure to high concentration 
of ATP - mimicking the ATP concentration in the tumor micro-environment – 
promoted nfP2X7 membrane expression, which in turn promoted cell survival 
(Gilbert et al. 2018). The role of P2X7 as an anti-tumour target is supported by a 
clinical study (phase I) for the treatment of basal cell carcinoma where targeting 
non-pore functional P2X7 (nfP2X7) with topical application of a specific antibody 
showed a reduction of over 10% of the tumour after a month of ointment 
application, with a good tolerance and safety profile (Gilbert et al. 2017). 
1.4.4.5 Diseases	   of	   the	   SNC:	   neurodegenerative	   diseases	   and	  
mood	  disorders	  
P2X7 is believed to be involved in multiple diseases of the central nervous system 
such as multiple sclerosis where some P2X7 polymorphisms have been linked  - 
together with P2X4 polymorphisms (Sadovnick et al. 2017) - to increase disease 
susceptibility in humans (Gu et al. 2015). In Alzheimer’s disease, P2X7 plays a role 
in the formation of amyloid plaque during the disease onset and progression, as 
activation of P2X7 triggers the α-secretase pathway that leads to the processing of 
the β-amyloid precursor into the amyloid form abundant in the extracellular 
noxious deposits. The administration of Brilliant Blue G (BBG) in a transgenic 
mouse model of Alzheimer’s disease led to reduced plaque formation (Burnstock 
2017; Chen et al. 2014; Miras-Portugal et al. 2015). P2X7 is also involved in 
Parkinson’s disease and research in this field has demonstrated that antagonizing 
P2X7 might be a potential approach to reduce the synapto-toxicity, neurotoxicity 
and gliosis seen in the progression of the disease (Carmo et al. 2014; Jorg et al. 
2014; Wang et al. 2017b).  
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An increasingly accredited hypothesis postulates that neuro-inflammation and 
prolonged (or altered) activation of the innate immune system is accountable for 
the development of mood disorders. Rodent models with stress-induced 
depression-like and anxiety-like phenotypes showed high levels of pro-
inflammatory cytokines (IL-1β in particular), TNFα and higher expression in NLRP3 
and caspase-1 in the hippocampus and pre-frontal cortex, the regions considered 
important in the development of mood disorders (Iwata et al. 2016). Furthermore 
Iwata et al. observed an improvement in mood disorder phenotypes when the 
expression of NLRP3 inflammasome was abolished by gene knockout or 
pharmacological blockade, observing also a consequent reduction in IL-1β	   levels	  
(Iwata et al. 2016). In multiple clinical studies an alteration of the innate immune 
system in patients with mood disorders was observed, in particular elevated 
plasma concentrations of NLRP3, caspase1 and IL-1β showed a positive correlation 
with the severity of depression (Alcocer-Gómez et al. 2014). The same markers of 
inflammation were found to be increased after a manic episode in individuals with 
bipolar disorder (Söderlund et al. 2011). The NRLP3 inflammasome pathway is 
triggered by P2X7 activation in immune cells (see Section 1.4.4); therefore the 
impact of blockage of P2X7 on mood disorders has been investigated in 
behavioural studies. Manic-like behaviours induced by amphetamine (as model for 
bipolar disorder) were greatly reduced in P2X7 knock-out mice compared to wild 
type controls (Basso et al. 2009; Csölle et al. 2013) and confirmed by 
pharmacological P2X7 blockade by treatment with P2X7 antagonists such as BBG 
(Csölle et al. 2013) and A-438079 (Gubert et al. 2016). In parallel, depression-like 
behaviours were better managed with low doses of imipramine in P2X7 knock-out 
mice (Basso et al. 2009). However, a significant difference between the knock-out 
and the wild type was not observed in all the conducted behavioural tests (Basso 
et al. 2009). Furthermore, in a rodent model of phencyclidine (PCP)-induced 
schizophrenia, the pharmacological blockade of P2X7 with the blood-brain-barrier 
permeant compound JNJ-42253432, and the genetic deletion of P2X7, resulted in 
a significant change in behaviour, including a decrease in stereotypical behaviour, 
a decrease in hyper-locomotion and improved social behaviours (Lord et al. 2014). 
A subsequent study confirmed the results obtained for P2X7 knock-out models but 
did not show an improvement in social behaviour when the receptor was blocked 
with JNJ-47965567 – another brain-permeant compound (Koványi et al. 2016). Still 
there is the need to shed light on the degree of involvement of P2X7 in the genesis 
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and development of mood disorders, as some studies do not show a significant 
correlation between P2X7 blockade and anti-anxiety and anti-depressant effects. 
In addition, genetic studies are sometimes conflicting and although most show an 
association between P2X7 single nucleotide polymorphisms and mood disorders 
some failed to support the correlation. 1405A>G P2X7 SNP (causing the Q460R 
mutation) is particularly prominent in patients showing major depression in 
multiple cohort studies across Europe (Barden et al. 2006; Lucae et al. 2006; 
McQuillin et al. 2009) (Hejjas et al. 2009; Soronen et al. 2011), although some 
studies did not observe this correlation (Ferreira et al. 2008; Green et al. 2009). 
To note, the Q460R mutation leads to the expression of a receptor that shows 
similar properties to the wild type in ion currents (in electrophysiology 
experiments) but that alters the function of receptors when forming heteromeric 
channels with WT subunits (Aprile-Garcia et al. 2016). 
1.4.5 P2X7	  agonists,	  antagonists	  and	  allosteric	  modulators	  
Among the P2X receptor family, P2X7 is one of the most studied subtypes in terms 
of its pharmacology. Distinct properties of P2X7 are its relatively low sensitivity to 
ATP (EC50>100 µM), many folds lower than other P2X subtypes, and its high 
sensitivity to BzATP - usually sold and tested as an isomeric mixture of 2'-O-(4-
Benzoylbenzoyl)ATP and 3'-O-(4-Benzoylbenzoyl)ATP - which is approximately 30-
fold more potent than ATP at the rat isoform (Surprenant et al. 1996).  Notably, 
the concentration-response relationships of P2X7 agonists are influenced by 
extracellular divalent cation concentrations (Surprenant et al. 1996). P2X7 is 
negatively regulated by extracellular divalent cations including Ca2+, Mg2+, Cu2+ 
and Zn2+, and mutagenesis studies have demonstrated a role for multiple histidine 
residues in the extracellular domain in this modulation (Acuña‐Castillo et al. 
2007). Furthermore, it has been demonstrated that ginsenosides (compounds 
isolated from Panax ginseng extract, Figure 1-14) are positive modulators of P2X7 
activity; co-administration with 50 µM ATP led to increased YO-PRO dye uptake, 
increased Ca2+ influx responses and increased ATP-evoked membrane currents at 
both human and mouse P2X7 (Helliwell et al. 2015). 
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Compound	   EC50	  (μM)	   Methods	   References	  
Full	  agonists	   	   	   	  
ATP;	  Adenosine	  triphosphate	  
	  
~100	  (rat)	  
	  
two-­‐electrode	  
voltage-­‐clamp	  
(extracellular	  low	  
divalent	  cation	  
solution)	  
a	  (Surprenant	  et	  al.	  
1996)	  
~130	  (rat)c;	  
870	  
(mouse)c;	  
~300	  
(human)e	  
	  
two-­‐electrode	  
voltage-­‐clamp	  
(extracellular	  low	  
divalent	  cation	  
solution),	  Yo-­‐pro	  
assay	  
b(Khakh	  et	  al.	  2001)	  	  
c(Young	  et	  al.	  2006)	  
d(Karasawa	  and	  
Kawate	  2016)	  
e(Stokes	  et	  al.	  2006)	  
BzATP;	  3'-­‐O-­‐(4-­‐Benzoylbenzoyl)	  
ATP	  (Note:	  sold	  as	  isomer	  
mixture	  with	  2'-­‐O-­‐(4-­‐Benzoyl)	  
benzoyl	  ATP,	  although	  in	  early	  
reports	  the	  mixture	  was	  
referend	  as	  3'-­‐O-­‐(4-­‐
Benzoylbenzoyl)	  ATP)	  
8-­‐20	  	  
(rat)a,c;	  
236	  
(mouse)c	  
voltage-­‐clamp	  
(extracellular	  low	  
divalent	  cation	  or	  
standard	  solution)	  
a(Surprenant	  et	  al.	  
1996)	  
c(Young	  et	  al.	  2006)	  
Positive	  Modulators	   	   	   	  
Ginsenosides	  (Rb1,	  Rd,	  Rh2,	  
CK)	  
~1	   Yo-­‐pro	  assay,	  Ca
2+	  
influx,	  patch-­‐clamp	  
(Helliwell	  et	  al.	  
2015)	  
Table 1.6: Potencies of P2X7 agonists and positive allosteric modulators 
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Figure 1-14: Structure of P2X7 competitive agonists and positive allosteric 
modulators. Note that BzATP is referred to 3'-O-(4-Benzoyl)benzoyladenosine 
5'-triphosphate although it is commercially available as mixture of isomers. 
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In contrast to the low number of small-molecule P2X7 agonists and positive 
modulators, the number of P2X7 antagonists is by far larger. Historically, most of 
the compounds identified as P2X7 antagonists are non-selective (see Table 1.7) 
such as PPADS, some dyes such as Brilliant Blue G and Cibacron, and suramin, 
which is also acts as inhibitor on a wide array of different protein targets including 
viral proteins (Albulescu et al. 2015; Ferla et al. 2018), transcription factors (Berg 
and Berg 2017) and channels (Papineni et al. 2002). The first classes of compounds 
developed as P2X antagonists were suramin or dye analogues with ameliorated 
selectivity and potency profiles (Carroll et al. 2009). Interestingly some P2X1 
antagonists were found to be significant antagonists at P2X7 such as NF279 
(Klapperstück et al. 2000) and MRS 2159 (Donnelly‐Roberts et al. 2009).  
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Compound	   IC50	  
(μM)	  
Methods	   References	  
Antagonists	  (and	  compounds	  with	  unknown	  binding	  mode)	  
Suramin;	  8,8'-­‐((3,3'-­‐((3,3'-­‐
(carbonylbis(azanediyl))bis(benzoyl))bis	  
(azanediyl)bis(4-­‐methylbenzoyl))	  
bis(azanediyl))bis(naphthalene-­‐1,3,5-­‐
trisulfonic	  acid)	  
78	  (rat),	  
92	  
(human)	  
whole-­‐cell	  
patch	  clamp,	  	  
yo-­‐pro	  assay	  
(Rassendren	  et	  al.	  
1997)	  
NF279;	  8,8'-­‐[Carbonylbis(imino-­‐4,1-­‐
phenylenecarbonylimino-­‐4,1-­‐
phenylenecarbonylimino)]bis-­‐1,3,5-­‐
naphthalenetrisulfonic	  acid	  
2.8	  
(human)	  
two-­‐
electrode	  
voltage-­‐
clamp	  
(Klapperstück	  et	  
al.	  2000)	  
KN62;	  [4-­‐[(2S)-­‐2-­‐[isoquinolin-­‐5-­‐
ylsulfonyl(methyl)amino]-­‐3-­‐oxo-­‐3-­‐(4-­‐
phenylpiperazin-­‐1-­‐yl)propyl]phenyl]	  
isoquinoline-­‐5-­‐sulfonate	  
0.013	  
(human)	  
Ethidium	  
bromide	  
uptake;	  
Ca2+	  influx	  
assay	  
(Gargett	  and	  
Wiley	  1997)	  
Briliant	  Blue	  G	  (BBG);	  3-­‐((((1E,4E)-­‐4-­‐((4-­‐
((4-­‐ethoxyphenyl)amino)phenyl)(4-­‐
(ethyl(4-­‐sulfonatobenzyl)amino)-­‐2-­‐
methylphenyl)	  methylene)-­‐3-­‐
methylcyclohexa-­‐2,5-­‐dien-­‐1-­‐ylidene)	  
(ethyl)ammonio)methyl)benzenesulfonate	  
0.2	  (rat)	  
whole-­‐cell	  
patch	  clamp,	  
yo-­‐pro	  assay	  
(single	  cell	  
imaging)	  
(Jiang	  et	  al.	  
2000a)	  
PPADS;	  (E)-­‐4-­‐(2-­‐(4-­‐formyl-­‐6-­‐methyl-­‐5-­‐oxo-­‐
3-­‐((phosphonooxy)methyl)pyridin-­‐2(5H)-­‐
ylidene)hydrazineyl)benzene-­‐1,3-­‐
disulfonic	  acid	  
51	  (rat),	  
62	  
(human)	  
whole-­‐cell	  
patch	  clamp,	  	  
yo-­‐pro	  assay	  
(Rassendren	  et	  al.	  
1997)	  
MRS	  2159;	  (E)-­‐4-­‐((4-­‐formyl-­‐5-­‐hydroxy-­‐6-­‐
methyl-­‐3-­‐((phosphonatooxy)methyl)	  
pyridin-­‐2-­‐yl)diazenyl)benzoate	  
~0.288-­‐
1.73	  
(human)	  
Yo-­‐pro	  assay,	  
two-­‐
electrode	  
voltage-­‐
clamp	  
(Donnelly‐
Roberts	  et	  al.	  
2009)	  
Probenecid;	  4-­‐(N,N-­‐dipropylsulfamoyl)	  
benzoic	  acid	  
203	  
(human)	  	  
whole-­‐cell	  
patch	  clamp,	  
Ca2+	  influx	  
(Bhaskaracharya	  
et	  al.	  2014)	  
TNP-­‐ATP;	  2',3'-­‐O-­‐(2,4,6-­‐Tri-­‐
nitrophenyl)adenosine-­‐5'-­‐triphosphate	  
>30	  
(human)	  
whole-­‐cell	  
patch	  clamp	  
(Virginio	  et	  al.	  
1998)	  
Reactive	  Blue	  2;	  1-­‐amino-­‐4-­‐((4-­‐((4-­‐chloro-­‐
6-­‐((2-­‐sulfonatophenyl)amino)-­‐1,3,5-­‐
triazin-­‐2-­‐yl)amino)-­‐3-­‐
sulfonatophenyl)amino)-­‐9,10-­‐dioxo-­‐9,10-­‐
dihydroanthracene-­‐2-­‐sulfonate	  
69	  
(human)	  
Ca2+influx	  
assay,	  
ethidium	  
bromide	  
uptake	  
(Wiley	  et	  al.	  
1993)	  
Table 1.7: List of non-selective, first generation of P2X7 antagonists. 
Receptor specie in brackets. 
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Figure 1-15: Structure of non-selective P2X7 antagonists 
In the last two decades following the identification of P2X7 as key role component 
in inflammatory conditions and its identification as valuable drug target, many 
efforts were made in the identification of potent and selective P2X7 antagonists 
leading to the discovery of novel compounds active in the low nanomolar 
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concentration range (Carroll et al. 2009; Guile et al. 2009; Gunosewoyo and 
Kassiou 2010), or to the repurposing of well-characterised drugs as anti-P2X7 
drugs. Multiple Nucleoside Reverse Transcriptase Inhibitor (NRTI) primarily used as 
antivirals in the management of HIV - such as stavudine and zidovudine (also 
known as azidothymidine) (Table 1.8 and Figure 1-16) - showed inhibition at P2X7 
in vitro and efficacy in rodent models of age-related macula degeneration where 
P2X7 activation is involved in photoreceptor death (Fowler et al. 2014) (see 
Section 1.4.4.2). Examples of recently discovered novel compounds are listed in 
Table 1.8 (see Figure 1-16 and Figure 1-17 for structures). Surprisingly, some of 
the potent antagonists initially believed to be competitive such as A740003 
(Honore et al. 2006) and A804598 (Donnelly-Roberts et al. 2009) were later 
demonstrated to act as allosteric ligands through mutagenesis and crystallographic 
data (see Section 1.5), underlining the need for deep pharmacological 
characterization of novel compounds. Some recently characterized compounds are 
also able to cross the blood-brain barrier, and have become of high interest as 
potential drug candidates in the treatment of CNS disorders (Bhattacharya 2018), 
among which are A438079 (Nelson et al. 2006), compound 7f developed by Pfizer 
(Chen et al. 2010), compound 16 (Beswick et al. 2010) compound 18 (Abberley et 
al. 2010) and GSK-1482160 (Abdi et al. 2010) developed by Glaxo Smith Kline 
(GSK). Additionally, the brain-penetrant JNJ-422534327 (Letavic et al., 2013)(Lord 
et al. 2014), JNJ-47965567 (Letavic et al., 2013), JNJ-54175446 (Alcazar-Vaca et 
al. 2013), JNJ-55308942 (Letavic et al. 2013) and JNJ-64413739 (Kolb et al. 2016) 
are among the compounds developed by Janssen. The ability of compounds to 
permeate across the blood-brain barrier has been exploited for the development 
of compounds as Positron emission tomography (PET) tracers as both (i) potential 
marker of neuro-inflammation and (ii) to monitor and quantify the occupancy in 
the CNS of a compound of interest co-administered with the PET tracer 
(Bhattacharya 2018). In particular one PET tracer, 18F-JNJ-64413739, has been co-
administered with JNJ-54175446 (ClinicalTrial.gov identifier: NCT03088644) in 
Phase I clinical trials involving healthy volunteers to investigate the safety, 
tolerability and pharmacokinetics of the compounds, although no study results are 
publicly available. Another Phase I study exploring 18F-JNJ-64413739 and JNJ-
55308942 (NCT03437590) is currently recruiting healthy volunteers (see Table 1.8, 
Table 1.9 and Figure 1-17).  
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Compound	   IC50	  (μM)	   Methods	   References	  
Negative	  allosteric	  Modulators	   	   	   	  
A740003;	  (Z)-­‐N-­‐(1-­‐(3-­‐cyano-­‐2-­‐
(quinolin-­‐5-­‐yl)guanidino)-­‐2,2-­‐
dimethylpropyl)-­‐2-­‐(3,4-­‐
dimethoxyphenyl)acetamide	  
0.0693	  
(panda)	  
whole-­‐cell	  
patch	  clamp,	  
yo-­‐pro	  assay	  
(Karasawa	  and	  
Kawate	  2016)	  
A804598;	  N-­‐cyano-­‐N'-­‐[(1R)-­‐1-­‐
phenylethyl]-­‐N''-­‐quinolin-­‐5-­‐ylguanidine	  
0.0217	  
(panda)	  
whole-­‐cell	  
patch	  clamp,	  
yo-­‐pro	  assay	  
(Karasawa	  and	  
Kawate	  2016)	  
A438079;	  3-­‐((5-­‐(2,3-­‐dichlorophenyl)-­‐
1H-­‐tetrazol-­‐1-­‐yl)methyl)pyridine	  
0.1	  
(human)	  
IL-­‐1β	  release,	  
yo-­‐pro	  assay,	  
Ca2+	  influx	  
assay	  
(Nelson	  et	  al.	  
2006)	  
AZ11645373;	  3-­‐[1-­‐[4-­‐(3-­‐
nitrophenyl)phenoxy]-­‐4-­‐pyridin-­‐4-­‐
ylbutan-­‐2-­‐yl]-­‐1,3-­‐thiazolidine-­‐2,4-­‐dione	  
0.005-­‐
0.09	  
(human)	  
IL-­‐1β	  release,	  
yo-­‐pro	  assay,	  
Ca2+	  influx	  
assay,	  whole-­‐
cell	  patch	  
clamp	  
(Stokes	  et	  al.	  
2006)	  
Compound	  7f	   0.027	  
(human)	  
yo-­‐pro	  assay	   (Chen	  et	  al.	  2010)	  
Compound	  16	   0.01	   n/a	   (Beswick	  et	  al.	  2010)	  
Compound	  18	   0.01	  
Ethidium	  
bromide	  
uptake	  
(Abberley	  et	  al.	  
2010)	  
GW791343;	  2-­‐(3,4-­‐difluoroanilino)-­‐N-­‐
[2-­‐methyl-­‐5-­‐(piperazin-­‐1-­‐
ylmethyl)phenyl]acetamide	  
0.1	  
(human),	  	  
8.9	  
(panda)	  
whole-­‐cell	  
patch	  clamp,	  
yo-­‐pro	  assay	  
(Karasawa	  and	  
Kawate	  2016;	  
Michel	  et	  al.	  2008)	  
JNJ-­‐422534327;	  2-­‐methyl-­‐N-­‐((1-­‐(4-­‐
phenylpiperazin-­‐1-­‐yl)cyclohexyl)	  
methyl)-­‐1,2,3,4-­‐tetrahydroisoquinoline	  
-­‐5-­‐carboxamide	  
~0.01a	  
(human)	   n/a	  
(Letavic	  et	  al.	  
2013;	  Lord	  et	  al.	  
2014)	  
JNJ-­‐47965567;	  2-­‐(Phenylthio)-­‐N-­‐
[[tetrahydro-­‐4-­‐(4-­‐phenyl-­‐1-­‐
piperazinyl)-­‐2H-­‐pyran-­‐4-­‐yl]methyl-­‐3-­‐
pyridinecarboxamide	  
~0.01a	  
(human);	  
11.9	  
(panda)	  
whole-­‐cell	  
patch	  clamp,	  
yo-­‐pro	  assay	  
(Karasawa	  and	  
Kawate	  2016;	  
Letavic	  et	  al.	  2013)	  
AZ10606120;	  2-­‐(1-­‐adamantyl)-­‐N-­‐[2-­‐[2-­‐
(2-­‐hydroxyethylamino)ethylamino]	  
quinolin-­‐5-­‐yl]acetamide	  
0.01	  
(human),	  
0.231	  
(panda)	  
whole-­‐cell	  
patch	  clamp	  
(Allsopp	  et	  al.	  
2017;	  Karasawa	  
and	  Kawate	  2016)	  
Azidothymidine	  (Zidovudine);	  1-­‐
[(2R,4S,5S)-­‐4-­‐azido-­‐5-­‐
(hydroxymethyl)oxolan-­‐2-­‐yl]-­‐5-­‐
Not	  
reported	  
whole-­‐cell	  
patch	  clamp	  
(Fowler	  et	  al.	  
2014)	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methylpyrimidine-­‐2,4-­‐dione	  
Stavudine;	  1-­‐[(2R,5S)-­‐5-­‐
(hydroxymethyl)-­‐2,5-­‐dihydrofuran-­‐2-­‐
yl]-­‐5-­‐methylpyrimidine-­‐2,4-­‐dione	  
Not	  
reported	  
whole-­‐cell	  
patch	  clamp	  
(Fowler	  et	  al.	  
2014)	  
Ca2+	   Not	  
reported	  
	   (Yan	  et	  al.	  2011)	  
Mg2+	   Not	  reported	   	  
(Acuña‐Castillo	  
et	  al.	  2007)	  
Copper	   Not	  reported	   	  
(Acuña‐Castillo	  
et	  al.	  2007;	  Liu	  et	  
al.	  2008)	  
Zn2+	   Not	  reported	   	   (Liu	  et	  al.	  2008)	  
Table 1.8: List of reported selective and potent P2X7 antagonists 
(selection). Receptor specie in brackets. aInhibition constant (Ki) instead of 
IC50. 
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Figure 1-16: Structures of reported selective and potent P2X7 antagonists 
(selection). 
In addition to PET tracers, multiple compounds have entered clinical trials and 
been demonstrated to be to safe and well tolerated in humans (Bhattacharya 
2018). For some of the compounds the published information is minimal. For EVT-
401, the structure has very recently been disclosed along with data regarding its 
instability in alkaline, acidic and oxidative stress conditions (Zhu et al. 2017), but 
there is still no published information regarding its advancements in clinical trials 
with the exception of press releases reporting the completion of Phase I trials and 
the continuation of the EVT-401 programme towards Phase II (Lanthaler 2012) 
(Evotec-AG 2012). 
The safety and pharmacokinetics of CE-224,535 (Pfizer) and AZD-9056 (Astra 
Zeneca) were investigated in multiple Phase I trials (NCT00838058, NCT00782600, 
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NCT00446784 and NCT00908934, NCT00700986, NCT00920608, NCT00736606 
respectively) before advancing to Phase II trials as treatment for rheumatoid 
arthritis and Chron’s disease (NCT00628095 and NCT00520572) and osteoarthritis 
(NCT00418782) where, although a significant reduction in swollen joints and pain 
for patients administered with AZD-9056 versus placebo was observed (Eser et al. 
2015; Keystone et al. 2012a), both drugs failed to show a reduction in 
inflammatory biomarkers and an improvement in patient conditions (Eser et al. 
2015; Keystone et al. 2012a) (Stock et al. 2012). A detailed report for the 
investigation of GSK1482160 in Phase I (NCT00849134) is available at the GSK 
Clinical Study Register (Study ID: 111383), reporting good tolerability for doses 
between 0.3 and 1000 mg with a single severe adverse event at the highest 
concentration that was not considered to be related to the treatment. The drug 
showed rapid absorption (1-2 hours, slowed down by concomitant food ingestion) 
and a rapid clearance (half life of 3 hours) and a concentration of GSK1482160 in 
blood approximately correlated to the administered dose was observed. To date 
there is no current information regarding Phase II testing of GSK1482160. 
Although there are currently no small molecule P2X7 modulators reported in 
clinical trials with anti-cancer properties, a 10% ointment formulation of antibody 
targeting non-functional P2X7 (nfP2X7, see Section 1.4.4.4) has shown promising 
results in a Phase I trial for patients with basal cell carcinoma (NCT02587819) 
where an average reduction of over 12% of cancer lesion was observed after twice 
daily treatment for 28 days (Gilbert et al. 2017). These results give new hope for 
the development of P2X7-targeted drugs after the failure of Phase II clinical trials 
targeting P2X7 as rheumatoid arthritis treatment. 
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P2X7	  antagonists	  in	  clinical	  trials	  
CE224535;	  2-­‐chloro-­‐N-­‐[(1-­‐
hydroxycycloheptyl)methyl]-­‐5-­‐[4-­‐[(2R)-­‐
2-­‐hydroxy-­‐3-­‐methoxypropyl]-­‐3,5-­‐dioxo-­‐
1,2,4-­‐triazin-­‐2-­‐yl]benzamide	  
0.0014-­‐
0.004	  
IL-­‐1β	  release,	  
yo-­‐pro	  assay	  
(Duplantier	  et	  al.	  
2011)	  
AZD-­‐9056;	  N-­‐(1-­‐adamantylmethyl)-­‐2-­‐
chloro-­‐5-­‐[3-­‐(3-­‐hydroxypropylamino)	  
propyl]benzamide	  
Not	  
reported	   Not	  reported	  
(Keystone	  et	  al.	  
2012a)	  
EVT-­‐401;	  2-­‐(3-­‐fluoro-­‐4-­‐
(trifluoromethyl)phenyl)-­‐N-­‐(2-­‐(1-­‐
hydroxypropan-­‐2-­‐yl)-­‐6-­‐methyl-­‐1-­‐oxo-­‐
1,2-­‐dihydroisoquinolin-­‐5-­‐yl)acetamide	  
Not	  
reported	  
Not	  reported	   (Lanthaler	  2012)	  
(Evotec-­‐AG	  2012)	  
GSK1482160;	  (2S)-­‐N-­‐[[2-­‐chloro-­‐3-­‐
(trifluoromethyl)phenyl]methyl]-­‐1-­‐
methyl-­‐5-­‐oxopyrrolidine-­‐2-­‐
carboxamide	  
0.002-­‐
0.01	  
Ethidium	  
bromide	  
uptake	  
(Abdi	  et	  al.	  2010;	  
Gao	  et	  al.	  2015;	  
Han	  et	  al.	  2017;	  Jin	  
et	  al.	  2018)	  
JNJ-­‐54175446;	  (R)-­‐(2-­‐chloro-­‐3-­‐
(trifluoromethyl)phenyl)(1-­‐(5-­‐
fluoropyrimidin-­‐2-­‐yl)-­‐4-­‐methyl-­‐1,4,6,7-­‐
tetrahydro-­‐5H-­‐[1,2,3]triazolo[4,5-­‐
c]pyridin-­‐5-­‐yl)methanone	  
Not	  
reported	  
Not	  reported	   (Alcazar-­‐Vaca	  et	  al.	  
2013)	  	  
JNJ-­‐55308942;	  (S)-­‐(3-­‐fluoro-­‐2-­‐
(trifluoromethyl)pyridin-­‐4-­‐yl)(1-­‐(5-­‐
fluoropyrimidin-­‐2-­‐yl)-­‐6-­‐methyl-­‐1,4,6,7-­‐
tetrahydro-­‐5H-­‐[1,2,3]triazolo[4,5-­‐
c]pyridin-­‐5-­‐yl)methanone	  	  
0.010	   Ca
2+	  influx	  
assay	  
(Chrovian	  et	  al.	  
2017)	  
18F-­‐JNJ-­‐64413739;	  (S)-­‐(3-­‐fluoro-­‐2-­‐
(trifluoromethyl)pyridin-­‐4-­‐yl)(6-­‐methyl-­‐
1-­‐(pyrimidin-­‐2-­‐yl)-­‐1,4,6,7-­‐tetrahydro-­‐
5H-­‐[1,2,3]triazolo[4,5-­‐c]pyridin-­‐5-­‐
yl)methanone	  
~0.001-­‐
0.012	  
Not	  reported	   (Kolb	  et	  al.	  2016)	  
Table 1.9: List of P2X7 antagonists entered in clinical trials. 
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Figure 1-17: Structures P2X7 antagonists entered in clinical trials. 
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Drug	   Clinical	  trial	  
ID	  
Phase	   Indication	   Status	  
GSK1482160	   NCT00849134	   Phase	  I	   Pain,	  Inflammatory	  
Completed:	  safe	  and	  
tolerated	  in	  25	  healthy	  
volunteers	  
CE-­‐224,535	   NCT00838058	   Phase	  I	   Rheumatoid	  Arthritis	  
Completed	  on	  11	  healthy	  
volunteers,	  no	  results	  
available	  
CE-­‐224,535	   NCT00782600	   Phase	  I	   Rheumatoid	  
Arthritis	  
Completed	  on	  16	  healthy	  
volunteers.	  Oral	  
Suspension	  Controlled	  
Release	  Formulation.	  no	  
results	  available	  
CE-­‐224,535	  +	  
methotrexate	   NCT00446784	   Phase	  I	  
Rheumatoid	  
Arthritis	  
Completed	  on	  20	  patients	  
receiving	  methotrexate:	  
no	  results	  available	  
CE-­‐224,535	   NCT00628095	   Phase	  
IIa	  
Rheumatoid	  
Arthritis	  
Completed	  on	  100	  
patients.	  (Stock	  et	  al.	  
2012)	  
CE-­‐224,535	  vs.	  	  
naproxen	   NCT00418782	   Phase	  II	   Osteoarthritis	  
Completed	  on	  212	  
patients:	  no	  results	  
available.	  
JNJ-­‐54175446	  +	  
18F-­‐JNJ-­‐64413739	   NCT03088644	   Phase	  I	   Healthy	  
Completed	  on	  16	  healthy	  
volunteers:	  no	  results	  
available	  
JNJ-­‐55308942	  +	  
18F-­‐JNJ-­‐64413739	  
NCT03437590	   Phase	  I	   Healthy	   Recruiting	  (estimated	  24	  
healthy	  participants)	  	  
AZD9056	   NCT00908934	   Phase	  I	   Healthy	  
Completed	  on	  24	  healthy	  
volunteers:	  no	  results	  
available	  
AZD9056	   NCT00700986	   Phase	  I	  
Rheumatoid	  
Arthritis.	  
Study	  
focused	  on	  
retinal	  
function	  
Completed	  on	  12	  healthy	  
volunteers:	  no	  results	  
available.	  
AZD9056	  +	  
methotrexate	   NCT00920608	   Phase	  I	  
Rheumatoid	  
Arthritis	   Withdrawn	  (12	  patients)	  
AZD9056	  +	  
simvastatin	   NCT00736606	   Phase	  I	   Healthy	  	  
Completed	  on	  12	  healthy	  
volunteers:	  no	  results	  
available.	  
AZD9056	  vs.	  
Etanercept	  
NCT00520572	   Phase	  II	   Rheumatoid	  
Arthritis	  
Completed	  on	  385	  
patients:	  etanercept	  
demonstrated	  
approximately	  double	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efficacy	  compared	  to	  
AZD9056.	  
anti-­‐nf-­‐P2X7	  
(antibody)	   NCT02587819	   Phase	  I	  
Carcinoma,	  
Basal	  Cell	  
Completed	  on	  21	  patients:	  
well	  tolerated	  with	  one	  
severe	  adverse	  effect	  
unrelated	  to	  the	  drug.	  
Reduction	  of	  cancer	  lesion	  
of	  12.86%	  in	  20	  patients.	  
Table 1.10: Clinical trials for small molecules and antibodies targeting P2X7 
receptor.
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1.5  The P2X crystal structures: a substantial 
help in homology modelling 
1.5.1 Crystal	  structures	  of	  P2X	  receptors:	  state-­‐of-­‐art	  
In 2009 the apo-form of zebrafish P2X4a receptor was the first published high-
resolution crystal structure of a member of the P2X receptor family (Kawate et al. 
2009a). Kawate et al. introduced the concept of visualizing each P2X receptor 
subunit as shaped like a dolphin in order to simplify the description of the 
subdomains (see Figure 1-18). The first structure was followed by those of 
zebrafish P2X4 in the apo- and ATP-bound states in 2012 (PDB ID: 4DW0 at 2.8Å 
and 4DW1 and 2.9Å resolution respectively) (Hattori and Gouaux 2012), shedding 
light on the mechanism of gating, the detailed 3-dimensional structure of the ATP 
binding site, and confirming the previous experimental data aimed at the 
identification of the residues lining in the ATP-binding site (Jiang et al. 2000b; 
Marquez-Klaka et al. 2007; Roberts and Evans 2004, 2006; Young 2010). The 
description of the gating and conformational changes induced by ATP-binding is 
described in more detail in Section 1.5.2 while the ATP-binding site is treated in 
Section 1.5.3.1. Although showing impaired receptor function, the crystal 
structure of a Gulf Coast tick (Ambylomma maculatum) P2X receptor solved in the 
presence of zinc and ATP, published in 2016 (PDB ID: 5F1C) permitted the first 
comparative studies among P2X receptor homologues (Kasuya, et al., 2016). 
Another important milestone was reached in the same year with the report of a 
series of human P2X3 crystal structures in the apo-, ATP-bound and antagonist-
bound forms; these structures were the first to describe the intracellular cytosolic 
cap architecture (see Section 1.5.2 for more information of the involvement of 
the cap in the receptor desensitization mechanism), and the first human P2X 
receptor structures to be solved (Mansoor et al. 2016). Most recently, further 
advancements have been achieved in our understanding of partial agonist, 
competitive antagonist and allosteric antagonist binding modes thanks to the 
publication of crystal structures of the CTP-bound form of zebrafish P2X4 (Kasuya 
et al. 2017a), giant panda P2X7 bound to a series of allosteric modulators 
(extremely important for the design of allosteric modulators using a structure-
based approach) (Karasawa and Kawate 2016), chicken P2X7 bound to the 
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competitive antagonist TNP-ATP (Kasuya et al. 2017b) and human P2X3 bound to 
the allosteric antagonist AF-219 (Wang et al. 2018). Table 1.11 lists all the P2X 
receptor structures (crystal data and NMR) published to date. 
It is important to note that the majority of the constructs used in crystal trials 
bears at least one point mutation, and that none of the crystal structures 
represents the full-length wild-type protein, all bearing some degree of truncation 
that in some cases drastically impairs receptor function (e.g. the first zebrafish 
P2X4, the Gulf Coast tick and the chicken P2X7 constructs (Kasuya et al. 2016; 
Kasuya et al. 2017b; Kawate et al. 2009b)). Notably, in other cases, including the 
zebrafish P2X4 constructs published in 2012 (used extensively for the homology 
modelling present in this work) and human P2X3, the ‘crystal constructs’ showed a 
functional profile comparable to the wild type receptor (Hattori and Gouaux 2012; 
Mansoor et al. 2016). 
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Figure 1-18: Cartoon of zebrafish P2X4 highlighting the canonical dolphin 
shape features (A) and their correspondence to the protein sequence (B). 
Each receptor subunit is formed by the subdomains such as the head, the 
flippers, the body the fluke and the dorsal fin. The ATP binding site (A, 
right) is enclosed between the left (in yellow) and the right (in red) 
flippers, the right the body (in blue) and the head (in purple) and the dorsal 
fin of the adjacent subunit (tan ribbon). 
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4DW1       36 RFTQALVIAY VIGYVCVYNK GYQDTDTVLS SVTTKVKGIA LTKTSELGER 85  
hP2X4      33 RAVQLLILAY VIGWVFVWEK GYQETDSVVS SVTTKVKGVA VTNTSKLGFR 82 
4DW1       86 IWDVADYIIP PQEDGSFFVL TNMIITTNQT QSKCAENPTP ASTCTSHRDC 135  
hP2X4      83 IWDVADYVIP AQEENSLFVM TNVILTMNQT QGLCPEIPDA TTVCKSDASC 132  
4DW1     136 KRGFNDARGD GVRTGRCVSY SASVKTCEVL SWCPLEKIVD PPNPPLLADA 185  
hP2X4    153 TAGSAGTHSN GVSTGRCVAF NGSVKTCEVA AWCPVEDDTH VPQPAFLKAA 182  
4DW1     186 ERFTVLIKNN IRYPKFNFNK RNILPNINSS YLTHCVFSRK TDPDCPIFRL 235  
hP2X4    183 ENFTLLVKNN IWYPKFNFSK RNILPNITTT YLKSCIYDAK TDPFCPIFRL 232 
4DW1     236 GDIVGEAEED FQIMAVRGGV MGVQIRWDCD LDMPQSWCVP RYTFRRLDNK 285  
hP2X4    233 GKIVENAGHS FQDMAVEGGI MGIQVNWDCN LDRAASLCLP RYSFRRLDTR 282 
4DW1     286 DPDNNVAPGY NFRFAKYYKN SDGTETRTLI KGYGIRFDVM VFGQAGKFNI 335  
hP2X4    333 DVEHNVSPGY NFRFAKYYRD LAGNEQRTLI KAYGIRFDII VFGKAGKFDI 332 
4DW1     336 IPTLLNIGAG LALLGLVNVI CDWI 359 
hP2X4    333 IPTMINIGSG LALLGMATVL CDII 356 
B 
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PDB	  ID	   Resolution	  
(A)	  
P2X	  subtype	  (Specie)	   State	  (ligand)	  
2BP5	   2.8	   P2X4	  (rat)	   n/a	  
2RUP	   *	   P2X4	  (rat)	   n/a	  
4DW0	   3.1	   P2X4	  (zebrafish)	   apo	  
4DW1	   3.46	   P2X4	  (zebrafish)	   bound	  (ATP)	  
5F1C	   2.9	   P2X	  (Gulf	  Coast	  tick)	   bound	  (ATP)	  
5SVJ	   2.98	   P2X3	  (human)	   apo	  
5SVK	   2.77	   P2X3	  (human)	   bound	  (ATP);	  open	  
5SVL	   2.9	   P2X3	  (human)	   bound	  (ATP);	  desensitised	  
5SVM	   3.09	   P2X3	  (human)	   bound	  (2-­‐methylthio-­‐ATP);	  desensitised	  
5SVP	   3.3	   P2X3	  (human)	   bound	  (2-­‐methylthio-­‐ATP);	  desensitised	  
5SVQ	   3.25	   P2X3	  (human)	   bound	  (TNP-­‐ATP)	  
5SVR	   3.13	   P2X3	  (human)	   bound	  (A-­‐317491)	  
5SVS	   4.03	   P2X3	  (human)	   apo	  
5SVT	   3.79	   P2X3	  (human)	   apo	  
5U1L	   3.4	   P2X7	  (giant	  panda)	   apo	  
5U1U	   3.6	   P2X7	  (giant	  panda)	   bound	  (A740003)	  
5U1V	   3.4	   P2X7	  (giant	  panda)	   bound	  (A804598)	  
5U1W	   3.5	   P2X7	  (giant	  panda)	   AZ10606120	  
5U1X	   3.2	   P2X7	  (giant	  panda)	   JNJ47965567	  
5U1Y	   3.3	   P2X7	  (giant	  panda)	   GW791343	  
5U2H	   3.9	   P2X7	  (giant	  panda)	   bound	  (ATP,	  A804598)	  
5WZY	   2.8	   P2X4	  (zebrafish)	   bound	  (CTP)	  
5XW6	   3.1	   P2X7	  (chicken)	   bound	  (TNP-­‐ATP)	  
5YVE	   3.4	   P2X3	  (human)	   bound	  (AF-­‐219)	  
*	  NMR	  structure	  
Table 1.11: List of P2X receptor structures published to date (September 
2018). Structures were obtained through X-ray diffraction pattern if not 
otherwise specified. * refers to structures obtained through NMR. n/a refers 
to short fragment sequences (less than 60 residues) where the canonical 
ligand binding pocket is not present. 
	   	  
Chapter 1 − Introduction 
 67 
1.5.2 Insight	   in	   the	  molecular	  mechanism	  of	   the	   receptor	  
activation	  based	  on	  crystal	  structure	  data	  
Among the available structures, the zebrafish P2X4 and human P2X3 structures are 
valuable candidates for the analysis of the conformational changes upon agonist 
and antagonist binding. By comparing the ATP-bound structure to the apo- form of 
zebrafish P2X4 it was possible to observe the tightening of the head around the 
ATP, the downward motion of the left flipper domain, the upward movement of 
the dorsal fin domain and the subsequent arching of the body domain induced by 
ATP binding (Hattori and Gouaux 2012). These movements create a 
conformational strain which is transmitted through the entire subunit, leading to 
the movement of the second transmembrane domain (TM2) relative to TM1, which 
opens the channel in a way similar to that of the iris of a camera, allowing cations 
to exchange from the extracellular lateral fenestration through the central pore 
and vice versa (Hattori and Gouaux 2012). A remarkable new advance was made 
with the solution of human P2X3 crystal structures in the open, closed and 
desensitized state (Mansoor et al. 2016). These structures give an insight into the 
presence and function of the cytoplasmic cap not captured in previous structures 
(Figure 1-19). In the crystal, both N- and C-terminus amino acids are part of the 
cytoplasmic cap with each N-terminal contributing with two consequent beta-
strands to one beta-strand of each of the C-terminal (Mansoor et al. 2016). The 
cap sits beneath the transmembrane domains and stabilizes the pore. Since it is 
only seen in the open ATP-bound structure, the hypothesis is that the cap forms a 
disordered domain in the closed state. As previously seen in zebrafish P2X4 
(Hattori and Gouaux 2012), the binding of ATP leads to closure of the head on the 
binding site and the upright movement of the dorsal fin, which transduces the 
movement to the TMs and ultimately leads to the opening of the pore. In human 
P2X3 TM2 rotates relative to TM1 and the α-helix gets stretched to a 310 helix. In 
the rotation, amino-acid residue I323 (that in the apo- state defines the inner 
pore on the extracellular side) moves outward, and a similar movement is 
mimicked by the residue defining the pore in the apo- state from the cytoplasmic 
space (T330) (Mansoor et al. 2016) (see Figure 1-19).  
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Figure 1-19: Receptor gating mechanism. Crystal structures of P2X3 in the 
ATP-bound open state (A), unbound state (B), ATP-bound desensitized state 
(C) and antagonist-bound state (D) highlighting the conformation of the 
trasmembrane helixes and the position of the residues lining the channel 
pore. A simplified cartoon represents the overall changes in receptor 
conformation. The cytoplasmic cap stabilizes the open state of the receptor 
(A). To date, the cytoplasmic cap has not been crystalized in other receptor 
conformations (dot lines). 
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1.5.3 Ligand	  binding	  pockets	  
1.5.3.1 Orthosteric	  binding	  site	  
The structural data of the ATP-bound zebrafish P2X4 obtained by Hattori et al. 
enabled the research group to identify 8 amino acids located between two 
subunits that directly interact with the physiological agonist ATP mainly through 
hydrogen bond (H-bond) interactions (Lys-70, Lys-72, Thr-189, Leu-191, Lys-193, 
Ile-232, Asn-296, Arg-298, Lys-316, see Figure 1-20A) (Hattori and Gouaux 2012). 
A sequence comparison between zfP2X4 and different receptor subtypes showed 
that the 8 aforesaid amino acids are not subtype-specific and are conserved across 
many species including rodent and human (Xu et al. 2014). ATP adopts a particular 
U-shaped conformation with the adenine moiety inserting in a narrow pocket 
within the lower body while the phosphates make contacts with a polar region in 
the upper body of the adjacent subunit. It is possible that the U-shape is favoured 
by a polar interaction between the 2’ hydroxyl of the ribose and the gamma-
phosphate. The hypothesis is supported by activity and docking studies on the 
2’deoxy ATP and 3’deoxy ATP where there is a further reduction of agonist 
activity when the hydroxyl responsible for the intra-molecular H-bond is removed 
(Fryatt et al. 2016). The adenine and the gamma phosphate are crucial for agonist 
potency and efficacy and this is supported by the observation that ADP and CTP 
are extremely weak or only partial agonists (Bowler et al. 2003; Soto et al. 1996), 
although covalent tethering of ADP to Arg-125 in P2X7 is capable of rendering ADP 
an agonist (Adriouch et al. 2008; Browne and North 2013). The partial agonist CTP 
displays a similar conformation of the 3 phosphate groups with the gamma 
phosphate interacting with the same polar residues and in close proximity to the 
2’-OH of the ribose (maybe forming a H-bond in a similar fashion to that 
hypothesized in ATP, see Figure 1-20B). As seen in Figure 1-20B, the cytosine 
moiety sits in a similar position to the adenine (although smaller) forming two H-
bonds between the N4 of the cytosine and the main chain of the Thr-189 and N4 
and Lys-70 backbone respectively. A further H-bond is formed between O2 and 
Arg-143 and the longer H-bond length might be the reason for CTP only being a 
partial agonist (Kasuya et al. 2016). 
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Figure 1-20: Binding of competitive ligands. ATP (4DW1, (A)) and CTP 
(5WZY, (B)) bound to crystal structures of zebrafish P2X4 respectively (water 
molecules shown in red). ATP (5F1C, (C)) bound to Gulf coast tick crystal 
structure. ATP (5SVK, (F)), 2-methylthio-ATP (5SVP, (E)), TNP-ATP (5SVQ, 
(G)) and A317491 (5SVR, (H)) bound to human P2X3 crystal structures. TNP-
ATP (5XW6, (D)) bound to the crystal structure of Chicken P2X7. H-bond 
interactions between ligand and receptor are displayed with blue dot lines. 
Crystal data is incomplete in the PDB file 5SVQ, (G) where the loop 
containing S275 is missing and in 5SVR (H) where K65 and S275 (labeled in 
italic) have missing atoms. Figure made with MOE2014.09 and modified from 
(Pasqualetto et al. 2018). 
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The structures of competitive antagonists have also been reported including A-
317491 and the non-selective TNP-ATP, co-crystallized in human P2X3 (Figure 
1-20H) and in both human P2X3 (hP2X3) (Figure 1-20G) and chicken P2X7 
(chP2X7) (Figure 1-20D) respectively. In both crystals the adenine moiety of the 
TNP-ATP sits in a similar conformation to the ATP while the gamma phosphate 
does not adopt the classical U-shape observed in the available ATP-bound P2X 
structures (Hattori and Gouaux 2012; Mansoor et al. 2016) (Figure 1-20D,G). 
When comparing the conformation of the tri-nitro phenyl group in hP2X3 and in 
chP2X7, their position is strikingly different with the tri-nitro phenyl pointing 
inward the pocket in the first and outward in the latter. Interestingly in the case 
of A-317491, the antagonist protrudes downwards into a hydrophobic pocket that 
is not being explored by agonists in the known structures. 
1.5.3.2 Allosteric	  sites	  
Two different research groups demonstrated the presence of a binding site for 
multiple antagonists at P2X7 (Allsopp et al. 2017; Karasawa and Kawate 2016), 
some of which were previously considered competitive (Bhattacharya et al. 2013; 
Donnelly-Roberts et al. 2009; Honore et al. 2006). An extensive mutagenesis and 
in silico analysis enabled the prediction of the allosteric binding site for 
AZ10606120 (Allsopp et al. 2017), later confirmed by structural and functional 
data of the co-crystallized ligand in the giant panda P2X7 receptor homologue 
(Karasawa and Kawate 2016) (ligands co-crystallised in the allosteric pocket are 
represented in Figure 1-21). The binding site is situated in the ectodomain 
between the head and the upper body domains of adjacent subunits and is mainly 
delimited by hydrophobic residues (Phe-95, Phe-103, Met-105, Phe-293, Tyr-295; 
panda P2X7 numbering). A charged residue (Lys-110) near the pocket entrance 
makes polar interactions with the quinolone group of A740003 and A804598 or the 
pyridine group of JNJ47965567 (Figure 1-21E,F,G). The sidechain of another 
lysine (Lys-297) further inside the pocket - fully resolved only in the structure 
bound to JNJ47965567 (shown in Figure 1-21E, residue label in bold; PDB ID: 
5U1X) - forms an H-bond with the aromatic amide of JNJ47965567. In all the other 
structures the missing atoms of Lys-297 (presents as solely backbone) do not allow 
the identification of possible H-bonds but may suggest a high degree of 
conformational flexibility for this residue side-chain. In comparison to the 
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orthosteric binding pocket, the entrance to the allosteric pocket is much narrower 
and deeper. Interestingly, the allosteric binding site extends towards and is in 
direct communication with the upper vestibule of the channel pore. Among the 
co-crystalized antagonists, JNJ47965567 is the molecule that extends the deepest 
with the phenyl-piperazinyl moiety lying almost completely in the upper vestibule 
(Figure 1-21B).  
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Figure 1-21: Allosteric antagonists bound to giant panda P2X7. (A) Top view 
of crystal structure (PDB ID: 5U1X) bound to JNJ47965567 antagonist (blue), 
ATP (in grey) was superposed as reference for comparison with the location 
of the orthosteric binding site. (B, Left) JNJ47965567 molecule protruding 
from the allosteric pocket to the upper vestibule of the channel pore as seen 
from a mid-section of 5U1X. Only one molecule of antagonist is shown for 
clarity. Approximate location of residues of the orthosteric pocket is circled 
in orange. (B, right) Schematic representation of the channel pore width 
computed and generate with MOLEonline (https://mole.upol.cz). 
Approximately 5.25 Å on the widest section of the cavity and 139.8 Å of 
cavity path-length. Colors represent increasing hydropathy of the residues 
facing the pore (from low, in yellow, to high, in blue) Crystal structure of 
panda P2X7 bound to AZ10606120 (5U1W, (C)), GW791343 (5U1Y, (D)), 
JNJ47965567 (5U1X, (E)), A740003 (5U1U, (F)) and A804598 (5U1V, (G)) and 
residues lining the allosteric pocket. Residues and ribbons colored according 
the color subunit in (A). F108 is not labelled for clarity. Figure C to G 
modified from (Pasqualetto et al. 2018). 
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Very recently, the crystal structure of human P2X3 bound to AF-219 has unveiled 
the presence of an allosteric pocket with a different location compared to the 
binding site identified by Karasawa and Kawate in the P2X7 receptor subtype 
(Wang et al. 2018). AF-219 binds in a pocket located between two adjacent 
subunits and formed by the left flipper and lower body of one subunit (light aqua 
in Figure 1-22) and the head, dorsal fin and lower body of the adjacent subunit 
(light slate, Figure 1-22). The 4-isopropyl-2-methoxybenzenesulfonamide moiety 
of AF-219 is buried deep in the site with the isopropyl group pointing inward 
where prevalently hydrophobic amino acids (Val-61, Leu-191, Val-238) are present 
while the sulphonamide group is establishing an H-bond with the sidechain of Lys-
176 (following a brief molecular dynamics simulation Wang et al. noted that the 
H-bond could be formed between Lys-176 and either of the O of the 
sulphonamide). The 2,4-diaminopiyrimidine occupies the solvent exposed portion 
of the pocket and establishes a H-bond with Asn-190. Multiple additional H-bonds 
formed between the backbone of Leu-191 were not observed in the crystal 
structure but were seen by Wang et al. after a brief (10-20 ps) molecular 
dynamics simulation (Wang et al. 2018). 
 
Figure 1-22: AF-219 allosteric antagonist bound to human P2X3. Top (A) and 
side (B) view of human P2X3 highlighting the location of the AF-219 binding 
site (AF-219 in orange). ATP (in grey) was superposed as orthosteric pocket 
reference. (C) Site view of AF-219 and nearby residues. Val-61 is not shown 
in (C). Note that an H-bond between Ser-267 backbone and N of the 
sulfonamide was recognized as interaction in MOE2014.09 during the making 
of this figure but has not been reported by Wang et al. (Wang et al. 2018). 
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Hypotheses have been advanced concerning the presence in other receptor 
subtypes of allosteric pockets corresponding to the ones identified to date 
(Karasawa and Kawate 2016), although no data is currently available to support 
this hypothesis. The confirmation of these hypotheses would be of great 
significance for the rational design of novel P2X allosteric modulators. 
1.5.4 P2X	   receptor	   structures	   as	   homology	   model	  
template	  
The recent publications of multiple crystal structures of P2X receptors has 
contributed a deep understanding of the receptor at a molecular level, although 
the human P2X3 structure is the sole human structure published to date. 
Therefore structural studies still rely heavily on homology models based on 
templates (NMR and crystal structures) available (further details regarding 
molecular modelling and homology modelling tools will be discussed in Section 
1.6 and Section 3.1). Fortunately, the sequence identity between of the human 
P2X subtypes and the crystal structures currently available is sufficient (sequence 
identity approximately 50% across subtypes and reaching even higher level of 
identity zebrafish P2X4 vs. hP2X4 and panda P2X7 and human P2X7) to allow their 
use as templates for human model generation (see Figure 1-23). It is important to 
note that none of the solved structures represents the full-length receptors and 
most of the truncations removed portions of the cytoplasmic domain, for which 
the structural data is still extremely limited, impacting unfavourably on any 
attempt at C-terminus structure prediction and validation (especially for P2X7). 
The modelling of human P2X receptor structures has been used successfully in 
previous studies to interpret functional and pharmacological data (Allsopp et al. 
2017; Evans 2010) and has also been extensively used in this work. 
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Figure 1-23: Comparison of structural data available to date in relationship 
to human P2X receptor sequences. 5XW6 and 5YVE are not included. For 
clarity purpose, sequences with over 99.5% identity were grouped together 
under a single PDB ID (e.g. 5SVL with 5SVM and 5SVP; 5SVQ with 5SVJ, 5SVK, 
5SVR, 5SVT and 5SVS; 4DW1 with 4DW0 and 3H9V; 5U1U with 5U1L, 5U1V, 
5U1W, 5U1X, 5U1Y and 5U2H). (A) Sequence identity among solved 
structures and human P2X sequences (Uniprot IDs: P51575, hP2RX1; Q9UBL9, 
hP2RX2; P56373, hP2RX3; Q99571, hP2RX4; Q93086, hP2RX5; O15547, 
hP2RX6; Q99572, hP2RX7). Sequence alignment and percentage identity 
obtained with ClustalW (values in percentage; from blue, low identity, to 
red for high identity; n/a, non-aligned). (B) Percentage coverage of human 
P2Xs sequence by crystal structures (calculated using Blastp). (C) Graphical 
representation of coverage of human P2Xs sequence by crystal structures 
showing aligned domains. Gaps are represented with white sections. 3ID5 
and 3H9V not included. 2BP5, which consists in a 10 amino acids long 
cytosolic C-terminal peptide was also not represented. Image made using 
Illustrator for Biological Sequences (IBS, http://ibs.biocuckoo.org).  Image 
modified from (Pasqualetto et al. 2018). 
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1.6  Structure-based drug design using P2X 
receptor homology models 
1.6.1 Drug	  discovery	  	  
For most of the commercialized drugs, their initial discovery dates back to several 
years before their first entry on the market with an estimated average of 14 years 
time-lapse between their identification as candidate and their official approval by 
the Food and Drug Administration (FDA) (Myers and Baker 2001).  Any discovery 
has unique features but the overall process can be generalized in two main stages 
(Figure 1-24): (i) drug discovery – leading to the identification of suitable drug 
candidates – and (ii) drug development, which involves in vivo characterization in 
terms of pharmacokinetics, toxicology and activity. The deep understanding of the 
role of the target in pathological conditions, biological pathways and the 
surrounding network of interactors is the first fundamental step to avoid drug 
development fails or market withdrawals (Wang et al. 2013). Once the target has 
been identified and validated, High Throughput Screening (HTS) biological assays 
on large compound libraries or in silico technique combined to biological 
evaluation of small-scale libraries are deployed to identify active compounds 
(‘hits’), whose activity and chemical profiles are further characterized and 
improved for the proof-of-concept and cytotoxicity evaluation. Optimized 
compounds (‘leads’) proceed to in vivo tests using animal models of disease for 
the evaluation of activity and the ADMET (Absorption, Distribution, Metabolism, 
Excretion and Toxicity) profile (Williams and Lemke 2002). Pre-clinical data must 
show a positive safety profile for the drug candidates to proceed to the clinical 
trials where the drug is initially tested in a small group of healthy volunteers to 
assess tolerability and dosage (Phase I, ‘first-in-human’). Subsequently, the 
efficacy of the drug is evaluated in patients (Phase II) further comparing the new 
drug to the others commercially available treatments focusing on patient 
outcome, compliance and severity and recurrence of adverse and side effects 
(Phase III) (Williams and Lemke 2002). The drugs that successfully pass the clinical 
trials are subjected to review and approval from the Food and Drug Administration 
(FDA) and can be commercialized. Their long-term effects on a worldwide scale 
are monitored post-approval through pharmaco-surveillance (Williams and Lemke 
2002).  
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Figure 1-24: The drug discovery and development process and stage 
requirements within the drug discovery phase (Bottom). During these stages 
compounds initially found active are regarded as ‘hits’ while compounds 
that presents improved physical- pharmacological- and chemical- properties 
are defined as ‘leads’. 
Each stage of the drug discovery and development process bears exponentially 
increasing costs that are highly aggravated by the elevated percentage of fails 
leading, in recent years, to an average of $2.5 billion in development costs per 
drug entered in the market (Plenge 2016). This, combined to a stalling trend in 
the number of approved drug per year, has urged pharmaceutical companies to 
approach the drug discovery and development process from different angles in 
order to reduce costs and increase success-rate by introducing strategies such as 
drug repositioning, phenotypic screening and computer-aided drug design 
(Ashburn and Thor 2004; Zheng et al. 2013) (Ooms 2000). 
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• Measured LogP 
and solubility 
• Active at ~10 µM 
• Cytotoxicity test 
From	  Hits	  
to	  Leads	  
• No Lipinsky rule 
infringements 
• Solubility >100 µg/
mL 
• Reduced 
cytotoxicity 
• Design of efficient 
synthetic route for 
scaling up 
• Characterization of 
chiral isomers 
• Active at <100 nM 
• SAR of 50-200 
analogues 
Lead	  
opzmizazon	  
• Characterization of 
binding kinetic  
• Crystal (or NMR) 
structure of the 
ligand-protein 
complex 
• Metabolism 
prediction 
    
FDA	  Review	   
&	  APPROVAL Clinical	  trials Pre-­‐clinical Drug	  discovery 3.5	  years 3	  years ~6	  years 
~1.5	  years ~5,000-­‐10,000	  
compounds 
~250	   
compounds 
~2-­‐5	   
compounds 
Drug	  development 
1.0
0.8
0.6
0.4
0.2
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1.6.2 Computer-­‐aided	   drug	   design:	   introducing	  molecular	  
mechanics	  and	  quantum	  mechanics	  
The introduction of computers as drug design tools backtracks to 1980s with the 
first attempts to relate compound structures to their activity and rationally 
predict the properties of molecules with similar 3-Dimensional features (Gund 
1977; Kaul 1998). Since then, computer-aided drug design has extensively risen in 
its application thanks to the exponential increase in computing power, which 
allows the handling of far more difficult tasks (Hassan Baig et al. 2016; Macalino 
et al. 2015; Song et al. 2009). While this work does not aim at describing the 
physics theories, mathematics and computer science principles on which 
computational chemistry and molecular modelling are based, a brief 
acknowledgement of some fundamentals is required. In computational chemistry, 
the description of a molecular or macromolecular system is indeed complex and 
can be studied at two different levels via Quantum Mechanics (QM) and Molecular 
Mechanics (MM) (Leach 2001; Williams and Lemke 2002). Although QM applies the 
Schrödinger’s equation and the molecular orbital theory to the modelling of the 
system being the most accurate approach available, it is extremely 
computationally demanding and therefore its use is often limited to the 
description of electron density studies or in simulations where studying chemical 
bond formation is the main goal (Leach 2001; Williams and Lemke 2002). In MM 
the molecules are seen as ball-and-spring models where atoms are usually treated 
as solid spheres and bonds are unbreakable; thus MM describes a system through 
classical mechanics via a potential energy function (namely ‘force field’), which 
represents the sum of bonded atoms interactions (e.g. bond stretching, angle 
bending and torsion rotation) and non-bonded atoms interactions (e.g. van der 
Waals and electrostatic interactions). Calculations through this potential energy 
function are less complex than Schrödinger’s equation allowing significantly lower 
computational costs – still largely the limiting factor in molecular modelling - and 
thus MM is the approach of choice in many of the techniques employed in 
computer-aided drug discovery (Leach 2001; Williams and Lemke 2002). 
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1.6.3 Virtual	  Screening	  and	  Structure	  based-­‐drug	  design	  
Nowadays, computer-aided techniques are established tools implemented in the 
drug discovery workflow - sometimes alongside or replacing the high throughput 
biological screening of large libraries. Aiming at time- and cost-effective 
identification of active compounds, virtual screenings are often performed on 
large virtual compound libraries in order to identify just a relatively small subset 
of compounds to be synthetized and biologically evaluated. This is usually 
attained by filtering a virtual library of compounds on the basis of the essential 
features that an ‘ideal compound’ specific for the target of choice should present 
(Bissantz et al. 2010). These features may be identified through a (i) ligand-based 
or (ii) structure-based approach depending on the availability of activity data of 
multiple ligands for the specific biological target to optimise ligand properties or 
on the availability of 3D structure of the target in order to enhance drug-target 
interactions, respectively (Leach 2001). Structure-based drug design relies on the 
availability of an X-ray crystal, NMR or cryo-EM structure of the biological target 
or the ligand-target complex (Leach 2001) and online databases such as the 
Protein Data Bank (PDB) give the opportunity to any researcher to access all the 
published structures (www.rcsb.org). Ideally, founding the design of active 
compounds on the study on multiple structures of the biological target in complex 
with diverse ligands gives the best chances of success but this is a rather rare 
situation. In most cases - where available - the structure is truncated, missing an 
important portion of the target, in the apo- state or is a homologue from a 
phylogenetically distant species, thus homology-modelling techniques are widely 
used (França 2015) for further applications such as docking simulations, molecular 
dynamics and target-based pharmacophore searches. A brief description of the 
homology modelling process is described in Section 3.1. 
1.6.4 Docking	  	  
Docking simulations are one of the most widely used computational tools in 
structure-based modelling, aiming to evaluate the ‘fit’ of a set of molecular 
conformations (derived from a compound library or a single molecule) in a protein 
cavity by estimating favourable protein-ligand interactions and steric hindrance. 
The method relies entirely on the availability of structural data of the target, 
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whether a crystal or NMR structure is available or a reliable homology model could 
be obtained from a closely related protein structure. The less complex docking 
scenario accounts only for the flexibility of the ligand - interacting with non-
covalent bonds - while the protein is treated as a rigid body, which is an 
approximation that needs to be carefully evaluated case by case (more complex 
scenarios that calculate protein flexibility are possible but not herein described). 
In general, every docking simulation is the result of the symbiotic combination of 
a (i) ‘searching algorithm’ and a (ii) ‘scoring function’. While the first is 
responsible for generating multiple ligand poses within the pocket (sampling) 
accounting for molecule rotations, translations, angle bending and torsions, the 
latter evaluates plausible poses and ranks them according to a non-exhaustive 
estimation of binding free energy value (therefore designated as ‘score’ instead) – 
an approximation that is due to the otherwise non-feasible and computationally 
demanding calculations (Trist et al. 2018). The searching algorithms are based on 
either stochastic (randomised) or systematic methods for the pose sampling whilst 
scoring functions can approximate binding energies through interaction 
predictions based on molecular mechanics, estimates based on experimental 
measurements of binding phenomena or from calculations derived from 
crystallographic data (Ferreira et al. 2015; Kitchen et al. 2004). To keep in mind 
as take-away message, the number of parameters considered within the ‘score’ 
calculations is directly correlated to the ameliorated accuracy but also to the 
time required to assign the ‘score’ to each sampled pose. This concept is 
particularly important when performing docking of large libraries of compounds – 
for instance as part of structure-based virtual screenings - where accuracy and 
speed needs to be finely balanced (Lyne 2002). One approach to speed up the 
process whilst maintaining good accuracy in final pose selection and ranking is 
based on multiple rounds of docking – each with increasing accuracy in the scoring 
function - where poorly scored poses are filtered out at the end of each round, 
effectively and drastically reducing the number of poses carried onward to the 
next round. This is, for instance, the method used by the automated Maestro 
Virtual screening workflow (Small-Molecule Drug Discovery Suite, Schrödinger, 
LLC, New York, NY) in combination with physico-chemical drug-likeness filters 
(i.e. predicted octanol/water repartition, reactivity, etc.). Another approach is 
the consensus score where the top-ranked poses obtained through a docking 
scoring function are rescored through diverse scoring functions and the final 
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selection falls on the poses that top-scored with each of the scoring functions 
(Charifson et al. 1999). Although scoring functions and in general all the 
computer-aided techniques are extremely helpful tools in the identification of 
drug candidates, researcher intervention and judgement still has a pivotal role in 
each step of the drug discovery process. 
1.6.5 Examples	  of	  drugs	  designed	  using	  in	  silico	  techniques	  	  
Ultimately, the effectiveness of a methodology needs to be supported by 
experimental data. There are numerous recent examples of successful 
identification of drug candidates through computer-aided drug design, among 
whose the discovery of potent carbonic anhydrase II inhibitors (using FlexX) 
(Grüneberg et al. 2001), the discovery and ligands targeting Factor Xa, Thrombin 
and Estrogen receptor (Baxter et al. 2000) and the development of 
farnesyltransferase inhibitors into ‘lead’ compounds (Perola et al. 2000). Most 
importantly, drugs already successfully approved by FDA such as Imatinib - initially 
known as CGP 57148 and STI571 - (now Glivec®, by Novartis) and indicated for 
chronic myeloid leukemia and Gefitinib (Iressa®, by AstraZeneca) for non-small 
cell lung cancer therapy have been some of the first to be developed through a 
rational and computational approach (Hickey et al. 1994; Traxler and Furet 1999; 
Ward et al. 1994). These examples indicate that using a rational design approach 
and computer-aided techniques can notably help in the discovery of active 
candidates and could improve the success rate while reducing time and costs 
related to the high throughput biological screening methods. Computer-aided drug 
design is a particularly relevant strategy in an academic setting where funds, time 
and ‘workforce’ involved in a project may be substantially reduced compared to 
industry. 
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1.7  Aims and objectives of the project 
The importance of developing novel compounds active at P2X4 and P2X7 receptors 
is underlined by their roles in control of vascular tone, neurotransmission, 
neuropathic pain, cancer, immunity and inflammation.  
Furthermore, the recently published structural data has given a very valuable 
opportunity for the use of structure-based drug design in an attempt to find hit 
compounds. This project aims: 
(i) to identify and develop novel P2X4 and P2X7 receptors small-molecule 
modulators with the assistance of structure-aided drug design; 
(ii) to understand the molecular basis for modulator selectivity at P2X4 and 
P2X7, using a combination of molecular docking and analysis of inter-
species and -subtype differences in pharmacology and selectivity. 
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Chapter	  2:	  
Materials	  and	  Methods	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2 MATERIALS AND METHODS 
2.1  Materials 
All chemicals and reagents were obtained from Sigma-Aldrich (Sigma-Aldrich 
Corporation, Dorset, UK), unless otherwise specified. Phosphate Saline Buffer 
(PBS, #10010023), Foetal bovine serum (FBS; #10270106), penicillin-streptomycin 
(10,000 U/mL; #15140122), trypsin-EDTA (0.05%) with phenol red (#2500062), 
Dulbecco’s modified Eagle’s medium (DMEM/F-12) with Glutamax (cat. No. 
#31331093), G-418 (Geneticin®; #10131027) and DMSO (#BP231-100) were 
purchased from Fisher Scientific (Fisher Scientific UK, Loughborough, UK). Cell 
culture flasks, 6-wells plates and 96-wells plates were obtained from Sarstedt 
(Sarstedt AG & Co. KG, Germany). 
2.2  Cell culture and protein expression 
2.2.1 Cell	  culture	  and	  preparation	  of	  frozen	  stocks	  
HEK293 and 1321N1 astrocytoma cells were pre-owned by Dr Mark Young’s lab and 
originally purchased from the European Collection of Authenticated Cell Cultures 
(ECACC, Salisbury, UK; catalogue no. #85120602 and #86030402, respectively). All 
cell lines were cultured (at 37°C, 5% CO2) in DMEM/F-12 with Glutamax 
supplemented with 10% FBS and 200 unit/mL of penicillin-streptomycin 
antibiotics. Stably transfected clones were grown in DMEM/F-12 with Glutamax 
medium supplemented with G-418, 600 µg/ml and 150 µg/ml during selection and 
maintenance respectively. Stable cells line expressing N-terminally Halo-tagged 
mouse P2X7 (Met-283 variant) receptor (HNFL2 cell line; see Appendix 3) were 
kindly provided by Dr Marta Radwan. Frozen stocks for each stable cell line were 
prepared by gently resuspending (pelleted at 1200 rpm, 4 min, room temperature) 
with ice cold 10% DMSO in FBS and quickly transferring 1mL of the suspension in 
cryo-vials to be stored long-term in liquid nitrogen (3x and 5x 1mL aliquots were 
prepared from a confluent 75 cm2 and 175 cm2 flask respectively). 
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2.2.2 Transient	  transfection	  and	  stable	  cell	  line	  generation	  
Cells were seeded in 6-well plates (at 5x105-1x106 cells/well) and transfected the 
following day with 1 µg plasmid DNA (see Table 2.1)	  and FuGene HD Transfection 
Reagent (Promega, Southampton, UK; #E2311) using a 1:3 (µg:µl) DNA:Fugene HD 
ratio, according to the manufacturer’s protocol (https://www.promega.co.uk).  
For transient transfection, subsequent analysis was performed on cells 24-72 hours 
post-transfection, as indicated. For stable cell line generation, sufficient time (30-
48h) was given to permit the development of antibiotic resistance before starting 
single colony selection, by plating transfected cells into 96-wells plates (10-100 
cells/well) with culture medium containing 600 µg/mL G418. Colony growth was 
monitored for 4-6 weeks and resistant single colonies were grown up via 24-well 
plates to confluent 25 cm2 flasks (or 2x9 cm2 wells). Each clone was tested for 
P2X4 receptor expression by Western blot and clones, which displayed receptor 
expression, were assessed for functionality using the Ca2+ influx assay (Section 
2.3.1 and Appendix 1). P2X7 stable cell line generation followed the same 
procedure but functionality was tested using the YO-PRO dye uptake assay 
(Section 2.3.2 and Appendix 3). 
Species	   Receptor	   Plasmid	  name	  
rat	   P2X4	   RML2	  (a	  kind	  gift	  from	  Prof	  Murrell-­‐Legnado)	  (Royle	  et	  al.	  2005)	  
rat	   P2X4	   RML2	  T312I	  (MTY)	  
human	   P2X4	   pL118,	  I312T	  (MTY)	  
human	   P2X4	   pL118,	  	  (MTY)	  
human	   P2X7	   hP2X7	  (EE-­‐tagged);	  (MTY)	  midi	  prep;	  28/11/13	  
Table 2.1: List of constructs used in the transfection protocol. All the 
constructs were prepared with Qiagen mini- or midi-prep. The concentration 
was measured with a Nanodrop spectrophotometer (Thermo Scientific) at 
260 nm. Constructs were provided by Dr Mark Young (MTY) unless otherwise 
specified. 
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2.2.3 Bradford	  protein	  assay	  	  
A series of BSA (Fraction V; Fisher Scientific; #BP1600-100) standards and each 
protein lysate sample were prepared in half-micro cuvettes (Fisher Scientific) (as 
reported in Table 2.2)	  and their absorbance (595 nm, n=2-3) was measured with a 
Biorad SmartSpec Plus spectrophotometer. The standard curve built with the 
known concentrations of the BSA (ranging between 0.5 µg/mL and 6 µg/mL) was 
used to approximate the overall protein concentration of each sample. 
Component	   Blank	   0.5	  μg/mL	  standard	  
1	  μg/mL	  
standard	  
2	  μg/mL	  
standard	  
4	  μg/mL	  
standard	  
6	  μg/mL	  
standard	   Sample	  
1x	  Protein	  
Assay	  
Reagent	  
980	  μL	   980	  μL	   980	  μL	   980	  μL	   980	  μL	   980	  μL	   980	  μL	  
PBS	   20	  μL	   19	  μL	   18	  μL	   16	  μL	   12	  μL	   8	  μL	   18	  μL	  
BSA	  (1	  
mg/mL)	   -­‐	   1	  μL	   2	  μL	   4	  μL	   8	  μL	   12	  μL	   -­‐	  
Protein	  
lysate	  
-­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   2	  μL	  
Table 2.2: Details of sample and standards preparation for Bradford assay. 
1x Protein Assay reagent was prepared by diluting Bio-Rad concentrated 
Protein Assay reagent (1:5 in distilled water). 
2.2.4 Cell	  lysis,	  SDS-­‐PAGE	  and	  Western	  blotting	  
2.2.4.1 Cell lysis and loading sample preparation  
Cells in individual wells from a 6-well plate were washed with 1 mL ice-cold PBS 
buffer then transferred to a 1.5 mL tube, either by pipetting up and down or using 
a cell scraper, and centrifuged at 4000x g for 3 minutes at room temperature. Cell 
pellets were resuspended in 100 μL of lysis buffer (see Table 2.3) and incubated 
on ice for 20 min with occasional gentle mixing. The supernatant containing 
solubilized protein was separated from cell debris by centrifugation (5 min at 4°C, 
16000x g) and the overall protein concentration of the supernatant was assessed 
by Bradford assay (Section 2.2.3). 80μL of protein lysate was mixed with 20 μL 
SDS-PAGE sample buffer (see Table 2.3) and denatured at 95°C for 5 min. 
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Buffer	   Components	  and	  final	  concentration	  
Lysis	  buffer	  (modified	  Schindler	  
buffer)	  
150	  mM	  NaCl	  
50	  mM	  HEPES	  pH	  7.5	  
10%	  glycerol	  
1	  mM	  EDTA	  
1	  mM	  DTT*	  
1%	  DDM*	  
1x	  Protease	  inhibitors*	  (Complete	  –EDTA,	  Roche)	  
SDS-­‐PAGE	  sample	  	  
buffer	  (5x)	  
12%	  (w/v)	  SDS	  
10mM	  EDTA	  
10%	  (v/v)	  Glycerol	  
100	  mM	  Tris-­‐HCl,	  ph	  6.8	  
0.05%	  (w/v)	  Bromophenol	  Blue	  
50	  mM	  TCEP	  
NaOH	  to	  pH	  6.8	  
Table 2.3: Buffers and gel compositions for the cell lysis and the sample 
preparation. *added fresh every time. 
 Gel electrophoresis 2.2.4.2
Either 10% or 12% polyacrylamide gels were prepared according to Table 2.4, 
allowing time for polymerisation of the separating gel before pouring the stacking 
gel (4.5% polyacrylamide). An equal quantity of each protein sample (3.5-10 μg) 
prepared as described above was loaded (alongside 4-5 μL of Precision Plus 
Protein Standard marker, BioJRad®, Hemel Hemstead) and gels were run in 1x 
TGS running buffer (Table 2.4) for 10min at 100 V (to allow the proteins to align 
at the bottom of the stacking gel) followed by 1 hour at 120 V. 
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SDS-­‐Page	  electrophoresis	  
Polyacrylamide	  gel	   Component	   Volume	  to	  add	  (mL)	  
Stacking	  gel	  (5	  mL)	  
H20	   3.5	  
1	  M	  Tris-­‐HCl	  pH	  6.8	   0.625	  
30%/0.8%	  Acrylamide/Bis-­‐acrylamide	  (w/v)	   0.75	  
20%	  SDS	  (w/v)	   0.025	  
30%	  APS	  	  ammonium	  persulfate	  (w/v)	   0.015	  
TEMED	   0.0040	  
10%	  polyacrylamide	  
Separating	  gel	  (10	  
mL)	  
H20	   4.1	  
1.5	  M	  Tris-­‐HCl	  pH	  8.8	   2.5	  
30%/0.8%	  Acrylamide/Bis-­‐acrylamide	  (w/v)	   3.4	  
20%	  SDS	  (w/v)	   0.050	  
30%	  APS	  	  ammonium	  persulfate	  (w/v)	   0.035	  
TEMED	   0.010	  
12%	  polyacrylamide	  
Separating	  gel	  (10	  
mL)	  
H20	   3.5	  
1.5	  M	  Tris-­‐HCl	  pH	  8.8	   2.5	  
30%/0.8%	  Acrylamide/Bis-­‐acrylamide	  (w/v)	   4.0	  
20%	  SDS	  (w/v)	   0.050	  
30%	  APS	  	  ammonium	  persulfate	  (w/v)	   0.035	  
TEMED	   0.010	  
Buffer	   Component	  and	  final	  concentration	   Quantity	  to	  add	  (g)	  
1x	  Running	  buffer	  (1	  
L)	  
25	  mM	  Tris-­‐HCl	   3.0	  
192	  mM	  Glycine	   14.4	  
0.1%	  SDS	  (w/v)	   1.0	  
Table 2.4: SDS-Page buffers and gel composition. 
 Blotting and protein detection  2.2.4.3
A Trans-blot Turbo Transfer system (Biorad Laboratories, Hercules, CA, USA) was 
used to transfer (7 min) the size-separated proteins from the polyacrylamide gel 
to PVDF membrane (Biorad), according to manufacturer’s instructions. The 
membrane was briefly rinsed in TBS-T buffer (Table 2.5), blocked on a rocking 
platform with 5% skimmed milk powder (in 20 mL TBS-T, at room temperature, 1 
hour) and then washed in TBS-T (3x5 min, room temperature) before overnight 
incubation (4°C) with the specific primary antibody solution on a rocking platform 
(see Table 2.5). Excess primary antibody was removed by repeated washing (TBS-
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T, 3x15 min, room temperature) before application of the secondary antibody 
solution under gentle shaking (in 20 mL TBS-T, at room temperature, 1 hour). The 
membrane was sequentially washed (TBS-T, 3x20 min, room temperature) and 
finally developed with 1.5 mL of ECL solution (Biorad; or LI-COR, Cambridge) using 
a Biorad ChemiDoc XRS chemiluminescence detector. 
Blotting,	  membrane	  blocking	  and	  incubation	   	  
Buffer	   Component	   	  
1x	  TBS-­‐T	  
buffer	  
25	  mM	  Tris/HCl	  pH	  7.4	   	  
150	  mM	  NaCl	   	  
0.02	  %	  Tween	  20	   	  
Antibody	   Concentration	   Host	   Specificity	   Supplier	   Cat.	  No.	  
Anti-­‐P2X4	  
1:2000	  in	  5%	  milk,	  TBS-­‐T	  
(from	  0.8	  mg/ml	  stock,	  
after	  reconstitution)	  
Rb	   H,	  M,	  R	  
Alomone	  
(Jerusalem,	  
Israel)	  
#APR-­‐002	  
Anti-­‐P2X7	  
1:2000	  in	  5%	  milk,	  TBS-­‐T	  
(from	  0.6	  mg/ml	  stock,	  
after	  reconstitution)	  
Rb	   H,	  M,	  R	   Alomone	   #APR-­‐004	  
Anti-­‐rabbit	  
HRPb	  
1:2000	  in	  5%	  milk,	  TBS-­‐T	  
(from	  0.25g/L	  stock)	   G	   Rb	  
Dako	  (Glostrup,	  
Denmark)	   #P0448	  
Anti-­‐
mouse	  
HRPb	  
1:5000	  in	  5%	  BSA,	  TBS-­‐T	  
(from	  0.25g/L	  stock)	  
Rb	   M	   Dako	   #P0260	  
a	  H:	  human	  (Homo	  sapiens);	  M:	  mouse	  (Mus	  musculus);	  R:	  rat	  (Rattus	  norvegicus);	  G:	  goat	  
(Capra	  aegagrus	  hircus);	  Rb:	  rabbit.	  
b	  HRP:	  Horseradish	  Peroxidase	  
Table 2.5: Buffer composition used for washing, blocking and incubation and 
list of antibodies and their optimum concentration. 
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2.3  FUNCTIONAL ASSAYS 
2.3.1 FLUO-­‐4	  fluorescent	  Ca2+	  influx	  assay	  	  
Cells were plated the day before assay into poly-Lysine (35 µL poly-Lysine 
incubation for 20 min followed by PBS wash) pre-treated 96-well plate at 40-
65,000 cells/ml concentration. Culture medium was replaced with modified 
Ringer’s buffer (140 mM NaCl, 10 mM HEPES, 10 mM Glucose, 1 mM MgCl2, 1 mM 
CaCl2, 2.5 mM KCl, 0.5% BSA, pH=7.4) containing 2.6 µM FLUO4-AM (Fisher 
Scientific, UK; #F14201) and 250 μM Probenecid (#P8761), cells were incubated for 
20-30 min and buffer was replaced with fresh Ringer’s buffer (containing 500 µM 
Probenecid). For compound testing, 1 μL of compound dissolved in a compatible 
vehicle was diluted 1:100 in modified Ringer’s buffer prior to addition of 1:10 
volume of the total well buffer volume (1% or 0.1% final concentration of ethanol 
or DMSO respectively). Appropriate vehicle controls were used in each experiment 
accordingly. Before the assay optimization, experiments to identify functional 
clones were conducted using extracellular solution (ECS; 147 mM NaCl, 10 mM 
HEPES, 13 mM Glucose, 1 mM MgCl2, 2 mM CaCl2, 2 mM KCl. pH=7.3 in MilliQ 
water) containing 2.6 μM FLUO4-AM. A Fluoroskan Ascent FL plate reader (Fisher 
Scientific) equipped with a solution dispenser and an appropriate filter pair 
(excitation: 485 nm, emission: 538 nm) was used to record 5 sec baseline followed 
by P2X4-mediated Ca2+ influx measurements for 20-25 sec after ATP (Sigma, 
#A26209) stimulation (20 μL injection).  The collected responses were normalized 
to the first data-point recorded after ATP injection. The amplitude of ATP 
responses was calculated as ΔF/F0, where ΔF = F1−F0, subtracting the fluorescent 
background as suggested by Bootman et al. (Bootman et al. 2013).	  
2.3.2 YO-­‐PRO	  fluorescent	  dye	  uptake	  assay	  
Cells were plated the day before assay in a 96-well plate at 35-45,000 cells/mL 
concentration (n=3-6). Culture medium was replaced with low divalent cation-
containing extracellular solution (ECS-LD; 147 mM NaCl, 10 mM HEPES, 13 mM 
Glucose, 0.2 mM CaCl2, 2 mM KCl. pH=7.4 in MilliQ water) - to reduce the 
inhibition caused by divalent cations at P2X7 (Young et al. 2007) – and containing 
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5 µM YO-PRO1 (Fisher Scientific, UK; #Y3603) . A Fluostar Optima plate reader 
(BMG Labtech, Ortenberg, Germany) was used for the fluorescence recording 
(filter pair: excitation 485 nm, emission 538 nM). The baseline was measured for 
10-12 cycles, followed by manual addition of ATP (1 µL) and a further 120 cycles 
recording. For recording and data analysis, only wells with cells that were initially 
impermeable to YO-PRO1 or did not present a de-touched layer of cells were 
selected. The initial gradient of the dye uptake curve was used to calculate the 
response to ATP.  
2.3.3 Electrophysiology	  
Dr Mark Young conducted part of the electrophysiology experiments. Briefly, 
whole-cell patch-clamp traces were recorded at room temperature using patch 
pipettes pulled from borosilicate glass (World Precision Instruments, Sarasota, FL, 
USA). Pipettes were filled with internal solution (IS) containing (in mM): 145 NaCl, 
10 EGTA and 10 HEPES, with the pH adjusted to 7.3 with NaOH and had 
resistances of 3–5 MΩ. Cells were constantly perfused in a bath with extracellular 
solution contained low concentration of divalent cations (ECS-LD, see Section 
2.3.2 for composition). Currents were recorded at a holding membrane potential 
of −60 mV using an Axon Instruments Axopatch Multiclamp 700A amplifier and 
Digidata 1322A A/D interface (Molecular Devices, Sunnyvale, CA, USA). ATP 
working solutions were prepared fresh and solutions with compounds had a final 
concentration of DMSO equal or lower than 0.1% (0.1% DMSO was included as 
vehicle control). ATP applications were made at 90-s intervals. Solutions were 
applied to patch-clamped cells with the help of a rapid perfusion system (RSC-
160, Biologic, Claix, France), allowing solution exchange times in the range 20–100 
ms. 
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2.3.4 Data	  processing	  and	  statistical	  analysis	  
 General expression in the figures (mean +/- SEM), 2.3.4.1
ANOVA and other tests used 
Data processing and data analysis were carried out with Microsoft Excel (2011) and 
Graphpad Prism version 6 for Mac (GraphPad Software, La Jolla California USA, 
www.graphpad.com), employing the latter for any bioassay data plotting. Figures 
are presented as Mean ± SEM (unless otherwise specified). In figures plotting data 
obtained through Ca2+ influx assay ‘Responses’ are expressed as (Formula 1): 
Formula 1: 
ΔF/F0  
Where: 
ΔF = F1−F0 
F0= Fluorescence intensity measured ~1 s after addition of ATP (or vehicle) 
F1= Maximal fluorescence intensity measured withing a 20 s time-window after 
addition of ATP (or vehicle) 
While responses obtained from YO-PRO assay represent the rate of fluorescence 
intensity increase and calculated as gradient (Formula 2): 
Formula 2: 
ΔF/Δt  
Where: 
ΔF = F1−F0 
F0= Fluorescence intensity measured at time 0 after addition of agonist (or 
vehicle) 
F1= Maximal fluorescence intensity measured after 10 cycles of recordings from 
when the addition of agonist (or vehicle) was made 
Δt = t1−t0 
t0= time of the first fluorescence recording after addition of agonist (or vehicle) 
t1= time after 10 cycles of recordings  
Statistical significance of any difference observed between samples was 
calculated through one-way ANOVA followed by Dunnett’s multiple comparisons 
test with a single pooled variance (control, unless otherwise specified) or, when 
Chapter 6 – Materials and Methods 
 94 
comparing only two sets of data, using an unpaired t test with Welch’s correction. 
When comparing data obtained from multiple independent experiments (N), each 
dataset was normalised to the mean value obtained for the vehicle control. The 
mean value was calculated also each sample (average of technical repeats, n) and 
then merged. Statistical analysis was conducted on the merged data constituted 
by N mean values. This applied also to the calculation of the EC50 and IC50 values 
and the following statistical analysis. 
 Calculation of the standard curve (Bradford 2.3.4.2
assay) and concentration of samples 
A standard curve was calculated using known concentrations of BSA standards 
plotting Concentration (mg/mL) vs. Absorbance at 595 nm and fitting the date 
using a linear regression plot (Y = mX + q; where ‘Y’ is the absorbance measured 
for the standard, ‘X’ is the known concentration of the standard, ‘m’ is the slope 
and ‘q’ the intercept on Y axis). Concentration of unknown samples was estimated 
applying the following equation (Formula 3):  
Formula 3: 
X = (Y - q)/m 
Where:  
X = unknown concentration of the sample 
Y = absorbance measured for the sample 
m = slope  
q = intercept on Y axis 
 
 Calculation of curve-fit (EC50, IC50, etc.) 2.3.4.3
A non linear regression (curve fit) with four parameters (constraints to Bottom=0 
and Top=100 where applied when considering ATP concentration-response curves) 
was applied to determine any dose-response correlation and the presence of any 
inhibition trend during the compound testing (Formula 4) (curve-fit constraints 
were applied to normalized data). The ATP EC20 and EC80 were calculated applying 
Formula 5. 
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Formula 4: 
Y = Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*Hill Slope)) 
Where: 
X: agonist (or antagonist) concentrations expressed as logarithmic scale. 
Y: response measurements (raw or normalized value) 
 
This formula was also used for inhibition curve fitting by substituting the value of 
EC50 with IC50. 
Formula 5: 
LogEC50 = logECF — (1/HillSlope)*log(F/(100-F)) 
Where: 
X: agonist (or antagonist) concentrations expressed as logarithmic scale. 
Y: response measurements (raw or normalized value) 
EC50: agonist concentration corresponding to the 50% of the total response. 
IC50: antagonist concentration corresponding to the 50% of inhibition of the total 
response 
Top and Bottom are defined as plateau values (in Y axis units). 
HillSlope: steepness of the curve. 
F: fraction of EC50 value to be calculated (to give EC20 or EC80) 
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2.4  MUTAGENESIS 
2.4.1 Site-­‐directed	  mutagenesis	  
 Mutagenesis and transformation of DH5α Mix&Go 2.4.1.1
competent cells 
Dr Mark Young generated the mutated plasmids containing rat P2X4 T312I and 
human P2X4 I312I. Briefly, after primer design (QuikChange Primer Design tool, 
http://www.genomics. agilent.com/primerDesignProgram.jsp) the two-step 
QuikChange site-directed mutagenesis method was applied by amplifying the 
desired templates with QuikChange Lightning Kit DNA polymerase (Agilent 
Technologies, Santa Clara, CA; #210518 or #210519) in 50 µL reactions (Table 2.6 
and Table 2.7 report details of the PCR reactions and the designed primers 
respectively). The thermal cycler was programmed as follows: initial denaturation 
at 95°C for 2 min; 18 cycles at 95°C for 20 s, 60°C for 10 s and 68°C for 3 min 30 
s; final extension at 68°C for 5 min. The unmutated (methylated) original 
templates were digested with 2 µL DpnI (5 min at 37°C, enzyme from QuikChange 
Lightning Kit; or 1 hour at 37°C, enzyme from NEB) and 2-3 µL of the PCR products 
were transformed into 50 µL aliquots of XL10 Gold ultracompetent cells according 
to the manufacturer’s protocol (Agilent Technologies, Santa Clara, CA; cells 
provided as part of the QuikChange Kit). Briefly; competent cells were thawed on 
ice, DNA was added and mixed gently, followed by heat shock for 30 seconds at 
42°C, the addition of 250 µL SOC medium (NEB; #B9020S) and outgrowth for 1h at 
37°C with shaking at 250 rpm to permit development of antibiotic resistance 
(required for kanamycin). 200 µl of cell suspension was plated onto sterile 
Lysogeny Broth (LB) Agar plates (Formedium, UK; #LMM0202) containing 50 µg/mL 
kanamycin (Formedium, UK) (or 100 µg/mL ampicillin in the case of pL118) and 
incubated overnight, 37°C to permit growth of colonies. 
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Step	  1:	  Point	  mutation	  
Reaction	  Component	   Qty	  for	  50	  μL	  reaction	   Final	  Concentration	  
10X	  	  QuikChange	  Reaction	  
Buffer	   5	  μL	   1X	  
10	  mM	  dNTPs	   1	  μL	   200	  μM	  
10	  μM	  forward	  primer	   2.5	  μL	   0.5	  μM	  
10	  μM	  reverse	  primer	   2.5	  μL	   0.5	  μM	  
50	  ng/μL	  DNA	  template	   1	  μL	   1	  ng/μL	  
QuikSolution	  Reagent	   1.5	  μL	   1X	  
Nuclease-­‐free	  water	   to	  50	  μL	   -­‐	  
QuikChange	  Lighting	  
Enzyme	  OR	  Phusion	  High-­‐
Fidelity	  DNA	  Polymerase	  
1	  μL	   1.0	  unit/reaction	  (OR	  2.0	  unit/reaction)	  
Polymerase	  used	   Thermal	  cycler	  program	   DNA	  Template	  	  
QuikChange	  Lighting	  
Enzyme	  
95°C	  for	  2	  min;	  95°C	  for	  20	  s,	  60°C	  
for	  10	  s	  and	  68°C	  for	  3	  min	  30	  s	  
(18	  cycles);	  final	  extension	  at	  
68°C,	  5	  min	  
RML2,	  pL118	  
Step	  2:	  DpnI	  digestion	  
Enzyme	  used	   Incubation	  	   Qty	  in	  	  50	  μL	   Supplier	  
DpnI	  QuikChange	  Lighting	  
Enzyme	   5	  min	  at	  37°C	   2	  μL	  
Agilent	  
Technologies,	  
Santa	  Clara,	  CA	  
Table 2.6: QuikChange Lightning Site-directed mutagenesis reaction 
conditions. 
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Template	   Desired	  Mutation	   Primer	  sequence	   Supplier	  
RML2	   T312I	   5’-­‐cagcgcacactcatcaaggcgtacggc	  	  -­‐3’	  
IDT	  (Integrated	  DNA	  
Technologies,	  Inc.,	  
Coralville,	  Iowa)	  
RML2	   T312I	   5’-­‐gccgtacgccttgatgagtgtgcgctg	  	  -­‐3’	  
IDT	  (Integrated	  DNA	  
Technologies,	  Inc.,	  
Coralville,	  Iowa)	  
pL118	   I312T	   5’-­‐cagcgcacgctcaccaaggcctatggc	  -­‐3’	  
IDT	  (Integrated	  DNA	  
Technologies,	  Inc.,	  
Coralville,	  Iowa)	  
pL118	   I312T	   5’-­‐gccataggccttggtgagcgtgcgctg	  	  -­‐3’	  
IDT	  (Integrated	  DNA	  
Technologies,	  Inc.,	  
Coralville,	  Iowa)	  
Table 2.7: Specifications of primers used for site-directed mutagenesis 
reactions 
 Isolation and verification of mutant DNA 2.4.1.2
constructs 
From each transformation, 2-3 single colonies of E. coli were grown overnight 
(37°C) in 5 mL LB medium (Formedium; #LMM0102) with 50 µg/mL kanamycin (for 
RLM2-derived plasmids, or 100 µg/mL ampicillin in the case of the pL118), and 
DNA was purified using the QIAprep® Spin Miniprep Kit (Qiagen, Duesseldorf, 
Germany) according to manufacturer’s instructions, and quantified using a 
Nanodrop spectrophotometer, 260 nm (Thermo Scientific TM, Life Technologies). 
A diagnostic enzymatic double-digestion was used to identify constructs 
corresponding to the correct band sizes (vector backbone and insert) by 
incubating (1h at 37°C) 1 µL of each enzyme (NEB, see Table 2.6), 6 µL H20, 1 µL 
DNA and 1 µL enzyme compatible buffer. After mixing the restriction digest with 2 
µl 6x Purple Gel Loading Dye (NEB), each sample was loaded in a 1% agarose gel 
along with 5 µL of 1 kb DNA ladder (New England Biolabs, Ipswich, MA), and run 
for 1hr in 1x TAE (40 mM Tris, pH 7.6, 20 mM acetic acid, 1 mM EDTA). Gel images 
were recorded using GelDocJItTM Imaging System (UVP, CA) and the selected 
mutants were DNA sequenced to confirm the presence of the desired mutation 
(MWG Eurofins). 
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2.4.2 Genomic	  DNA	  Purification	  
Approx. 6-7 x 106 of mammalian cells, washed and pelleted in a 1.5 mL tube, were 
re-suspended in 120 µL ice-cold PBS, 3 parts (v/v) of deionized water and 1 part 
(v/v) ice-cold sucrose buffer (1.28 M Sucrose, 40 mM Tris-HCl, pH 7.5, 20 mM 
MgCl2, 4% Triton X-100). After 10 min incubation on ice, the suspension was 
centrifuged (1300 x g, 15-20 min at 4°C) and pellets (cell nuclei) were washed in 
sucrose buffer diluted 1:4 in deionized water to remove any remaining cell debris. 
Nuclei were thoroughly resuspended in 450µL of H-bond disrupting buffer (800 mM 
guanidine HCl, 30 mM Tris-HCl, 30 mM EDTA, pH 8.0, 5% Tween-20, 5% Triton-100, 
100 µg/ml RNAse) and 5 µL of Proteinase K (20mg/mL); this solution was then 
neutralized with 0.1 volumes (v/v) of 3M sodium Acetate (pH 5.2). To precipitate 
DNA, 0.7 volumes (v/v) of ≥98% isopropanol was added, the solution was 
centrifuged (13300 rpm for 15 min at 4°C), the precipitate washed (1-1.5 mL ≥98% 
ethanol, 13300 rpm for 15 min at 4°C), air-dried for 2-3 min and, finally, the 
purified DNA was solubilized in 30-50 µL TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM 
EDTA).  
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2.5  MOLECULAR MODELLING AND COMPUTER-
AIDED DRUG DESIGN 
In silico simulations were performed on a MAC pro 2.80 GHz Quad-core Intel Xeon 
running Ubuntu 12.04 LTS. Graphical representations of molecular structures were 
generated using UCSF Chimera package (http://www.rbvi.ucsf.edu/chimera) 
(Pettersen et al. 2004) on a MacBook Pro (Retina, Mid-2014) 2.6 GHz Intel Core i5 
processor running OS X Yosemite (v 10.10.2) or with MOE (Molecular Operating 
Environment (MOE), 2014.09; Chemical Computing Group ULC, 1010 Sherbooke St. 
West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018.), if not otherwise 
specified. Within Chimera molecular environment, the molecular surfaces were 
created with the help of MSMS package (Sanner et al. 1996). All crystal structure 
files used were retrieved from RCSB Protein Data Bank (http://www.rcsb.org) as 
PDB file format. All the compound structures considered in this work were sourced 
either from the specs.net database (a commercially available drug-like compound 
library) or PDB database, or were built using MOE Builder tool, protonated and 
energy minimised using MMFF94x forcefield. 
2.5.1 Preliminary	  model	  and	  initial	  virtual	  screening	  
The hP2X4 homology model was built by Dr Mark T. Young with MODELLER 
software (Šali and Blundell 1993) adopting the zfP2X4 ATP-bound crystal structure 
(PDB ID: 4DW1) as template. A conformational library based on specs.net database 
was generated with LigPrep module (LigPrep, Schrödinger, LLC, New York, NY, 
2018) and subsequently screened through docking with the PLANTS (Korb et al. 
2006) in the competitive site. 16 of the compounds that displayed the best-fitting 
profile were selected, purchased and subsequently biologically evaluated.  All the 
above in silico simulations were performed by Dr Marcella Bassetto. 
2.5.2 Homology	  models	  	  
All the subsequent homology models were generated with MOE 2014.09 (or more 
recent version), Chemical Computing Group ULC) using the single template mode 
(unless otherwise stated. See Table 2.8 for further details and the list of 
templates used). Briefly, the protein sequence of interest (in FASTA file format, 
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containing three consecutive whole-sequence repeats) and the sequence of the 
crystal structure (as PDB file format) to be used as template were aligned and 
checked manually by constraining the alignment of conserved cysteines. Further 
preparation implied the deletion of water molecules, cations and ligands (such as 
sugar or solvent molecules), joining the chains, the automatic calculation of 
hydrogens and partial charges according to AMBER99 force field or AMBER10:EHT 
force field when the induced-fit option was selected and a small molecule was 
included in the environment (Table 2.8).  MOE homology model tool was then 
employed with default settings and the final model was refined from the best-
scored among 10 intermediate models. Each model was checked visually and via 
Rampage Server, Molprobity (Lovell Simon et al. 2003) and PROCHECK (Laskowski 
et al. 1993) to exclude gross errors in protein geometry.  
Model	  
Sequence	  
(Uniprot	  ID)	  
Template(s)	  
PDB	  ID	   Force	  field	  
hP2X4	  ATP-­‐bound	   Q99571	   4DW1	   AMBER10:EHT	  
hP2X4	  APO	  form	   Q99571	   4DW0	   AMBER99	  
rP2X4	  ATP-­‐bound	   P51577	   4DW1	   AMBER10:EHT	  
rP2X4	  APO	  form	   P51577	   4DW0	   AMBER99	  
hP2X4	  I312IT	  APO	  form	  
Q99571	  	  
(manually	  mutated)	  
4DW0	   AMBER99	  
rP2X4	  APO	  form	  
P51577	  	  
(manually	  mutated)	  
4DW0	   AMBER99	  
hP2X7	  ATP-­‐bound	   Q99572	   5U2H.B	   AMBER10:EHT	  
hP2X7	  	  APO	  form	   Q99572	   5U1L	   AMBER99	  
mP2X7	  A127K	  ATP-­‐bound	  
Q9Z1M0	  	  
(manually	  mutated)	  
5U2H.B	   AMBER10:EHT	  
 
Table 2.8: list of homology models, force fields, templates and sequences 
used. 
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2.5.3 Docking	  with	  LeadIT	  FlexX	  and	  PLANTS	  
Molecules prepared with MOE2014.09 were exported in PLANTS-compatible or 
FlexX-compatible format before use. The structure of ATP from the crystal was  
superposed to binding site of the homology model prior docking, thus serving as 
mere reference for the centroid coordinates of the grid. A box of 10Å3 served as 
grid for the docking for both LeadIT FlexX 2.1.3 (Rarey et al. 1996) and PLANTS 
(Korb et al. 2006) simulations (same used for Glide, validation of the model). 20 
aco ants were set as parameter for simulations with PLANTS and 25 poses were 
generated per simulation and subsequently visually inspected.  
2.5.4 Maestro	  LigPrep	  ligand	  preparation	  
Molecules and databases generated with MOE2014.09 or imported as 2-
Dimensional structures from Specs.net, were prepared using LigPrep with standard 
settings: all ionization state between pH:7.0 ± 2.0 using Epik (Epik, Schrödinger, 
LLC, New York, NY, 2018) (Greenwood et al. 2010; Shelley et al. 2007) and 
OPLS_2005 forcefield. For the virtual screenings performed in the ATP-binding site 
and in the allosteric binding pocket, the downloaded library of SPECS 
commercially available compounds (~300,000 entries) was exploited. 
2.5.5 Glide	  docking	  
When appropriate, the homology model file was pre-processed with MOE2014.09 
by superposition of the ATP structure in the binding pocket with the sole intent of 
simplifying the identification of the ATP-binding site by Glide. In all cases, the 
protein structure was prepared with Maestro Protein Preparation Wizard 
(Schrödinger Suite, Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, 
NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, 
LLC, New York, NY, 2018) − correcting any bond order wrongly assigned − before 
grid generation. The centre of the binding region was defined by either manual 
selection of the pocket residues or by selecting the superposed ligand. The area 
for the docking was confined within a box set to be similar in size to the length of 
the superposed ligand (if present) or appropriate to the dimensions of the ligands 
to be docked during the simulation. Usually the box size was <20 Å3 (unless 
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otherwise stated); grids used in blind docking were 32 Å3 and had centroids set 
manually in order to have a consistent overlap of >10 Å per side. Glide Standard 
Precision (SP) protocol was used in all simulations (unless otherwise specified) 
while the number of generated poses per ligand and retained after the post-
docking minimization stage was chosen accordingly to the dimension of the 
database of ligands, generally 3 poses per ligand when the database contained >20 
distinct molecules. Table 2.9 lists Schrodinger packages directly used in this work 
or as crucial components of it. 
Application	   Main	  use	  
Canvas	   Analysis	  of	  2-­‐Dimensional	  fingerprints	  for	  improved	  virtual	  screening	  	  
Epik	   Prediction	  of	  ionization	  states	  and	  favoured	  tautomers	  
Glide	   Docking	  and	  scoring.	  
LigPrep	  
Preparation	  of	  the	  small-­‐molecule	  ligands	  by	  generating	  a	  
database,	  which	  includes	  possible	  tautomers,	  enumeration	  
of	  enantiomers,	  ionization	  stages.	  
Maestro	   Graphical	  interface	  
OPLS3,	  OPLS_2005	   Force	  fields	  used	  to	  define	  the	  molecular	  environment	  and	  as	  part	  of	  ligand	  preparation	  
Prime	   Protein	  structure	  preparation	  (employed	  by	  Protein	  Preparation	  Wizard)	  
Protein	  Preparation	  
Wizard	  
Protein	  structure	  prepossessing;	  correction	  of	  common	  
structure	  mistakes.	  	  
QikProp	   Calculation	  of	  ligand-­‐based	  Absorption,	  Distribution,	  Metabolism,	  Excretion	  (ADME)	  prediction	  
Table 2.9: Schrodinger packages. Schrodinger suite offers a wide range of 
applications to manage modelling and drug design tasks; each of these 
packages can be accessed and managed by the same graphical interface, 
Maestro.  
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2.5.6 Virtual	   screening	   workflow	   via	   combined	   scoring	  
functions	  
This method uses a combination of consecutive Glide docking simulations followed 
by the rescoring of the generated poses with three different docking algorithms ( 
Glide, FlexX LeadIT and PLANTs) and filtered according a consensus score.   
 Serial Glide docking simulations  2.5.6.1
For the virtual screenings, the library of prepared ligands was initially docked 
using Glide High throughput Screening (HTVS) protocol allowing flexibility to the 
ligand but penalizing non-planar conformations of amides. No additional 
constraints were applied while the number of docked conformations (poses) were 
limited to 2 per ligand after post-docking minimization (3 poses were retained in 
the virtual screening of the allosteric pockets). The top 15% best scored poses 
were re-docked with Glide Standard Precision protocol maintaining the same 
protein grids and settings. Poses were then rescored (without performing ulterior 
docking) through Glide Extra Precision (XP) protocol. The top 15% poses were 
rescored through additional scoring functions as lower number of final selected 
molecules was desired. 
 LeadIT FlexX and PLANTs rescoring, Consensus 2.5.6.2
score 
Both LeadIT FlexX and PLANTS were employed in parallel at this stage. Each 
scored docked conformation of the output library - obtained from the Glide XP 
step – was re-scored in place (receptor grid of 16 Å radius) applying both scoring 
functions and therefore obtaining 3 docking scores values for each pose, which 
served for the calculation of the consensus score developed in Prof Andrea 
Brancale’s research group (Bassetto et al. 2013). In brief, this consisted in 
assigning a positive value (+1) to the top scored quartile conformations according 
to each function. Poses that obtained a total value equal to 3 – meaning that 
ranked among the best scored quartile according to Glide XP, FlexX and PLANTS – 
were selected for visual inspection. 
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2.5.7 Maestro	  virtual	  screening	  workflow	  (vsw)	  
For the screening in the allosteric binding site (and the blind docking), the Virtual 
screening workflow was employed in order to automate the consecutive Glide 
docking (HTVS, SP then XP) on multiple receptor grids. For the allosteric pocket, 3 
conformations for each compound were generated for each grid in during the 
HTVS stage, 10% of those were retained for the re-dock with Glide SP and the 
subsequent Glide XP stage. A total of 5,000 best scored poses obtained for each 
receptor grid input were merged, clustered according to molecular descriptors 
and visually inspected. A pre-dock filter, which included Lipinski’s rule of 5 
(molecular weight <500 g/mol,LogP <5, number of H-bond acceptor <10, number 
of H-bond donor <5) and the removal of molecules with reactive groups was 
included to skim the initial compound library. For the blind dock simulations, the 
virtual screening workflow was employed merely for the possibility to handle a 
large number of receptor grids through a semi-automated process thus no pre-
dock filter was applied, 3 poses were generated in the HTVS stage retaining 34% of 
them after docking, while the later re-dock stages maintained 100% of poses with 
good score. Poses generated from each grid were subsequently merged in one 
database and visually inspected.  
2.5.8 Pharmacophore	  
All pharmacophores were built employing MOE2014.09 Pharmacophore Query 
Editor after superposition of ligands. The Unified scheme was selected and 
features in common to ≥2/5 were considered essential. The radius of the spheres 
assigned to each feature was visually inspected to determine if a manual 
adjustment was needed. 
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Chapter	  3:	  
P2X4	  modulators,	  competitive	  binding	  
site	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3  P2X4 MODULATORS, COMPETITIVE 
BINDING SITE 
3.1  Chapter introduction 
As previously discussed (Section 1.2), P2X4 plays an important role in 
neurotransmission and pathological conditions, particularly in rodent models of 
neuropathic pain where P2X4 expression is up-regulated in microglial cells (in the 
spinal cord) after nerve injury, leading to pain-hypersensitivity (Tsuda et al. 2003; 
Ulmann et al. 2008). The activation of P2X4 in microglia causes the release of 
brain-derived neurotrophic factor (BDNF), which in turn affects intracellular Cl- 
levels, changing GABAergic signalling from inhibitory to excitatory (Coull et al. 
2005; Hildebrand et al. 2016). Also, in rodent models of neuropathic pain, P2X4 
pharmacological blockage or silencing (via siRNA) results in a decrease of pain 
hypersensitivity (Matsumura et al. 2016; Nagata et al. 2009; Yamashita et al. 
2016). Despite rising interest and effort in the development of novel P2X4 
antagonists, only relatively few selective modulators – including 5-BDBD (Fischer 
et al. 2004), PSB-12054 and PSB-12062 (Hernandez-Olmos et al. 2012) and 
carbamazepine derivatives (Tian et al. 2014) - had been described before the 
beginning of this work. Most of them display an insufficient drug-likeness profile 
and none of them progressed to clinical trials. During the course of this study, 
more novel P2X4 antagonists structures were reported – namely BX430 (Ase et al. 
2015) and NP-1815-PX (Matsumura et al. 2016). The latter compound showed an 
anti-allodynic effect in pre-clinical trials (Matsumura et al. 2016) and a blood 
brain barrier (BBB)-permeable analogue (undisclosed structure) has very recently 
progressed to Phase I clinical trials (Inoue and Tsuda 2018). 
3.1.1 Ca2+	  influx	  assay	  
Measuring ATP-induced responses in P2X-expressing cells - in order to test the 
activity of small molecules at P2X4 – can be achieved through different 
established methods such as Ca2+ imaging, electrophysiology recording and Ca2+ 
influx assay with fluorescent reporter. The latter was elected as the method of 
choice for this project. Briefly, the assay involves the pre-incubation on P2X-
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expressing cells with FLUO-4AM, a membrane permeant dye that is retained in the 
cell upon hydrolysis (non-permeant), forming complexes with Ca2+, which emit 
fluorescence (Figure 3-1). Essentially, the assay measures the ATP-induced 
increase of fluorescence caused by activation of P2X receptors and consequence 
influx of Ca2+ in the cytoplasm. In presence of a P2X antagonist, the increased of 
fluorescence would look reduced or abolished. This is an indirect measure of the 
receptor functionality that measure the total changes of Ca2+ concentration in the 
cytoplasm and for this reason the presence of other purinoceptors in the cells 
used in the assay is quite important. 
 
 
Figure 3-1: Schematic of the Ca2+ influx assay principle. 
3.1.2 HEK293	  and	  1321N1	  cell	  lines	  
Preliminary Ca2+ assay experiments performed by Dr Leanne Grimes conducted on 
HEK293 stably expressing human P2X4 indicated low cell responses to ATP and 
significant limitations in assay reproducibility (data not shown). The initial 
hypothesis attributed the poor quality of signal and variability to (i) the low 
solubility of 5-BDBD and PSB-12054 (used as controls) and (ii) the activation of P2Y 
receptors (endogenously present in HEK293 by ATP (Schachter et al. 1997). The 
pre-incubation with 2-Aminoethoxydiphenyl borate (2-APB; a blocker of 
intracellular Ca2+-release) (Bootman et al. 2002) did not improve the data quality 
(Dr Leanne Grimes, unpublished) prompting the need of a more appropriate cell 
model. Therefore, the 1321N1 astrocytoma cell line (reported not to express any 
endogenous P2X or P2Y receptors) (Ullmann et al. 2005) was used in this work to 
 
 
 Nucleus 
  
 
 
 
 
ATP 
P2X 
  
Ca
2+
 
 
Ca
2
+
Fluo	  4	  AM 
Fluo	  4	  AM 
 
esterases 
Fluo	  
4
-­‐
+ 
Ca
2+
 
P2Y 
   
 
ADP 
Ca
2+
 Ca
2+
 
 
Ca
2+
 Endoplasmatic	  
reticulum 
[Fluo	  4-­‐Ca]  
494	  nm 
516	  nm  
 
+ 
Chapter 3 – Results: P2X4 modulators, competitive binding site 
 109 
generate a cell model stably expressing human P2X4 subsequently employed in 
testing anti-P2X4 activity of compound candidates selected through an in silico 
approach. 
3.1.3 Homology	  modelling	  
Back at the start of the project, the low number of reported ligand structures 
limited their use to design novel antagonists through a ligand-based approach. 
Conversely, the publication of zebrafish P2X4 structure in the apo- and ATP-bound 
state – the only structures available at the start of my research – strongly 
impacted on the direction of this study towards a structure-based approach.  
Often, species-specific structural information is not available for the target 
protein and this was indeed the case for human receptors at the start of this 
project, and is still the case for human P2X4. In silico tools offer the opportunity 
to build a model of the desired biological target starting from an empirically 
determined structure of a homologue protein that shares enough similarity. This is 
based on the observation that the 3-dimensional structure of evolutionary related 
proteins is more conserved than their amino acid sequences (Kaczanowski and 
Zielenkiewicz 2010); therefore using as template a structure with over 50% 
sequence identity with the target usually results in model suitable for drug design 
applications (Baker and Sali 2001). The sequence identity observed between 
human P2X receptors and the available templates (reported in Figure 1-23) is 
generally approximately 50-60%, which combined with the conservation of 
important structural features (i.e. disulfide bonds, residues interacting with the 
ATP as identified by Hattori et al. (Hattori and Gouaux 2012)) allow the creation 
of an adequate model. Once the appropriate template has been identified and 
aligned with the target sequence the model is built starting from the core 
structure with sequence identity. Loops and non-conserved regions are usually 
modelled with lower reliability (Baker and Sali 2001). Importantly, many of the 
factors influencing the model quality are strongly related to the quality of the 
template used such as resolution (if X-ray crystal structure), percentage of 
residues with favourable geometry, flexibility of sidechains and loops. The model 
quality can be assessed to exclude substantial errors through visual inspection, 
computing the RMSD between the template and the model backbone, using online 
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servers (e.g PROCHECK (Laskowski et al. 1993), Rampage Server and MolProbity 
(Lovell Simon et al. 2003)) – usually assessing the model geometry through the 
Ramachandran plot – and docking known ligands in the binding site.  
3.1.4 Docking	  simulations:	  Glide,	  FlexX	  and	  PLANTs	  
Docking is a widely used structure-based method estimating the fit of a molecule 
within a target cavity. Each simulation is formed by a first phase where ligand 
poses are generated through a searching algorithm and a second phase consisting 
in selecting and ranking the poses according to a scoring function. In this work the 
simulations were conducted using Glide (HTVS, SP and XP), PLANTS (Korb et al. 
2009) and FlexX (LeadIT). The 3 tools employ different searching algorithms for 
the generation of the pool of ligand conformations. Glide, for instance, uses a 
complete systematic approach where the space is thoroughly explored in a 
positional, conformational and orientational manner (Friesner et al. 2004). Both 
FlexX and PLANTS instead adopt stochastic methods. The first uses and 
incremental construction approach by placing a first ligand fragment within the 
pocket and rebuilding the complete molecule using a greedy strategy to drive the 
process (Rarey et al. 1996). A greedy algorithm is a problem solving strategy that 
aims at finding the local optimal solution for each step of the process, usually not 
producing ‘the’ optimal global solution but identifying a relative optimal solution 
that approximate to the global solution within an acceptable number of steps. 
PLANTS uses the nature-inspired artificial ant colony optimization (ACO) 
algorithm, which drives the conformational space exploration toward the best 
solutions on the basis of ‘rewards’ given to acceptable conformations generated in 
previous algorithm iterations similarly to ants laying down and following 
pheromone trails (left by other ants of the swarm) in the search for food (Korb et 
al. 2006). The scoring functions used to rank the best fit conformation can also be 
very diverse depending on the number of parameters considered in order to assign 
the score, which also impacts on the computation speed. Glide offers 3 different 
scoring functions from less accurate but less computationally demanding (HTVS, 
approximately 2 seconds/compound), to increasingly accurate but more time-
consuming SP (10 seconds/compound) and XP (2 minutes/compound) (Friesner et 
al. 2006; Schrödinger 2018). Such flexibility is easily applicable to virtual 
screening workflows where Glide HTVS is used to quickly exclude non-fitting 
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compounds from >100,000 compound libraries before iterating the docking with 
more accurate scoring functions. Finally, the combination of multiple docking 
tools through applying a post-docking consensus score has resulted in the 
discovery of potent hits (Bissantz et al. 2000; Wang et al. 2018).  
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3.2  Generation of human P2X4 1321N1 
stable cell line 
1321N1 cells were transfected with 1 µg DNA and antibiotic-resistant single-cell 
foci were selected with 600 µg/mL G418. 22 colonies were assessed through 
western blotting for protein expression and positive clones were tested for 
function through Ca2+ assay with a single dose of 100 µM ATP (Appendix 1).  Clone 
WB34 (later named G34) showed high expression levels of human P2X4 receptor 
and the highest functionality and therefore it was chosen for all the subsequent 
experiments involving human P2X4.  
3.3  Development and optimization of the 
Ca2+ influx assay 
Initial experiments on 1321N1 P2X4-expressing cells revealed very high sample-to-
sample variability and although the maximal response to ATP (100 µM) exhibited 
by the clone G34 was significant, the responses to lower concentrations of ATP 
were unacceptably inconsistent. This indicated that the background noise caused 
by P2Y activation in HEK cells was not the only aspect affecting the consistency of 
the results. For this reason, a number of factors, which could affect the 
consistency of results were considered (Table 3.1) and certain were optimised, 
including buffer and seeding conditions, dye loading and ATP preparation and 
storage.  
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Factor	   Variables	  
ATP	  
Degradation	  rate,	  	  
pH	  and	  concentration	  of	  stock	  solution	  
Storage	  temperature	  
Supplier	  
Water	  purity	  (used	  to	  make	  the	  stock	  solution)	  
Cell	  preparation	  
Seeding	  concentration	  
Time	  before	  measurement	  
Cell	  health	  
Passage	  number	  
Growing	  medium	  
Extracellular	  
Solution	   Components	  concentrations	  
Equipment	  
Top/bottom	  reading	  
Settings	  
Fluo-­‐4	  Dye	  
Solubilisation	  
Loading	  time	  
Stability	  
Table 3.1: List of factors influencing the measurements outcome in the Ca2+ 
influx assay including some considered during assay optimization. 
The use of a more complex buffer (Figure 3-2A), in line with similar studies by 
Ase et al. (Ase et al. 2015) but different from Hernandez-Olmos et al. 
(Hernandez-Olmos et al. 2012)), considerably increased the cellular response 
(buffer composition and calculated osmolarity is listed in Table 3.2). Responses 
registered using modified Ringer’s buffer were remarkably improved by the 
introduction of Pluronic-127 and Probenecid, which might acted as dye loading 
enhancers (Figure 3-2B,C).  
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Figure 3-2: Impact of buffer composition and FLUO4-AM loading enhancers 
on ATP responses. Response is expressed as Relative Fluorescence Unit 
(RFU). ΔRFU = (max-min)/min and calculated from 1 or 2 independent 
experiments (n=3-4). A. Influence of the different types of extracellular 
buffers during incubation and measurements (n=3). Buffers were prepared 
according to the recipe reported in Table 3.2. Data were recorded using a 
Fluoroskan Ascend and normalized to the maximal response recorded with 
Standard ECS solution, which was the buffer used in the preliminary work 
conducted before optimization. B. Influence of Probenecid at 0.25mM and 
2.5mM concentrations on ATP dose-responses. Data were measured with a 
Fluorostar Optima. C. influence of absence/presence of Probenecid (2.5 mM) 
and/or Pluronics-P127 (P-127, at final concentration of 0.02%) on responses 
elicited by 0.1 µM, 1.5 µM, 4 µM and 30 µM.  
  
A B 
C 
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Buffer	   Components	   Osmolarity	  (mOsm)	  
ECS	  
147	  mM	  NaCl,	  10	  mM	  HEPES,	  13	  mM	  
Glucose,	  1	  mM	  MgCl2,	  2	  mM	  CaCl2,	  2	  mM	  
KCl,	  pH=7.3	  in	  MilliQ	  water.	  
330	  
Recipe	  A	  
140	  mM	  NaCl,	  10	  mM	  HEPES,	  10	  mM	  
Glucose,	  1	  mM	  MgCl2,	  5mM	  CaCl2,	  2	  mM	  
KCl,	  pH=7.35	  in	  MilliQ	  water.	  
322	  
Modified	  
Ringer’s	  
140	  mM	  NaCl,	  10	  mM	  HEPES,	  10	  mM	  
Glucose,	  1	  mM	  MgCl2,	  1	  mM	  CaCl2,	  2.5	  
mM	  KCl,	  0.5%	  BSA,	  pH=7.4.	  
311	  
Table 3.2: Composition of the buffers used in the optimization trials. 
Osmolarity was calculated considering the contribution of each ionic 
species. All calculated buffer osmolarities resulted within the range of 
osmolarity values guaranteed by the supplier for the culture medium (290-
330 mOsm/kg). The general addition of NaOH to adjust the pH did not 
change the osmolarity considerably as calculated for the modified Ringer 
buffer for which approx. 2 mM was used. 
The optimization included also the test of the optimal number of cells seeded, the 
ideal time window between seeding and the assay and the preparation and storage 
of ATP stock solutions (data not shown). Overall the assay conditions found 
optimal included the following and were used in subsequent experiments:  
•  Cells seeded between 35’000 and 45’000 cells/mL 
•  Measurements taken approx. 14-20 hours after seeding (depending on seeding 
cell concentration of 35’000 cells/mL or 45’000 cells/mL) 
•  Modified Ringer’s buffer added with 500 µM Probenecid as extracellular solution 
•  100 mM ATP (pH = 7.5 - 8) stock at -80°C prepared in ultra-pure water. Working 
concentration diluted just before the injection. 
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3.4  Concentration-response curve and EC50 
of ATP at human P2X4 
Once the optimization was completed, the ATP dose-response was calculated 
using ATP concentrations ranging from 100 to 0.003 µM obtaining an ATP EC50 of 
1.3 µM (Figure 3-3 and Table 3.3), which was in good agreement with previously 
published data (Jones et al. 2000; Soto et al. 1996; Stokes et al. 2011) and has 
been used as reference for all the further experiments. 
 
 
Figure 3-3: ATP-induced response in human P2X4-expressing cells. A. Cell 
Ca2+ influx upon addition of increasing concentrations of ATP (at time = 0 
s). Data represents fluorescence intensity increase (Raw data, 
representative traces) and is expressed in arbitrary units. B. ATP dose-
response curve. Response is calculated as ΔRFU = (max-min)/min from 3 
independent experiments (n=5-6) and was normalized to the mean of the 
maximal response obtained for each independent experiment. GraphPad 
Prism 6 was used to compute a nonlinear regression (curve fit) with variable 
slope and the values of EC20, EC50 and EC80 reported in Table 3.3. 
  
A B 
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ATP at human P2X4 WT 
Hill Slope: 1.094 (±0.1359) 
LogEC50 -5.901 (±0.05549) 
EC20 0.35 µM  
EC50 1.3 µM  
EC80 4.4 µM  
Table 3.3: ATP EC50 and Hill Coefficient calculated for human P2X4-
experessing cells. 
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3.5  Assay validation with a known human 
P2X4 antagonist 
To validate our antagonist screening assay with an appropriate positive control, 
we measured the concentration-inhibition curve of BX-430, a reported antagonist 
of human P2X4 (Ase et al. 2015) demonstrating that it was capable of antagonizing 
ATP responses with a calculated IC50 of 2.02 µM (Figure 3-4), compared to 
reported IC50 of 0.54 µM (Ase et al. 2015). 
  
 
Figure 3-4: Block of ATP-induced response by BX-430 in human P2X4-
expressing cells. Final concentration of DMSO (vehicle) did not exceeded 
0.1%. A. Reduction in fluorescence Intensity increase (Raw data, 
representative traces from a single experiment) caused by incubation with 
increasing concentration of antagonist. Fluorescence intensity increase 
expressed in arbitrary units. B. BX-430 dose-inhibition curve. Response is 
calculated as ΔRFU = (max-min)/min from 3 independent experiments (n=4-
5) and was normalized to the mean of the maximal response obtained from 
the vehicle control of each independent experiment. GraphPad Prism 6 was 
used to compute a nonlinear regression (curve fit) with variable slope. 
  
A B 
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3.6  Preliminary model and initial virtual 
screening on human P2X4 
3.6.1 Previous	  virtual	  screening	  	  
In previous work, Dr Mark Young built the hP2X4 homology model with MODELLER 
software (Šali and Blundell 1993) employing the zfP2X4 ATP-bound crystal 
structure (PDB ID:  4DW1).	   In silico tools were also employed to (i) generate a 
conformational database of small-molecules from a commercially available drug-
like compound library (www.specs.net) using LigPrep (Schrödinger) and to (ii) 
identify drug candidates through a structure-based drug design approach. A virtual 
screening was performed - by Dr Marcella Bassetto - by docking the molecule 
conformations into the ATP-binding site using the PLANTS algorithm (Korb et al. 
2006). The 16 compounds that displayed the best-fitting profile were selected and 
purchased from Specs (www.specs.net). The list of compounds (in this work 
referred as compounds from 1 to 16) and their corresponding molecular structures 
are reported in Table 3.4 while an example of selected compounds docked in the 
ATP-binding site is displayed in Figure 3-5.  
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ID	   Structure	   Specs	  ID	   MW	   Chemical	  Name	  
1	  
	  
AK-­‐968/	  
15604856	  
428.45	  
N-­‐(3-­‐(N-­‐(5-­‐(1H-­‐
pyrazol-­‐1-­‐ylmethyl)-­‐2-­‐
furoyl)	  
ethanehydrazonoyl)ph
enyl)isonicotinamide	  
2	  
	  
AK-­‐968/	  
15603434	  
465.89	  
N-­‐(4-­‐(N-­‐(1,3-­‐
benzodioxol-­‐5-­‐
ylcarbonyl)	  
ethanehydrazonoyl)	  
phenyl)	  -­‐2-­‐(4-­‐
chlorophenoxy)	  
acetamide	  
3	  
	  
AP-­‐048/	  
15614119	  
308.36	  
4-­‐(2-­‐(1H-­‐indol-­‐3-­‐yl)-­‐
1,3-­‐thiazol-­‐4-­‐yl)-­‐1,2-­‐
benzenediol	  
4	  
	  
AJ-­‐292/	  
11658708	  
384.43	  
2-­‐(2-­‐(4-­‐hydroxy-­‐3-­‐
methoxyphenyl)	  
vinyl)-­‐3-­‐(4-­‐
methylphenyl)-­‐4(3H)-­‐
quinazolinone	  
5	  
	  
AO-­‐081/	  
42039434	  
477.54	  
2-­‐(5-­‐((1-­‐(4-­‐
hydroxyphenyl)-­‐2,5-­‐
dimethyl-­‐1H-­‐pyrrol-­‐3-­‐
yl)	  methylene)-­‐2,4-­‐
dioxo-­‐1,3-­‐thiazolidin-­‐
3-­‐yl)-­‐N-­‐(4-­‐
methoxyphenyl)aceta
mide	  
6	  
	  
AQ-­‐390/	  
41639213	  
464.49	  
N-­‐(3-­‐acetyl-­‐2-­‐methyl-­‐
1-­‐benzofuran-­‐5-­‐yl)-­‐N-­‐
isonicotinoyl-­‐4-­‐
methoxybenzenesulfo
namide	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7	  
	  
AQ-­‐149/	  
43243677	  
466.53	  
3-­‐hydroxy-­‐1-­‐(2-­‐(1H-­‐
indol-­‐3-­‐yl)ethyl)-­‐4-­‐(4-­‐
methoxybenzoyl)-­‐5-­‐(4-­‐
methylphenyl)-­‐1,5-­‐
dihydro-­‐2H-­‐pyrrol-­‐2-­‐
one	  
8	  
	  
AN-­‐465/	  
12944090	  
394.46	  
2-­‐(2-­‐(((1-­‐(2-­‐amino-­‐2-­‐
oxoethyl)-­‐1H-­‐
benzimidazol-­‐2-­‐
yl)methyl)	  sulfanyl)-­‐
1H-­‐benzimidazol-­‐1-­‐yl)	  
acetamide	  
9	  
	  
AN-­‐465/	  
43369673	  
345.36	  
N-­‐(1,3-­‐benzodioxol-­‐5-­‐
ylmethyl)-­‐N-­‐(3-­‐
(1,3)oxazolo(4,5-­‐
b)pyridin-­‐2-­‐
ylphenyl)amine	  
10	  
	  
AI-­‐204/	  
31689056	  
376.51	  
2,3-­‐bis((4-­‐
pyridinylsulfanyl)	  
methyl)quinoxaline	  
11	  
	  
AP-­‐853/	  
42476447	  
486.93	  
N-­‐(4-­‐chlorophenyl)-­‐2-­‐
(1,1-­‐dioxido-­‐3-­‐oxo-­‐
1,2-­‐benzisothiazol-­‐
2(3H)-­‐yl)-­‐N-­‐(4-­‐
hydroxy-­‐3-­‐
methoxybenzyl)	  
acetamide	  
12	  
	  
AO-­‐476/	  
43417572	  
368.44	  
6-­‐((2-­‐oxo-­‐2-­‐(2-­‐
thienyl)ethyl)thio)-­‐5-­‐
phenyl-­‐1,5-­‐dihydro-­‐
4H-­‐pyrazolo(3,4-­‐d)	  
pyrimidin-­‐4-­‐one	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13	  
	  
AO-­‐476/	  
43421005	  
396.43	  
N-­‐(((5-­‐oxo-­‐6-­‐(3-­‐
pyridinylmethyl)-­‐4,5-­‐
dihydro-­‐1,2,4-­‐triazin-­‐
3-­‐yl)thio)acetyl)-­‐N'-­‐
phenylurea	  
14	  
	  
AP-­‐853/	  
43445408	  
436.95	  
2-­‐((4-­‐benzyl-­‐5-­‐(4-­‐
pyridinyl)-­‐4H-­‐1,2,4-­‐
triazol-­‐3-­‐yl)sulfanyl)-­‐
N-­‐(5-­‐chloro-­‐2-­‐
pyridinyl)acetamide	  
15	  
	  
AO-­‐080/	  
43441481	  
384.89	  
(2-­‐chlorophenyl)-­‐N-­‐(3-­‐
(2-­‐(4-­‐
pyridinyl)vinyl)phenyl)
methanesulfonamide	  
16	  
	  
AN-­‐329/	  
43449168	  
345.40	  
N-­‐(3-­‐((3-­‐
phenylpropanoyl)	  
amino)phenyl)isonicot
inamide	  
Table 3.4: List of compounds (1-16) resulted from the preliminary screening 
and purchased from Specs.net. Specs ID, Compound Identifier as in 
Specs.net commercially available library; MW, molecular weight (g/mol). 
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Figure 3-5: Compound 3 (A), Compound 7 (B) and Compound 14 (C) (in 
green) docked inside the human P2X4 model compared to the conformation 
of the ATP (orange) solved in the zebrafish P2X4 crystal (PDB ID: 4DW1). In 
yellow, the two molecules of glycerol present in the crystal. (Left) 2D 
structures of Compound 3, Compound 7 and Compound 14. 
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3.7  Biological evaluation of compounds 1-16 
from the preliminary virtual screening  
The activity of the 16 compounds purchased from SPECS was assessed at 10 µM 
concentration (20 minutes pre-incubation) using a Ca2+ influx assay on stably 
hP2X4-expressing cell line (G34 cell line, described and characterised in Section 
3.2 - 3.5). Figure 3-6 summarises the effect of the compounds on the cell 
response elicited by ATP at a concentration corresponding to EC20, EC50 or EC80 
(values calculated from the ATP concentration-response curve presented in 
Section 3.4 and corresponding to ~0.4 µM, ~1.2 µM and ~4 µM, respectively). The 
experimental data showed that none of the compounds displayed a statistically 
significant reduction in the response compared to the 0.1% DMSO control (P value 
= 0.8719, Ordinary One-way ANOVA and Dunnett’s multiple comparison test). The 
negative outcome of the first compound screening led me to perform a second 
virtual screening within the ATP-binding site, and new human P2X4 molecular 
models were also generated for this task. 
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Figure 3-6: Reduction of ATP responses caused by incubation with 10 µM 
SPECS compounds (1 to 16) when receptor activation was induced by 
concentration of ATP corresponding to EC20 (A), EC50 (B) and EC80 (C). DMSO 
final concentration was not higher than 0.1% One-way ANOVA and Dunnet’s 
test performed on the set highlighted not significance differences between 
the compounds and ctrl in all the different experiments (P>0.05). Data 
represents 2 or more independent experiments (n=3-4 each). 
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3.8  Homology models 
The human P2X4 model in the closed state and in the ATP-bound state were 
modelled from 4DW0 and 4DW1 employing MOE software (according to the 
procedure described in the Section 2.4.2). For the ATP-bound model, the induced 
fit option was chosen and the 3 ATP molecules present in 4DW1 were selected for 
this purpose. The models were then minimized and checked using PROCHECK 
(Laskowski et al. 1993), Rampage Server and Molprobity (Lovell Simon et al. 2003) 
to exclude gross errors due to bad geometry or implausible angles of the 
backbone.  Finally, the ATP-bound model was visually inspected and a computed 
RMSD of 0.541 Å over 22 residues defining the binding pocket was obtained 
between the model and the crystal structure (PDB ID: 4DW1). The RMSD for the 
superposed model-crystal whole structures was 0.642 Å and 0.714 Å for the 
backbone and for all atoms respectively. A further check of the model used for 
the virtual screening was carried out with docking simulations to ensure the ATP 
could be harboured in the binding site retaining the expected interactions. 
3.9    Docking of ATP in human P2X4 
homology model 
As seen in Figure 3-7A-C, the docking simulations performed on the open-state 
human P2X4 model using Glide SP, FlexX and PLANTS algorithms shown that ATP 
poses had a good overlapping with the conformation of the ATP co-crystalized in 
4DW1 (in dark gray, superposed to the docked pose for clarity). Indeed the 
particular U-shaped ATP conformation observed in the ATP-bound crystals of both 
P2X4 and P2X3 was retained in the docked poses obtained from all three docking 
algorithms with a calculated RMSD of 1.2496 Å, 1.5754 Å and 2.5540 Å for Glide 
SP, PLANTS and FleXX respectively (via Schrodinger atom-pairing ligand 
superposition tool). A visual inspection revealed that the ATP triphosphate group 
of all the docked conformations entertains multiple H-bonds interactions with Lys-
67, Lys-69, Arg-295 and Lys-313 of the human P2X4 model (corresponding to the 
Lys-70, Lys-72, Arg-298, Lys-316 zfP2X4 numbering). The H-bond with Thr-186 and 
Asn-293 (Thr-189 and Asn-296 in the crystal) was retained in most of the poses. 
Interestingly, two additional interactions were observed between both Lys-190 
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and the sidechain of Ser-289 (non-conserved in the crystal and corresponding to 
Ala-292) and the alpha phosphate of the poses obtained with Glide SP and PLANTS. 
In the crystal structure the OH group of the ribose (in 3’ position) interacts with 
nearby residues via a molecule of water. As the model and the docking simulation 
did not include any water molecules, this interaction is not present, although the 
same group is stabilized by an H-bond with the nearby Leu-214 backbone (Leu-217 
in the zfP2X4) in both Glide SP and PLANTS conformations. A Protein-Ligand 
Interaction Fingerprint (PLIF), generated using MOE tool and reported in Figure 
3-7D, summarizes and compares the interactions detected in the crystal versus 
the docked poses. With the assumption that ATP would make similar contacts with 
interacting residues conserved in the human receptor, the docking simulations 
showed (i) a satisfactory ability of all the three docking algorithms in predicting 
plausible conformations and ligand-protein interactions − also re-confirmed by 
docking of ATP in the zfP2X4 structure (data not shown) − and (ii) a reasonable 
pocket residue sidechain conformation. 
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Figure 3-7: Dock of ATP in human P2X4 model (generated from 4DW1) using 
PLANTS (A, magenta) FlexX (B, yellow) and Glide SP (C, green) docking 
algorithm. Residues lining the pocket have been labelled according to human 
P2X4 numbering. H-bond interactions are shown in blue dot lines and the ATP 
crystal conformation (dark grey) has been superposed for ready comparison. (D) 
Barcode plot representing Protein-ligand Interaction Fingerprint (PLIF) of the 
interactions formed between each docked pose (PLANTS, Glide SP, FlexX) and 
the human model compared to the ones detected in the crystal (4DW1), where 
grey-filled boxes indicate presence of the interaction type specified by single-
letter (at the top) for the indicated residue (at the bottom). White boxes 
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indicate no such interactions. Interaction types obey the following single-letter 
coding: ‘A’, sidechain hydrogen bond acceptor; ‘a’, backbone hydrogen bond 
acceptor, ‘C’, surface contact, ‘d’, sidechain hydrogen bond donor; ‘I’, ionic 
attraction; ‘O’, solvent hydrogen bond. 
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3.10  Virtual screening and selection of 
compounds (compound 17-42) 
A database of ~300,000 commercially available compounds (from SPECS) was 
screened through docking in the ATP-binding site of human P2X4 homology model 
using Glide for their ability to fit the pocket. The number of docking poses was 
repeatedly filtered through docking iterations with increasing precision (Glide 
HTVS, SP and XP) obtaining 138,840 docking poses, which were re-scored using 
PLANTS and LeadIT-FlexX docking programs. An internal consensus score – a 
method routinely applied in Prof Andrea Brancale’s research group (Bassetto et al. 
2013) - was applied to the values obtained from each scoring functions and only 
the 25% best ranked poses in all the three scoring functions were retained for 
further analysis. These 5561 compound conformations were subsequently 
clustered according to their similarity in functional groups, in 3-dimensional 
occupancy and in interactions with residues within the pocket.  After visual 
inspection, 26 compounds were selected - favouring a choice of molecules with 
diverse chemical scaffolds - and finally purchased from SPECS (see Figure 3-8 for 
example of docked ligands). Table 3.5 lists the selected compounds that were 
biologically evaluated in human P2X4-expressing cells through Ca2+ influx assay as 
illustrated in the following section. 
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ID	   Structure	   Specs	  ID	   MW	   Chemical	  Name	  
17	  
	  
AE-­‐641/	  
00786016	  
423.42	  
4-­‐(benzoylamino)-­‐5-­‐
hydroxy-­‐2,7-­‐
naphthalenedisulfoni
c	  acid	  
18	  
	  
AE-­‐641/	  
42133418	  
407.40	  
2-­‐	  ((9,10-­‐dioxo-­‐9,10-­‐
dihydro-­‐2-­‐
anthracenyl)sulfonyl)
amino)benzoic	  acid	  
19	  
	  
AF-­‐399/	  
40634562	  
338.45	  
2-­‐((4-­‐amino-­‐5,6,7,8-­‐
tetrahydro(1)benzot
hieno(2,3-­‐
d)pyrimidin-­‐2-­‐
yl)sulfanyl)-­‐N-­‐(2-­‐
hydroxyethyl)acetam
ide	  
20	  
	  
AF-­‐399/	  
41900709	  
459.50	  
3-­‐hydroxy-­‐4-­‐(5-­‐
methyl-­‐2-­‐furoyl)-­‐5-­‐
(3-­‐phenoxyphenyl)	  -­‐
1-­‐(tetrahydro-­‐2-­‐
furanylmethyl)-­‐1,5-­‐
dihydro-­‐2H-­‐pyrrol-­‐2-­‐
one	  
21	  
	  
AF-­‐399/	  
42810490	  
327.43	  
1-­‐(4-­‐methylphenyl)-­‐
4-­‐oxo-­‐6-­‐sulfanyl-­‐2-­‐
(2-­‐thienyl)-­‐1,2,3,4-­‐
tetrahydro-­‐5-­‐
pyrimidinecarbonitril
e	  
22	  
	  
AF-­‐407/	  
33312043	  
320.35	  
2-­‐((4-­‐
acetylphenyl)hydraz
ono)-­‐N-­‐benzyl-­‐2-­‐
cyanoacetamide	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23	  
	  
AG-­‐205/	  
36698032	  
417.54	  
N-­‐(5-­‐(ethylsulfanyl)-­‐
1,3,4-­‐thiadiazol-­‐2-­‐
yl)-­‐2-­‐((5-­‐methyl-­‐5H-­‐
(1,2,4)triazino(5,6-­‐
b)indol-­‐3-­‐
yl)sulfanyl)acetamid
e	  
24	  
	  
AG-­‐670/	  
36765017	  
309.32	  
5-­‐phenyl-­‐5-­‐(2-­‐(4-­‐
pyridinyl)	  ethyl)-­‐
2,4,6(1H,3H,5H)-­‐
pyrimidinetrione	  
25	  
	  
AH-­‐487/	  
14758206	  
484.30	  
(4-­‐bromo-­‐2-­‐(3-­‐
(methoxycarbonyl)-­‐
2-­‐methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridin-­‐
4-­‐yl)phenoxy)acetic	  
acid	  
26	  
	  
AH-­‐487/	  
40935627	  
435.84	  
2-­‐chloro-­‐4-­‐(5-­‐((3-­‐(2-­‐
ethoxy-­‐2-­‐oxoethyl)-­‐
2,4-­‐dioxo-­‐1,3-­‐
thiazolidin-­‐5-­‐
ylidene)methyl)-­‐2-­‐
furyl)benzoic	  acid	  
27	  
	  
AH-­‐487/	  
41955121	  
352.34	  
	  
4-­‐(5-­‐((1-­‐allyl-­‐2,5-­‐
dioxo-­‐4-­‐
imidazolidinylidene)
methyl)-­‐2-­‐furyl)-­‐3-­‐
methylbenzoic	  acid	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28	  
	  
AK-­‐778/	  
40984985	  
425.46	  
3-­‐(2-­‐(4-­‐
fluorophenyl)-­‐2-­‐
oxoethyl)-­‐3-­‐hydroxy-­‐
1-­‐(1-­‐
naphthylmethyl)-­‐1,3-­‐
dihydro-­‐2H-­‐indol-­‐2-­‐
one	  
29	  
	  
AK-­‐778/	  
41182449	  
339.35	  
2-­‐(3-­‐(2-­‐(3-­‐
aminophenyl)-­‐2-­‐
oxoethyl)-­‐3-­‐hydroxy-­‐
2-­‐oxo-­‐2,3-­‐dihydro-­‐
1H-­‐indol-­‐1-­‐
yl)acetamide	  
30	  
	  
AK-­‐968/	  
41925442	  
396.85	  
ethyl	  5-­‐
(aminocarbonyl)-­‐2-­‐
(((4-­‐
chlorophenoxy)acety
l)amino)-­‐4-­‐methyl-­‐3-­‐
thiophenecarboxylat
e	  
31	  
	  
AM-­‐807/	  
41462255	  
474.26	  
((((6-­‐(4-­‐
bromophenyl)-­‐3-­‐
cyano-­‐4-­‐
(trifluoromethyl)-­‐2-­‐
pyridinyl)sulfanyl)ace
tyl)amino)acetic	  acid	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32	  
	  
AN-­‐988/	  
40787450	  
513.63	  
(9-­‐(4-­‐
(benzyloxy)phenyl)-­‐
3,3,6,6-­‐tetramethyl-­‐
1,8-­‐dioxo-­‐
2,3,4,5,6,7,8,9-­‐
octahydro-­‐10(1H)-­‐
acridinyl)acetic	  acid	  
33	  
	  
AN-­‐988/	  
40787687	  
381.43	  
(9-­‐(4-­‐
methoxyphenyl)-­‐1,8-­‐
dioxo-­‐2,3,4,5,6,7,8,9-­‐
octahydro-­‐10(1H)-­‐
acridinyl)acetic	  acid	  
34	  
	  
AO-­‐022/	  
43453859	  
394.51	  
N-­‐((2,2-­‐dimethyl-­‐5-­‐
oxo-­‐2,3,5,9b-­‐
tetrahydro(1,3)thiaz
olo(2,3-­‐a)isoindol-­‐3-­‐
yl)carbonyl)(methyl)
homocysteine	  
35	  
	  
AO-­‐080/	  
43441580	  
306.36	  
5-­‐(4-­‐(4-­‐
morpholinylmethyl)a
nilino)-­‐5-­‐
oxopentanoic	  acid	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36	  
	  
AO-­‐081/	  
42096259	  
409.44	  
methyl	  6-­‐methyl-­‐2-­‐
oxo-­‐4-­‐(4-­‐(2-­‐oxo-­‐2-­‐(4-­‐
toluidino)	  
ethoxy)phenyl)-­‐
1,2,3,4-­‐tetrahydro-­‐5-­‐
pyrimidinecarboxylat
e	  
37	  
	  
AO-­‐476/	  
41610193	  
370.47	  
((2-­‐
((carboxymethyl)sulf
anyl)-­‐5,6,7,8-­‐
tetrahydro(1)benzot
hieno(2,3-­‐
d)pyrimidin-­‐4-­‐
yl)sulfanyl)acetic	  
acid	  
38	  
	  
AO-­‐990/	  
15068055	  
321.38	  
N-­‐((2-­‐(4-­‐
hydroxybenzoyl)hydr
azino)carbothioyl)-­‐2-­‐
thiophenecarboxami
de	  
39	  
	  
AP-­‐263/	  
43370864	  
353.25	  
4-­‐((2-­‐
(trifluoromethyl)anili
no)carbonyl)isophth
alic	  acid	  
40	  
	  
AQ-­‐149/	  
43372338	  
391.42	  
5-­‐(2-­‐fluorophenyl)-­‐3-­‐
hydroxy-­‐1-­‐(2-­‐(2-­‐
hydroxyethoxy)ethyl)
-­‐4-­‐(2-­‐
thienylcarbonyl)-­‐1,5-­‐
dihydro-­‐2H-­‐pyrrol-­‐2-­‐
one	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41	  
	  
AQ-­‐360/	  
42595959	  
342.35	  
4-­‐(2-­‐((2-­‐
methoxyanilino)carb
onyl)anilino)-­‐4-­‐
oxobutanoic	  acid	  
42	  
	  
AS-­‐871/	  
41438012	  
434.49	  
2-­‐((1-­‐(3-­‐
(ethoxycarbonyl)-­‐5-­‐
ethyl-­‐2-­‐thienyl)-­‐2,5-­‐
dioxo-­‐3-­‐
pyrrolidinyl)sulfanyl)
nicotinic	  acid	  
Table 3.5: List of compounds (17-42) identified in the virtual screening 
performed in the ATP-binding site described in Section 3.10. Specs IDs, 
identification number according to the supplier (specs.net). MW, molecular 
weight (g/mol). 
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Figure 3-8: Dock of compound 20 (A), compound 31 (B) and compound 41 
(C) and their molecular structures (on the left handside). 
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3.11  Biological evaluation of compounds 17-42 
SPECS compounds identified through the virtual screening where purchased and 
tested on hP2X4-expressing cells through Ca2+ influx assay similarly to that 
described in Section 2.2.1. Figure 3-9A reports ATP responses elicited by 1.2 µM 
ATP after cells were pre-incubated with 10 µM compounds, vehicle only or 2 µM 
BX430 – a concentration corresponding to the approximated IC50 value (as 
calculated in Section 3.5). Compound 23 was not included in the test at 10 µM 
due to its extremely poor solubility in DMSO. Normalised data from 3 independent 
experiments were combined and analysed through One-way ANOVA followed by 
Dunnet’s multiple comparison test (P=0.0102). None of the compound tested 
showed a statistically significant reduction in receptor activation at 10 µM, 
besides 2 µM BX430 (used as positive control). Additionally, for each compound, a 
single experiment with increasing concentration (ranging from 0.003 µM to 100 
µM) was performed to measure any inhibitory effects at higher concentrations. 
Such an experiment performed using Compound 25 (#25) is shown in Figure 3-9B-
C as an example. No compounds showed an inhibition-curve trend within the range 
of tested concentrations and no further compound characterisation was carried 
out. These negative results led to the development of an alternative strategy to 
identify potential hit compounds.   
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Figure 3-9: Biological evaluation of Compound 17-42 through Ca2+ influx 
assay. (A) ATP responses (at 1.2 µM ATP) when cells were pre-incubated (20 
min) with 10 µM compounds (labeled 17-42) compared to the vehicle (0.1% 
DMSO, blue) or 2 µM BX-430 (green). Final concentration of DMSO did not 
exceed 0.1%. Normalized data (to the vehicle) combined from 3 independent 
experiments (n=2-4/each). (B) and (C) Lack of inhibitory effects at 
increasing concentrations of Compound 25 on ATP responses (elicited by 1.2 
µM ATP). Data from single experiment (n=5) was normalized to the 0.1% 
DMSO (100% response). 
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3.12  Discussion 
The initial low reproducibility of the Ca2+ influx assay improved mainly by the use 
of Probenecid - an inhibitor of various drug transporters - that reduced the dye 
leakage during the incubation potentially caused by the expression of multi-drug 
resistant proteins (BCRP and PgP) in 1321N1 (Bhatia et al. 2012). 
Following two rounds of virtual screening and manual inspection of binding poses a 
total of 42 compounds were selected and 41 were tested at 10 µM (Compound 23 
was tested at 2 µM, data not shown), yet none displayed a statistically significant 
antagonist activity at human P2X4. There could be several potential explanations 
for this disappointing outcome ranging from inaccuracies in the initial starting 
human P2X4 models to straightforward ‘bad luck’ (i.e. not enough compounds 
were tested). The models used in the two different rounds of screening were 
created independently with two different modelling software (MODELLER and 
MOE) but using the zebrafish P2X4 ATP-bound crystal as template, which bears 
61% sequence identity to human P2X4 and multiple conserved features (i.e. 
disulphide bonds, numerous conserved residues within the ATP-binding site). 
Though the percentage identity is suitable to build a reliable model for drug 
discovery applications (Baker and Sali 2001) and indicates quite reliably a 
conserved 3-dimensional structure similarity, it also bears some limitations 
derived from the nature itself of a computational prediction. However, a similar 
recent structure-based approach successfully identified hit compounds active 
against human P2X7 creating a valid precursor for the application of structure-
based drug design for the receptor family (Caseley et al. 2016), perhaps 
suggesting that it is not our molecular modelling or virtual screening approach 
that is responsible for the negative result. 
Interestingly, no potent orthosteric P2X4 antagonists have been reported to date, 
in contrast to the situation for other P2X receptor subtypes, such as TNP-ATP and 
A-317491 co-crystallised in the ATP-binding site of P2X3 (Mansoor et al. 2016). The 
lack of reported orthosteric antagonists binding P2X4 raises the intriguing 
possibility that, for some reason, it is harder to ‘fit’ the ATP-binding site of P2X4 
with a ligand than for other subtypes. 
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Notably, while the selected compounds lacked activity at human P2X4, more than 
one compound displayed antagonist activity at P2X7 (this will be the focus of 
Chapter 5). 
The negative results obtained from virtual screenings performed on the ATP-
binding site has led to a different approach in identifying potential P2X 
modulators by considering allosteric binding sites and modulators and will be 
described in Chapter 4. 
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Chapter	  4:	  
P2X4	  modulators,	  allosteric	  binding	  sites	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4  P2X4 MODULATORS, ALLOSTERIC 
BINDING SITES 
4.1  Chapter introduction 
4.1.1 Defining	  allosteric	  binding	  sites	  of	  human	  P2X4	  	  
To date, most of the available modulators of P2X4 are reported to be allosteric 
(Ase et al. 2015; Hernandez-Olmos et al. 2012) (Matsumura et al. 2016; Wang et 
al. 2017), although their binding locations remain unknown. The following sections 
(i) attempt to give an in silico interpretation of ivermectin (IVM) positive allosteric 
modulator dual effect contextualizing available pharmacological and mutagenesis 
data within the human P2X4 homology model (Section 4.2), (ii) explore the 
hypothesis of further allosteric binding sites in the P2X4 receptor subtype 
corresponding to the pocket recently identified in giant panda P2X7 (Section 4.3 
to Section 4.6) and (iii) employ this hypothesis to conduct a virtual screening for 
negative allosteric modulators (Section 4.7). 
4.1.2 Ivermectin	  –	  a	  positive	  allosteric	  binding	  site	  in	  the	  
transmembrane	  domain	  
Ivermectin (IVM) is an FDA-approved anti-helminthic drug acting on glutamate-
gated chloride channels of nematodes and is indicated in the treatment of 
onchocerciasis (human river blindness) and lice in humans and for parasitosis in 
veterinary medicine (Zemkova et al. 2014). IVM also modulates the activity of 
numerous other receptors (Chen and Kubo 2018) including GABA receptors, 
nicotinic acetylcholine receptors, glycine receptors (Du et al. 2015; Huang et al. 
2017), Farnesoid X receptors (Jin et al. 2013) and P2X4 (Zemkova et al. 2014). The 
potential toxicity of IVM is due to its non-selectivity, although risks of CNS effects 
are observed only in animals that bear mutations in P-glycoprotein, as IVM does 
not readily cross the blood brain barrier (Menez et al. 2012). 
Structural data from glycine receptors and glutamate-gated chloride receptors 
reveals that IVM exerts its positive allosteric modulation by binding between the 
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helices of the transmembrane domain and favouring the channel open state (Du et 
al. 2015; Hibbs and Gouaux 2011; Huang et al. 2017). When bound to P2X4, IVM 
has two effects: it decreases the deactivation rate (with a EC50 of 2 μM) and 
increases the maximum current amplitude (with an EC50 of 0.25 μM) in 
electrophysiology experiments (Priel and Silberberg 2004). However both effects 
might be due to two (or more) binding modes in the same receptor domain – 
potentially between transmembrane domains (TMs) as observed in cys-loop ligand 
gated ion channels (Du et al. 2015; Huang et al. 2017). Extensive mutagenesis and 
structure-function studies (mainly on rat P2X4) strongly corroborate this 
hypothesis by identifying residues important for IVM activity to be located in the 
lower portion of the TM2 and the upper portion of the TM1 (Samways et al. 2012; 
Silberberg et al. 2007; Tvrdonova et al. 2014). In this chapter, we suggest a 
possible binding mode for IVM using the rat P2X4 homology model.  
4.1.3 BX430	  –	  hypothesising	  a	  negative	  allosteric	  binding	  
site	  in	  the	  extracellular	  domain	  
The rationale behind the hypothesis of the allosteric pocket location herein 
described is based upon (i) the recently published P2X7 crystallographic data 
combined with (ii) species-specific pharmacology data available for the human 
P2X4 allosteric antagonist, BX430.  
The giant panda P2X7 crystal structures in complex with A740003, A804598, 
AZ10606120, GW791343 and JNJ47965567 were the first to report the location of 
an allosteric pocket (Karasawa and Kawate 2016). Prof. Kawate’s research group 
compared the newly solved crystal structures of P2X7 with those of zebrafish P2X4 
(Hattori and Gouaux 2012) and human P2X3 (Mansoor et al. 2016) observing that in 
P2X3 and P2X4 the pocket is narrower (Karasawa and Kawate 2016).  With this 
observation in mind the question that followed next was: Is it possible that any of 
the known P2X4 allosteric antagonists binds to the same binding site? Our interest 
was directed towards BX430 – among other compounds initially considered such as 
5-BDBD, PSB-12054, PSB-12062 – due to its extremely interesting pharmacology 
data. According to Ase et al., BX430 displays different pharmacological profiles 
among human, zebrafish, mouse and rat P2X4 receptor (Ase et al. 2015).  Indeed, 
BX430 displayed similar potency at human and zebrafish P2X4 subtypes (reported 
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IC50 values of 0.54 μM and 1.89 μM, respectively), whereas it was ineffective at 10 
μM on rat and mouse P2X4 despite their higher sequence identity to human P2X4 
(Ase et al. 2015). Considering the high level of sequence identity among rat, 
mouse and human P2X4, such a difference in potency could likely be affected by a 
difference in a small number of amino acids or even a single point mutation in the 
binding pocket. In order to identify any residue potentially affecting BX430 specie-
selectivity and to reduce the risk of biased development and testing of the 
hypothesis, the whole aligned sequences of the extracellular domain were 
searched for residues that shared (i) identity (‘restrictive criteria’) or (ii) 
similarity (similar residue properties or retention of the ability to form H-bond, 
‘less-restrictive criteria’) within the zebrafish/human subgroups and the 
mouse/rat subgroups but differing between the two subgroups. Ile-312 (human 
P2X4 numbering) is the only residue that obeys to the ‘restrictive criteria’ (above 
mentioned) by sharing identity in zebrafish but being a threonine at the 
corresponding position in mouse and rat sequence (Thr-312) therefore having a 
polar amino acid sidechain (instead of hydrophobic) (Figure 4-1A, highlighted in 
green). Three residues (Val-68, Val-101, Lys-222) obey to the ‘less-restrictive’ 
criteria maintaining either hydrophobicity or the ability to act as H-bond donor 
(Figure 4-1A, highlighted in yellow). Figure 4-1B shows the location of the 4 
residues in the human P2X4 homology model.  
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hP2X4   ---MAGCCAALAAFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWVFVWEKGYQET 57  
zfP2X4  MSESVGCCDSVSQCFFDYYTSKILIIRSKKVGTLNRFTQALVIAYVIGYVCVYNKGYQDT 60 
mP2X4  ---MAGCCSVLGSFLFEYDTPRIVLIRSRKVGLMNRVVQLLILAYVIGWVFVWEKGYQET 57 
rP2X4    ---MAGCCSVLGSFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWVFVWEKGYQET 57 
  
hP2X4  DSVVSSVTTKVKGVAVTNTSKLGFRIWDVADYVIPAQEENSLFVMTNVILTMNQTQGLCP 117 
zfP2X4 DTVLSSVTTKVKGIALTNTSELGERIWDVADYIIPPQEDGSFFVLTNMIITTNQTQSKCA 120 
mP2X4 DSVVSSVTTKAKGVAVTNTSQLGFRIWDVADYVVPAQEENSLFIMTNMIVTVNQTQGTCP 117 
rP2X4   DSVVSSVTTKAKGVAVTNTSQLGFRIWDVADYVIPAQEENSLFIMTNMIVTVNQTQSTCP 117 
  
hP2X4  EIPDATTVCKSDASCTAGSAGTHSNGVSTGRCVAFNGSVKTCEVAAWCPVEDDTHVPQPA 177 
zfP2X4 ENPTPASTCTSHRDCKRGFNDARGDGVRTGRCVSYSASVKTCEVLSWCPLEKIVDPPNPP 180 
mP2X4 EIPDKTSICDSDANCTLGSSDTHSSGIGTGRCVPFNASVKTCEVAAWCPVENDAGVPTPA 177 
rP2X4   EIPDKTSICNSDADCTPGSVDTHSSGVATGRCVPFNESVKTCEVAAWCPVENDVGVPTPA 177 
  
hP2X4  FLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTTYLKSCIYDAKTDPFCPIFRLGKIVE 237 
zfP2X4 LLADAENFTVLIKNNIRYPKFNFNKRNILPNINSSYLTHCVFSRKTDPDCPIFRLGDIVG 240 
mP2X4 FLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTSYLKSCIYNARTDPFCPIFRLGQIVA 237 
rP2X4   FLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTSYLKSCIYNAQTDPFCPIFRLGTIVE 237 
  
hP2X4  NAGHSFQDMAVEGGIMGIQVNWDCNLDRAASLCLPRYSFRRLDTRDVEHNVSPGYNFRFA 297 
zfP2X4 EAEEDFQIMAVHGGVMGVQIRWDCDLDMPQSWCVPRYTFRRLDNKDPDNNVAPGYNFRFA 300 
mP2X4 DAGHSFQEMAVEGGIMGIQIKWDCNLDRAASHCLPRYSFRRLDTRDLEHNVSPGYNFRFA 297 
rP2X4   DAGHSFQEMAVEGGIMGIQIKWDCNLDRAASLCLPRYSFRRLDTRDLEHNVSPGYNFRFA 297 
  
hP2X4  KYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDIIPTMINIGSGLALLGMATVLCDIIV 357 
zfP2X4 KYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLLNMGAGLALLGLVNVICDWIV 360 
mP2X4 KYYRDLAGNEQRTLTKAYGIRFDIIVFGKAGKFDIIPTMINVGSGLALLGVATVLCDVIV 357 
rP2X4  KYYRDLAGKEQRTLTKAYGIRFDIIVFGKAGKFDIIPTMINVGSGLALLGVATVLCDVIV 357 
  
hP2X4  LYCMKKRLYYREKKYKYVEDYEQGLASELDQ 388 
zfP2X4 LTFMKRKQHYKEQKYTYVDDFGLLHNEDK-- 389 
mP2X4 LYCMKKRYYYRDKKYKYVEDYEQGLSGEMNQ 388 
rP2X4   LYCMKKKYYYRDKKYKYVEDYEQGLSGEMNQ 388 
 
 
Figure 4-1: Identification of the residues potentially responsible for BX430 
specie-selectivity. (A) Sequence alignment of zebrafish (zf), human (h), rat 
(r) and mouse (m) P2X4. Residues that share identity with human P2X4 
sequence are highlighted in gray, residues obeying to the ‘restrictive 
 A 
B 
I312 
I312 
V68 
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K222 
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criteria’ in green, residues obeying to the ‘less-restrictive criteria’ in 
yellow. Leu-107 corresponding to valine in rodents and describe in Section 
4.6 is highlighted in cyan. Residues of human P2X4 corresponding to the 
transmembrane domains are underlined. (B) Location of the residues 
obeying to the selection criteria in the human P2X4 homology model, top 
view (Left) and side view (Right). 
Val-68 is located in the ATP-binding pocket, Lys-222 appears to be in a loop 
almost completely exposed to solvent while Val-101 and Ile-312 are buried in the 
receptor within the same site and Ile-312 corresponds to one of the residues of 
the allosteric pocket identified by Karasawa et al. in giant panda P2X7 crystal 
structure (see Figure 4-2 and Section 1.5.3.2). For these reasons our interest has 
been focused on Ile-312 (described in Section 4.3 and following).  
 
5U1X     KAEILENGMKKMVSGVFDTADYTFPLQ-GNSFFVMTNFIKTEG 93 
hP2X7   KEEIVENGVKKLVHSVFDTADYTFPLQ-GNSFFVMTNFLKTEG 113 
4DW0    KTS-------ELGERIWDVADYIIPPQEDGSFFVLTNMIITTN 88 
zfP2X4  NTS-------ELGERIWDVADYIIPPQEDGSFFVLTNMIITTN 113 
hP2X4   NTS-------KLGFRIWDVADYVIPAQEENSLFVMTNVILTMN 110 
rP2X4    NTS-------QLGFRIWDVADYVVPAQEENSLFIMTNMIVTVN 110 
mP2X4  NTS-------QLGFRIWDVADYVIPAQEENSLFIMTNMIVTVN 110 
 
 
5U1X     GYNFRYAKYYKEN-NVEKRTLIKVFGIRFDILVFGTGGKFNVI 311 
hP2X7   GYNFRYAKYYKEN-NVEKRTLIKVFGIRFDILVFGTGGKFDII 331 
4DW0    GYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNII 311 
zfP2X4  GYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNII 336 
hP2X4   GYNFRFAKYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDII 333 
rP2X4    GYNFRFAKYYRDLAGNEQRTLTKAYGIRFDIIVFGKAGKFDII 333 
mP2X4  GYNFRFAKYYRDLAGKEQRTLTKAYGIRFDIIVFGKAGKFDII 333 
Figure 4-2: Sequence alignment of giant panda P2X7 residues in the 
allosteric pocket with P2X4 sequences. Zebrafish (zf), human (h), rat (r) and 
mouse (m) residues that share identity with PDB 5U1X sequence are in dark 
aqua, residues facing the allosteric pocket identified by Karasawa et al. 
highlighted in cyan, residues corresponding to Ile-312 across P2X4 subtype 
highlighted in green, residues corresponding to Val-101 across P2X4 subtype 
highlighted in yellow. 
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 Docking of ivermectin (IVM) 4.2
An homology model of rat P2X4 (Uniprot sequence: P51577) was built using the 
ATP-bound zebrafish P2X4 crystal (PDB ID: 4DW1), assessed with PROCHECK 
(Laskowski et al., 1993) and Rampage Server (Lovell Simon et al. 2003) and 
prepared with Protein Preparation Wizard (Schrödinger Suite 2015-1 Protein 
Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2018; Impact, 
Schrödinger, LLC, New York, NY, 2018; Prime, Schrödinger, LLC, New York, NY, 
2018) prior to performing the docking simulation. Site Finder (Molecular Operating 
Environment (MOE), 2014.0901; Chemical Computing Group ULC, 1010 Sherbooke 
St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018) was used to identify a 
potential binding site at the level of the trasmembrane domains that was taken as 
reference to position the receptor grid (box) while LigPrep (LigPrep, Schrödinger, 
LLC, New York, NY, 2018) served to prepare IVM. Figure 4-3A highlights the 
dioleandrose disaccharide (boxed in salmon), the hydrogenated benzofuran (in  
liliac) and the spiroketal (yellow) moieties – same color-coding is maintained in 
Figure 4-3B-D for clarity. The docking simulation was performed within a 35Å3 box 
using Glide XP - whose scoring function also accounts for hydrophobic interactions. 
The docked IVM inserts between subunits like a ‘wedge’ with the disaccharide 
moiety (dioleandrose, salmon) located near the extracellular face of the 
membrane entertaining hydrophobic interactions with Tyr-42, Trp-46, and Val-47 
at the TM1 of one subunit (light blue, Figure 4-3C,D) while forming a H-bond 
between the hydroxyl of the disaccharide and the side-chain of Asn-338 in the TM2 
of the adjacent subunit (light green, Figure 4-3C,D). The hydrogenated 
benzofuran moiety (liliac) instead points toward the intracellular face of the lipid 
bilayer (Figure 4-3B) establishing hydrophobic interactions with Leu-345 and Val-
348 near the bottom of the TM2 of one subunit (light blue, Figure 4-3C,D). 
According to our docking IVM is therefore stabilizing the open state of the channel 
by entertaining interactions with the top of TM1 and TM2 of one subunit and the 
bottom of TM2 of the adjacent subunits. The conformation obtained from the 
docking simulation does not prevent IVM from binding to more than one equivalent 
sites between the subunits of the trimer. Residues of rat P2X4 sequence (in bold) 
nearby IVM are indicated in Figure 4-3E by arrows (light blue or green according 
to subunit colour scheme) while the arrowhead indicates Asn-338, which 
entertains a H-bond interaction with the disaccharide moiety of IVM. Sequences of 
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IVM-sensitive P2X receptors along with non-sensitive subtypes were compared 
aiming at the identification of key amino acids determining IVM selectivity. Figure 
4-3E reports aligned sequences of transmembrane domains of rat, mouse and 
human P2X1, P2X1, P2X3, P2X4, and P2X7, together with those of Schistosoma 
mansoni (sm)P2X (Agboh et al. 2004) and Hypsibius dujardini (Hd)P2X (Bavan et 
al. 2009) – both also found sensitive to IVM (IVM-sensitive receptors are 
encapsulated in a yellow box). Human P2X7 has not been included in the yellow 
box as it had been initially reported as positively modulated by IVM in whole-cell 
patch clamp experiments (Nörenberg et al. 2012), however a later study 
investigating IVM activity in human P2X7 expressed in Xenopus oocytes detected 
no potentiation (Schneider et al. 2017). 
Silberberg et al. identified 9 rat P2X4 residues (highlighted in red boxes in Figure 
4-3E) that significantly reduced IVM activity when mutated to tryptophan 
(Silberberg et al. 2007). In our docking, IVM is located within 4.5 Å distance from 7 
out of 9 residues – indicated by arrows and arrowheads in Figure 4-3E (the colour 
of the arrows match the colour of the receptor subunit) showing an interesting 
parallel between the docking simulation and the experimental data.  
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Figure 4-3: Docking of ivermectin (IVM) in the rat P2X4 homology model. 
Figure reproduced from (Pasqualetto et al. 2018). (A) Important chemical 
groups of IVM B1a including the dioleandrose (disaccharide) (salmon), 
spiroketal (yellow), and hydrogenated benzofuran (liliac) moieties. The color 
scheme is maintained throughout the Figure 4-3 for clarity. (B) Predicted 
IVM binding site in rat P2X4. Receptor structure represented in ribbons and 
colored according to different subunits while red lines delimit the 
membrane bilayer for reference. (C) Dock of IVM between two subunits and 
nearby residues are displayed (same color coding as in (A)). Receptor 
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surface nearby the ligand is shown in white; colored areas correspond to the 
highlighted residues. (D) 180◦ rotation of the IVM pose displayed in (C). The 
transmembrane (TM) domains of the third subunit (yellow in B) are omitted 
for clarity. (E) Sequence alignment of the transmembrane domains of rat (r), 
human (h), mouse (m) P2X1, P2X2, P2X3, P2X4 and together with 
Schistosoma mansoni (Sm) and Hypsibius dujardini (Hd) P2X receptor 
sequences; rP2X4 TMs in bold. Receptors sensitive to IVM are enclosed in a 
yellow box while conserved residues across all IVM-sensitive receptors are 
boxed in gray. Conserved residues are represented in grey fonts while blue 
fonts are used for conserved residues in IVM-sensitive receptors. Red boxes 
indicate residues that reduce IVM activity when mutated to tryptophan as 
identified by Silberberg et al. (Silberberg et al. 2007). Arrows highlight the 
amino acid within a distance of 4.5Å of IVM in our docking simulation (arrow 
color according to the subunits, as in B-D); while the arrow head indicates 
Asn-338 that interacts through an H-bond with the disaccharide moiety of 
IVM. 
According to the conformation obtained in our docking simulation, the 
dioleandrose moiety of IVM entertains a hydrogen bond with the sidechain of Asn-
338. In their tryptophan mutagenesis study, Silberberg et al. observed that the rat 
P2X4 N338W retained IVM sensitivity with a fold effect of IVM on current 
amplitudes comparable to rat P2X4 wild-type (Silberberg et al. 2007). 
Interestingly their reported traces suggest that the N338W mutant decreases the 
IVM effect on receptor desensitization (faster rate of desensitization compared to 
wild-type treated with IVM), however this effect has not been investigated further 
in the study (Silberberg et al. 2007). By mutating the rat P2X4 model at Asn-338 to 
an energetically favorable Trp rotamer (using the Protein Builder tool, MOE), we 
briefly explored whether the hindrance of Trp was impeding the IVM fit. 
Interestingly, IVM was still able to make an H-arene interaction with the 
tryptophan (Figure 4-4) - however this type of interaction is usually weaker than 
a hydrogen bond, which may give a potential explanation to the lower ability of 
IVM in slowing down the deactivation in rat P2X4 N338W mutant (Silberberg et al. 
2007).  
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Figure 4-4: IVM superposed to rat P2X4 mutant N338W (labeled in bold in 
(A)). (A) Predicted Trp-338 rotamer position relative to IVM. Color scheme as 
in Figure 4-3. (B) Ligand-protein interaction diagram highlighting residues 
located near IVM (residues color-coded according to the corresponding 
receptor subunit). A grey arrow indicates the mutated residue forming a H-
arene interaction with IVM. 
The binding site of IVM has several limitations to be used for drug discovery (see 
also Section 4.8 - chapter discussion) ranging from higher inaccuracy of the model 
to the actual volume of the site. Therefore this binding pocket has not been used 
for a structure-based drug design approach. Instead, following the hypothesis 
described in the introduction of this chapter an alternative allosteric pocket has 
been identified (see following sections). 
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 BX430 binding site discovery – 4.3
generation, selection and validation of 
RML2, RTI-13 and HIT-08 cell lines 
To test our hypothesis that BX430 occupies the corresponding binding pocket to 
that of the allosteric P2X7 modulators (Section 4.1.2), cell lines expressing rat 
P2X4 wild type, rat P2X4 Thr-312 to Ile mutant (RTI in this work) and human P2X4 
Ile-312 to Thr mutant (HIT) were generated according to the procedure described 
in Section 2.2.1. Refer to Appendix 1 for protein expression levels and 
functionality of single-cell clones. RML2 13, HIT 08 (name standing for ‘Human, Ile 
to Thr’, clone 8) and RTI 13 (standing for ‘Rat, Thr to Ile’, clone 13) clones 
showed high level of protein expression and receptor functionality in Ca2+ influx 
assay and were therefore selected and expanded for the experiments described in 
the following sections. 
 ATP concentration-response curves for 4.4
wild-type and mutant rat and human 
P2X4 
ATP concentration-responses were measured through Ca2+ influx assay for cell 
lines stably expressing rat P2X4 wild-type (RML2 13), human P2X4 bearing the 
I312T mutation (HIT 08) and rat P2X4 T312I ‘mirror’ mutant (RTI 13). Applied 
concentrations of ATP ranged from 0.03 μM to 100 μM. Data for human P2X4 wild 
type ATP is repurposed here from Section 3.4 for easier comparison and clarity 
(dotted line in Figure 4-5 and Table 4.1).  ATP EC50 values for human and rat 
mutated P2X4 were 0.77 µM and 0.73 µM respectively, compared to 1.26 µM and 
1.70 µM, for human and rat P2X4 wild type. Hill slopes values for human I312T and 
rat T312I were 2.057 and 2.475, while rat wild type and human wild type had a 
lower values. (1.441 and 1.098, respectively) Notably, a reduction in ATP 
responses was observed for both mutants when high ATP doses were applied 
(especially at 30 μM and 100 μM) with a decrease in the response up to 
approximately 25% (see Figure 4-5: Mean ATP concentration-response curves of 
rat P2X4 wild type (rP2X4 WT, grey full squares), rat P2X4 T312I mutant (rP2X4 
T312I, gray empty squares), human P2X4 wild type (hP2X4 WT, black full circles), 
human P2X4 I312T (hP2X4 WT, black empty circles). Human P2X4 wild type data 
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repurposed from Section 3.4 (black dotted line). Responses represent fluorescent 
increase following ATP addition (see Section 2.2) and were normalized to the 
maximum response mean value recorded among the concentration tested. Data 
merged from 3 or more independent experiments (n=4-6/each) representing data 
as mean ± SEM. EC50 and Hill coefficient values reported in Table 4.1 were 
calculated with GraphPad through curve fit (using log(agonist) vs. normalized 
response with variable slope equation). Statistical analysis showed no significant 
difference (ns) when comparing ATP LogEC50 values from the 4 different cell lines, 
exception made for rat P2X4 WT vs. human P2X4 I312T (One-way ANOVA, Tukey’s 
multiple comparison test, p=0.0321, *). 
 
Figure 4-5: Mean ATP concentration-response curves of rat P2X4 wild type 
(rP2X4 WT, grey full squares), rat P2X4 T312I mutant (rP2X4 T312I, gray 
empty squares), human P2X4 wild type (hP2X4 WT, black full circles), human 
P2X4 I312T (hP2X4 WT, black empty circles). Human P2X4 wild type data 
repurposed from Section 3.4 (black dotted line). Responses represent 
fluorescent increase following ATP addition (see Section 2.2) and were 
normalized to the maximum response mean value recorded among the 
concentration tested. Data merged from 3 or more independent experiments 
(n=4-6/each) representing data as mean ± SEM. EC50 and Hill coefficient 
values reported in Table 4.1 were calculated with GraphPad through curve 
fit (using log(agonist) vs. normalized response with variable slope equation). 
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Cell line ATP EC50  ATP LogEC50 (±SEM) Hill Coefficient 
Human P2X4 WT 1.26 μM -5.901 (± 0.0577) 1.098  
Rat P2X4 WT 1.70 μM -5.770 (*) (± 0.0507) 1.441  
Human P2X4 I312T 0.77 μM -6.112 (*) (± 0.0.028) 2.057 
Rat P2X4 T312I 0.73 μM -6.136 (± 0.0645) 2.475  
Table 4.1: ATP EC50, pEC50 and Hill Coefficient values for wild type and 
mutated rat and human P2X4 cell lines. *statistical significance between rat 
P2X4 WT and human P2X4 I312T LogEC50 values (P≤0.05; One-way ANOVA, 
Tukey’s multiple comparison test) 
 BX430 inhibition curves for wild type 4.5
and mutant receptors 
BX430 potency was determined through Ca2+ influx assay using 1 μM ATP 
concentration for both mutants and wild types. As reported in Section 3.5 and 
repurposed here for comparison (Figure 4-6, dotted line), BX430 inhibited ATP 
responses at human P2X4 wild type with an IC50 of 2.12 μM (see Table 4.2). In 
accordance with what previously reported (Ase et al. 2015), BX430 was only a 
weak antagonist at rat P2X4 homologues displaying approximately 30-fold 
decrease in potency when rat P2X4 receptor was activated with 1 μM ATP 
(computed IC50 of 66.1 μM). Remarkably, BX430 potency was reduced by 
approximately 46-fold in cells expressing human P2X4 bearing the I312T mutation 
(calculated IC50 of 102.4 μM over 2 independent experiments). Conversely, the rat 
P2X4 T312I point-mutation alone accounted for a far higher susceptibility to BX430 
inhibition compared to rat P2X4 wild type (48-fold) with a calculated IC50 of 1.4 
μM, restoring BX430 potency to a IC50 value comparable to the one calculated for 
human P2X4 wild type (IC50 of 2.12 μM). Inhibition curve-fits for each independent 
experiment are reported in Appendix 2. Note that IC50 values for human P2X4 
I312T and rat P2X4 WT are largely approximated due to a poor fit (no inhibition) 
or interrupted curve fit (see Appendix 2), therefore LogIC50 values for human 
P2X4 cell lines were not included in the statistical analysis (only the values 
calculated with no ambiguity in the fit were considered for rat). An ordinary One-
way ANOVA followed by Dunnett’s multiple comparison test, with a single pooled 
variance revealed a statistically significant difference in LogIC50 mean values 
(P=0.0006, ***) between human P2X4 WT and rat P2X4 WT (***) but no statistical 
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significance (ns) when comparing human P2X4 WT and rat P2X4 T312I. This results 
reveals that the single point mutation alone is capable of rescuing BX-430 potency 
at rat P2X4. 
 
Figure 4-6: Mean BX430 inhibition curves of rat P2X4 wild type (rP2X4 WT, 
grey full squares), rat P2X4 T312I mutant (rP2X4 T312I, gray empty squares), 
human P2X4 wild type (hP2X4 WT, black full circles), human P2X4 I312T 
(hP2X4 WT, black empty circles). Human P2X4 wild type data repurposed 
from Section 3.5 (black dot line). Responses represent fluorescent increase 
elicited by 1 uM ATP addition after incubation with increasing 
concentrations of BX430. Data points were normalized to the response 
obtained with vehicle-only (0.1% DMSO) and are presented as mean ± SEM. 
IC50 and Hill coefficient values reported in Table 4.2 calculated with 
GraphPad through curve fit (using log(antagonist) vs. response, parameters 
equation). Data merged from 2 (for hP2X4 WT) or more independent 
experiments (n=3-5/technical repeats each). 
Cell line BX-430 IC50  BX-430 LogEC50 (±SEM) Hill Coefficient 
Human P2X4 WT 2.12 µM -5.673 (± 0.06963) -2.793  
Rat P2X4 WT 66.1 µM -4.180 (★) (± 0.6884) -1.213 
Human P2X4 I312T >100 µM -3.990 (★) (± 2.641) -1.977 
Rat P2X4 T312I 1.4 µM -5.858 (± 0.1575)  -1.072 
★ n.c.: non congruent when calculated from each independent experiment.  
Table 4.2: BX430 IC50 values for wild type and mutated rat and human P2X4 
cell lines. 
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 Docking of BX430 in human P2X4 and rat 4.6
P2X4 models 
A docking simulation of BX430 in the pocket of the human P2X4 homology model 
where Ile-312 is located was performed to assess from an in silico molecular 
modelling perspective whether BX430 is able to sterically fit the allosteric site and 
form interactions with residues nearby. Additionally to the homology model of 
human P2X4 in the closed state (described in Section 3.1.3), a rat P2X4 model in 
the closed state was also generated using zebrafish P2X4 crystal structure (PDB ID: 
4DW0) as template and subsequently validated with Rampage Server (Lovell Simon 
et al. 2003) and PROCHECK (Laskowski et al. 1993) obtaining a model with 
satisfactory geometry (84.2% residues found in the most favourable region and 
0.0% residues in the disallowed regions of the computed Ramachandran Plot) given 
the sequence identity between rat and the template (62.4% respectively) and its 
resolution (2.9 Å). To a visual inspection, the region of the human P2X4 model 
corresponding to the pocket identified in panda P2X7 presents a cavity with 
narrower entrance at the top of the trimer that connects it - similarly to a tunnel 
– to the vestibule at the receptor core. The presence of such a cavity in the model 
allowed its exploration through performing docking. The Glide Standard Precision 
(SP) protocol was employed for the docking simulation considering only the ligand 
as flexible entity and taking the location of the co-crystallised P2X7 allosteric 
antagonist GW791343 (PDB ID: 5U1Y) as a reference (after superposition) for the 
centroid of a 30Å cubical docking grid (Figure 4-7A depicts the location set for 
the docking grid). As seen in Figure 4-7B, all BX430 output conformations adopt a 
similar orientation with the pyridine portion close to the solvent-exposed cavity 
entrance whilst the di-bromo-isopropyl-phenyl moiety occupies a deeper and more 
hydrophobic portion of the pocket at close proximity to Ile-312, Tyr-299 and Leu-
107, which may establish hydrophobic interactions with BX430. The carbamide 
group of BX430 potentially stabilizes the conformation by forming two H-bond 
interactions with the Glu-307 sidechain (Figure 4-7B). In addition, a docking 
simulation was run maintaining the same settings and utilizing rat P2X4 homology 
model and aiming at the identification of any remarkable difference in the ligand 
binding conformation. In this case the output conformations could be clustered 
according to the two opposite ligand orientations as shown in Figure 4-7D and 
Figure 4-7E. No conformation was able to emulate the double H-bond observed in 
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the docking of BX430 in the human model homologue, instead a single H-bond 
interaction was observed between the carbamide and the Arg-301 sidechain when 
the pyridine moiety was oriented towards the pocket entrance.  
As described in the Section 1.5.3.2 for panda P2X7 crystal structures, Lys-297 
(panda P2X7 numbering) – corresponding to Lys-298 in the human P2X4 model – has 
missing atoms, which suggests a high degree of flexibility (not surprising for a 
lysine residue). From a visual inspection of the human P2X4 model, Lys-298 
appears to be capable of assuming multiple conformations within the nearby space 
and might therefore operate as ‘gateway’ controlling the access to the upper 
vestibule of the channel pore – as seen partially occupied by allosteric antagonists 
(such as JNJ47965567) in panda P2X7. For this reason a docking simulation of 
BX430 was performed also in the human P2X4 model with the Lys-298 assuming a 
different energetically-allowed rotamer. In this case, the isopropyl moiety lies 
near Ile-312 and Leu-107 – both residues not conserved in rat and mouse 
(corresponding to threonine and valine in rodents). Together with Ile-312, the 
close proximity of Leu-107 may increase the contribution of hydrophobic 
interactions due to its longer aliphatic chain compared to Val (Figure 4-7C). While 
the dibromo-4-(isopropyl)phenyl moiety occupies a similar location to that 
observed with the non-rotated Lys-298 (although an opposite orientation, Figure 
4-7B), the pyridinyl-urea moiety inserts deeper in the cavity with the pyridine 
accessing the upper vestibule and the urea entertaining a double hydrogen bond 
interaction with the backbone of Asp-88 (Figure 4-7C). In the following sections 
the cavity explored through docking simulations and virtual screening will be 
referred to as the ‘BX-430 pocket’.   
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Figure 4-7: Docking of BX430 in P2X4 homology models (green ribbons for 
human P2X4 model, blue ribbons for rat). (A) Location and box dimensions 
(in green, 30Å x 30Å x 30Å) used as grid for the docking of BX430. As 
reference for the location of the allosteric pocket identified in panda P2X7, 
one molecule of GW791343 (in red spheres) present in the crystal (PDB ID: 
5U1Y) was superposed to the human P2X4 model (closed state). (B) docking 
of BX430 in human P2X4 model. All poses obtained showed similar 
orientation with the di-bromo-isopropyl-phenyl moiety pointing inward the 
pocket. (C) docking of BX-430 in human P2X4 when an alternative 
conformation of Lys-298 was considered. (D), (E) Docking of BX430 in rat 
P2X4 gave poses showing two opposite ligand orientations.  
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 Virtual screening in the ‘BX430 pocket’ 4.7
According to visual inspection, the flexibility of Lys-298 influences the volume and 
the conformation of the ‘BX-430 pocket’ and therefore both models described in 
Section 4.6 (bearing 2 different Lys-298 residues conformations) were used to 
perform a virtual screening. This was achieved with the use of the Virtual 
Screening Workflow tool (Schrödinger), which allows the use of multiple receptor 
grids as ensemble and automatizes the docking iterations (Glide HTVS followed by 
Glide SP and finally Glide XP) after applying drug-likeness filters to the SPECS 
library (used as source of ligand conformations). The resulting dataset of docked 
ligands (10,000 poses) included the 5,000 top-scored structures from each 
receptor grid used, which were filtered, clustered and visually inspected selecting 
20 hits. Table 4.3 lists the structures of compounds that are proposed for 
purchase and biological assay while Figure 4-8 displays selected examples of hit 
compounds docked in the binding site.  
 
ID	   Structure	   Specs	  ID	   MW	   Chemical	  Name	  
70	  
	  
AG-­‐690/	  
09390064	  
284.32	  
N'-­‐(3-­‐
hydroxybenzylidene)-­‐
4,5,6,7-­‐tetrahydro-­‐1H-­‐
indazole-­‐3-­‐
carbohydrazide	  
71	  
	  
AG-­‐690/	  
40751404	  
426.5	  
ethyl	  3-­‐((((4-­‐ethyl-­‐5-­‐
(4-­‐hydroxyphenyl)-­‐4H-­‐
1,2,4-­‐triazol-­‐3-­‐
yl)sulfanyl)acetyl)amin
o)benzoate	  
N
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O
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72	  
	  
AH-­‐487/	  
41938124	  
376.33	  
2-­‐(((4-­‐
fluorophenyl)sulfonyl)
amino)-­‐N-­‐(4-­‐
(trifluoromethyl)	  
phenyl)acetamide	  
73	  
	  
AJ-­‐292/	  
14921026	  
439.84	  
N-­‐(4-­‐chloro-­‐3-­‐
(trifluoromethyl)phen
yl)-­‐2-­‐((6-­‐oxo-­‐4-­‐phenyl-­‐
1,6-­‐dihydro-­‐2-­‐
pyrimidinyl)sulfanyl)	  
acetamide	  
74	  
	  
AK-­‐778/	  
11467118	  
359.38	  
3-­‐ethoxy-­‐N-­‐(4-­‐
(1,3)oxazolo(4,5-­‐
b)pyridin-­‐2-­‐
ylphenyl)benzamide	  
75	  
	  
AK-­‐968/	  
40605344	  
467.26	  
4-­‐(2-­‐(2-­‐hydroxy-­‐3-­‐
methoxybenzylidene)h
ydrazino)-­‐N-­‐(2-­‐
iodophenyl)-­‐4-­‐
oxobutanamide	  
76	  
	  
AN-­‐329/	  
43211370	  
375.22	  
3-­‐(3-­‐bromophenyl)-­‐N-­‐
(2-­‐hydroxy-­‐5-­‐
methylphenyl)-­‐4,5-­‐
dihydro-­‐5-­‐
isoxazolecarboxamide	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77	  
	  
AN-­‐465/	  
42784360	  
494.32	  
4-­‐amino-­‐N-­‐(2-­‐((3-­‐
bromo-­‐4-­‐((2-­‐
fluorobenzyl)oxy)-­‐5-­‐
methoxybenzyl)amino
)ethyl)-­‐1,2,5-­‐
oxadiazole-­‐3-­‐
carboxamide	  
78	  
	  
AO-­‐476/	  
43071656	  
404.47	  
N-­‐(4-­‐
(aminosulfonyl)phenyl
)-­‐2-­‐((5-­‐(4-­‐
methylphenyl)-­‐1,3,4-­‐
oxadiazol-­‐2-­‐
yl)sulfanyl)acetamide	  
79	  
	  
AO-­‐567/	  
40646811	  
441.51	  
2-­‐(1,3-­‐benzothiazol-­‐2-­‐
ylamino)-­‐N-­‐(1,1'-­‐
biphenyl)-­‐4-­‐yl-­‐6-­‐oxo-­‐
1,4,5,6-­‐tetrahydro-­‐4-­‐
pyrimidinecarboxamid
e	  
80	  
	  
AP-­‐853/	  
42877593	  
391.25	  
2-­‐((5-­‐(3-­‐
bromophenyl)-­‐1,3,4-­‐
oxadiazol-­‐2-­‐
yl)sulfanyl)-­‐N-­‐(2-­‐
pyridinyl)acetamide	  
81	  
	  
AP-­‐853/	  
43387162	  
269.72	  
N-­‐(5-­‐chloro-­‐2-­‐
pyridinyl)-­‐2-­‐(4H-­‐1,2,4-­‐
triazol-­‐3-­‐ylsulfanyl)	  
acetamide	  
82	  
	  
AP-­‐853/	  
43405648	  
348.81	  
4-­‐(3-­‐(2-­‐chlorophenyl)-­‐
1,2,4-­‐oxadiazol-­‐5-­‐yl)-­‐
N-­‐(1,3-­‐thiazol-­‐2-­‐yl)	  
butanamide	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83	  
	  
AQ-­‐088/	  
42471813	  
439.99	  
N-­‐(5-­‐((2-­‐(4-­‐(3-­‐
chlorophenyl)-­‐1-­‐
piperazinyl)-­‐2-­‐
oxoethyl)sulfanyl)-­‐
1,3,4-­‐thiadiazol-­‐2-­‐yl)-­‐
2-­‐methylpropanamide	  
84	  
	  
AP-­‐853/	  
42160294	  
359.84	  
N-­‐(3-­‐chlorophenyl)-­‐3-­‐
((5-­‐phenyl-­‐1,3,4-­‐
oxadiazol-­‐2-­‐yl)	  
thio)propanamide	  
85	  
	  
AS-­‐871/	  
43478038	  
347.44	  
N-­‐(2,4-­‐
dimethylphenyl)-­‐2-­‐((5-­‐
(2-­‐hydroxyethyl)-­‐4-­‐
methyl-­‐6-­‐oxo-­‐1,6-­‐
dihydro-­‐2-­‐
pyrimidinyl)sulfanyl)	  
acetamide	  
86	  
	  
AE-­‐641/	  
40262184	  
330.43	  
N-­‐((1-­‐benzyl-­‐5-­‐oxo-­‐3-­‐
pyrrolidinyl)methyl)-­‐4-­‐
methyl-­‐1-­‐piperazine	  
carboxamide	  
87	  
	  
AN-­‐329/	  
43211272	  
294.74	  
4-­‐((3-­‐(4-­‐chlorophenyl)-­‐
4,5-­‐dihydro-­‐5-­‐
isoxazolyl)carbonyl)	  
morpholine	  
88	  
	  
AK-­‐918/	  
42814019	  
407.69	  
1-­‐benzyl-­‐N-­‐(4-­‐bromo-­‐
2-­‐chlorophenyl)-­‐5-­‐
oxopyrrolidine-­‐3-­‐
carboxamide	  
89	  
	  
AP-­‐124/	  
42855935	  
399.32	  
N-­‐(2,5-­‐
dichlorophenyl)-­‐2-­‐(4-­‐
(piperidine-­‐1-­‐
carbonyl)piperazin-­‐1-­‐
yl)acetamide	  
Table 4.3: List of compounds (70-89) obtained from the virtual screening 
performed in the BX430 bindig site. 
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Figure 4-8: Dock of Compound 82 (AP-853/43405648, A), Compound 86 (AE-
641/40262184, B) and Compound 89 (AP-124/42855935, C) obtained from 
the virtual screening and comprising examples comparing ligands binding 
either of the  two different Lys-298 conformations (A versus B, C) used for 
the generation of the docking grid. 
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A retrospective check found that - although the structure of BX430 does not 
appear in the compound library sourced from SPECS (~300,000 compounds) and 
used in the virtual screening - a small proportion of structures belonged to the 
same class of compounds as BX430 (containing a carbamate moiety bound to a 
pyridine and/or a phenyl). Notably, among the 5% top-scored conformations (500 
poses) obtained from the screening in the BX430 pocket, numerous compounds 
showed remarkable similarity to BX430 (selected example of such compounds are 
reported in Table 4.4). All these compounds docked in the deeper site of the 
cavity of the receptor bearing the Lys-298 as shown in Figure 4-9 with a similar 
binding mode to that observed in the corresponding BX430 docked pose (dark grey 
for reference), which suggests that the BX430 pose situated deeper in the cavity 
might be more favoured. 
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ID	   Structure	   Specs	  ID	   MW	   Chemical	  Name	  
B01	  
	  
AN-­‐329/	  
40200574	  
278.71	  
N-­‐(4-­‐chlorophenyl)-­‐N’-­‐
(3-­‐fluoro-­‐4-­‐
methylphenyl)urea	  
B02	  
	  
AI-­‐204/	  
31695001	  
324.26	  
6-­‐(((3-­‐
(trifluoromethyl)anilin
o)carbonyl)amino)	  
nicotinamide	  
B03	  
	  
AI-­‐204/	  
31695053	  
296.16	  
N-­‐(3,4-­‐
dichlorophenyl)-­‐N'-­‐(2-­‐
pyridinylmethyl)urea	  
B04	  
	  
AI-­‐204/	  
31696018	  
275.74	  
N-­‐(2-­‐chlorophenyl)-­‐N'-­‐
(2-­‐(2-­‐
pyridinyl)ethyl)urea	  
B05	  
	  
AT-­‐057/	  
43469652	  
341.8	  
N-­‐(2-­‐chloro-­‐4-­‐
methylphenyl)-­‐N'-­‐(4-­‐
(1H-­‐1,2,4-­‐triazol-­‐1-­‐
ylmethyl)phenyl)urea	  
Table 4.4: list of selected compounds that present similar structural 
features to BX430 and were among the 5% top-scored 10,000 poses obtained 
from the virtual screening. 
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Figure 4-9: Dock of compound B01 (AN-329/40200574) in human P2X4 
model. BX430 pose described in Section 4.6 was superposed as reference 
(dark grey wires). H-bonds are depicted in blue dotted lines. 
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 Chapter discussion 4.8
IVM has been proposed by Davies et al. as a potential treatment for alcohol 
dependence disorder acting at the CNS level (Franklin et al. 2015) (Roche et al. 
2016). However there are multiple challenges and drawbacks for this therapeutic 
indication, for example IVM’s low permeability through the blood brain barrier 
(Schinkel et al. 1997) (Turner et al. 2005), which is responsible for its good safety 
profile (otherwise worsened by IVM interaction at the GABAergic system in the 
CNS) (Menez et al. 2012). Nevertheless, IVM has been a pivotal pharmacological 
tool in the study of P2X receptors and its binding site has been extensively 
explored through mutagenesis studies. This work applied in silico tools (namely 
homology modelling and docking) to combine structural and mutagenesis data in 
order to describe the IVM binding mode in 3-dimensional molecular space. Our 
docked ligand agrees with the experimental data by fitting IVM in close proximity 
to 7 out of 9 amino-acids identified by Silberberg et al. (Silberberg et al. 2007) in 
a tryptophan mutagenesis study to be important for IVM activity. Futhermore, the 
docking simulation shows a potential interaction between the Asn-388 sidechain 
and the disaccharide moiety of the ligand. As reported in Section 4.2, we 
explored potential interactions when mutated to tryptophan – as the rat 
P2X4 N338W mutant investigated by Silberberg et al. maintained an IVM effect on 
current amplitudes similar to that observed forrat P2X4 wild-type (Silberberg et 
al. 2007).  We found that IVM can entertain a potential H-arene interaction with 
the tryptophan, which is generally weaker than a hydrogen bond and may explain 
why IVM potentiation was comparable to that observed at rat P2X4 wild-type, 
while showing a lower ability to decrease receptor deactivation (Silberberg et al. 
2007). Unfortunately the study conducted by Silberberg et al. did not further 
focus on the IVM effect on receptor deactivation. In order to test our hypothesis, 
we suggest the mutation of Asn-338 to a residue incapable of forming H-bonds or 
H-arene interactions (such as Ala, Val, Ile or Leu). This should significantly weaken 
IVM binding and therefore impact on IVM’s ability to potentiate current responses 
at rat P2X4. We also propose that a combination of F33N, T333I, T334N, I341L, 
and F342L mutations at human P2X1 may confer IVM sensitivity to this subtype 
since a sequence alignment of the transmembrane domains revealed that human 
P2X1 has the highest sequence similarity to the IVM-sensitive subtypes. 
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The IVM binding site presents an atypical cavity – non-enclosed and of large 
volume – in a challenging location where lipids are closely interacting with the 
transmembrane domains and therefore potentially playing a crucial role in the 
ligand binding mode. A further limitation in simulating ligand binding between 
transmembrane domains is the lower structural resolution of the transmembrane 
region in the crystal, which may negatively impact on the accuracy of the model. 
These represent highly challenging pitfalls in the use of the IVM binding site for 
structure-based drug design and therefore, in this work, the focus has been 
directed to other potential allosteric sites. 
The search for allosteric pockets in P2X4 receptor took full advantage of the 
recently published structures of giant panda P2X7 co-crystallised with 5 different 
allosteric antagonists (Karasawa and Kawate 2016). Karasawa et al. spotted that a 
corresponding pocket to the one discovered is detectable in the crystal structures 
of P2X3 and P2X4 although smaller (Karasawa and Kawate 2016). The hypothesis 
that BX430 binds to P2X4 in that pocket was tested through mutagenesis studies 
based on the different pharmacology that BX430 displays at human and rodents 
P2X4 (Ase et al. 2015). The observed difference in BX430 potency between the 
generated stable cell lines expressing rat P2X4 and human P2X4 wild-types is in 
line with the BX430 species-selectivity reported by Ase et al. (Ase et al. 2015). A 
single point mutation (I312T) at human P2X4 revealed to be responsible for a 49-
fold reduction in BX430 activity according to the calculated IC50 measured by Ca2+ 
influx assay. Conversely, the corresponding point mutation (T312I) in rat P2X4 
increased the potency of BX430 by 48-fold (compared to rat P2X4 wild-type), 
effectively making BX430 as potent as in human P2X4 wild-type. These results 
strongly support the hypothesis that BX430 binds in close proximity to Ile-312.  
A docking simulation was employed in the attempt to explain the potential 
reasons for such an effect caused by a single point mutation. Two simulations 
were generated – one taking into account the flexibility of Lys-298, which may  
play a crucial role in determining the volume of the narrow tunnel-like cavity and 
the access to the upper vestibule of the channel. Both BX430 poses suggest that 
Ile-312 may directly stabilize the ligand through hydrophobic interactions with the 
hydrophobic and aromatic portion of BX430. The cavity is solvent-accessible and 
water molecules might be less favourably displaced in the presence of a polar 
residue (Thr-312 in rat P2X4) – providing an alternative explanation to BX430 
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species-selectivity. According to the docking, the major interactions between 
P2X4 and BX430 major interactions are 2 or 3 hydrogen bonds entertained 
between the carbamate and residue backbones and with Lys-298. The design of 
potential mutations that abolish BX430 activity is therefore challenging and might 
be accomplished by focusing on Lys-298, which appears to be spatially distant 
from the orthosteric binding site (according to both ATP-bound and apo-state 
models) and has not been reported as a residue interacting with ATP by Hattori et 
al. (Hattori and Gouaux 2012).  
The positive outcome of the mutagenesis study that led to the identification of 
the BX430 binding site has enabled us to perform a virtual screening in the pocket 
and select 20 hit candidates for biological assay, which unfortunately could not be 
performed due to time constraints of this project. Interestingly, among the top 
scored structures obtained through the structure-based simulations, many show 
structural similarity to BX430. This further suggests, together with the 
mutagenesis study and the docking of BX430, that BX430 might bind to the 
identified pocket and that BX430 more favourably binds deeper in the tunnel-like 
pocket with the Lys-298 controlling the access to the upper vestibule of the 
channel.  
Taken together the results strongly supports (i) the identification of an allosteric 
binding site in P2X4 not previously discovered and (ii) the discovery and validation 
of the binding site for one of the most potent P2X4 allosteric antagonists reported 
to date. 
Unfortunately, due to limited time, this work only focuses on the identification 
and experimental validation of only one allosteric binding site, however the 
recent publication of the human P2X3 bound to AF-219 raises the question of 
whether a corresponding allosteric pocket might be found in P2X4 (Wang et al. 
2018). 
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5 IDENTIFICATION	  OF	  A	  NOVEL	  P2X7	  ANTAGONIST	  
5.1  Chapter introduction 
In evolutionary terms, P2X7 is closely related to P2X4 bearing ~48% amino acid 
sequence identity in human and the two genes are located only ~26 kBp apart in 
the same chromosome, thus P2rx7 gene is likely to have originated by gene 
duplication (Buell et al. 1998; Dubyak 2007). Compared to the other receptor 
subtypes, P2X7 possesses an additional ~240 amino acids at the C-terminal, which 
may have resulted from a transposon insertion event involving a family member of 
the Kolobok transposons in a common vertebrate ancestor, leading to the fusion 
protein that is now termed P2X7 (Kapitonov and Jurka 2007). The much longer C-
terminal domain – unique to the subtype 7 – is responsible for interacting with 
multiple proteins and strongly involved in trafficking and subtype-specific 
signalling pathways, mainly pro-apoptotic (http://www.p2x7.co.uk) (see Section 
1.4). P2X7 activation in M1 macrophages leads to the activation of NLRP3 
inflammasome, the rapid release of pro-inflammatory cytokines via microvescicle 
shedding and the activation of the immune response (Dubyak 2012; Kanneganti et 
al. 2007; MacKenzie et al. 2001). In pathophysiology, P2X7 plays a significant yet 
dualistic role in the destiny of the cell as seen in cancer cells and mouse 
embryonic stem cells (Thompson et al. 2012) where its activation has been linked 
both to increased proliferation – potentially when the ATP stimulation is at a basal 
level (Ferrari et al. 2017; Thompson et al. 2012) – and – when over-stimulated – to 
apoptosis with further activation of the immune system response (Garg et al. 
2017; Savio et al. 2018; Thompson et al. 2012). Due to its complex involvement in 
cell signalling, P2X7 has been identified as potential target for multiple conditions 
including cancer (Gilbert et al. 2017), inflammatory and neuropathic pain (Honore 
et al. 2006), diseases and disorders of the central nervous system (Basso et al. 
2009; Carmo et al. 2014; Csölle et al. 2013; Gubert et al. 2016; Jorg et al. 2014; 
Wang et al. 2017) and age-related macular degeneration (Fowler et al. 2014) 
(further details of the role played by P2X7 in pathophysiology can be found in 
Section 1.4). P2X7 pharmacology has been extensively explored and numerous 
classes of antagonists have been developed over the recent years (Gunosewoyo 
and Kassiou 2010) (see Section 1.4), including A804598, AZ10606120, GW791343, 
JNJ47965567 and A740003 - of  interest for this work primarily because co-
Chapter 5 – Results: Identification of a novel P2X7 antagonist 
 173 
crystallised with panda P2X7 receptor, shedding new light on allosteric modulation 
at P2X7 (Karasawa and Kawate 2016) and because A740004 has been employed as 
control in the course of this work. Bearing in mind that P2X7 is an attractive 
target and that the receptor share substantial structural similarities with P2X4, 
the original compounds obtained from the virtual screening conducted on P2X4 
were tested also on P2X7 receptor. 
 BzATP	  5.5.1
P2X7 subtype requires very high concentration of ATP for its activation, although a 
significant variability is observed in EC50 across subtypes, ranging from ~120 μM at 
rat to ~900 μM at mouse (Young et al. 2007). P2X7 is also strongly activated by 2′-
(3′)-O-(4-benzoyl)benzoyl ATP (BzATP), a structural analogue of ATP with the 
addition of a di-benzoyl moiety substituting the –OH of the ribose either in 
position 2’ or 3’. It was initially synthetized by Williams et al. and reported as 
single isomer (with substitution in 3’) (Williams and Coleman 1982), however later 
characterization of the synthetic product reported a mixture of 2’ and 3’ in a 
60:40 ratio (Mahmood et al. 1987) and it is commercially available as isomeric 
mixture. BzATP is only partially selective towards P2X7 as it has also been 
reported to be the full agonist at P2Y (Boyer and Harden 1989), P2X1, P2X2 and 
P2X5 (Bo et al. 2003; Evans et al. 1995) and a partial agonist at P2X4 (Bowler et 
al. 2003). Yet, at P2X7, BzATP causes larger responses - as observed by Suprenant 
et al. through whole-cell patch clamp experiments (Surprenant et al. 1996) - and 
is more potent than ATP (~3-fold more potent at mouse and 34-fold at rat). A 
surprisingly difference in pharmacology - though a very high amino acid sequence 
identity - was explored through the generation of chimeras and mutagenesis 
finally identifying Lys-127 as responsible for a much higher potency at rat P2X7, 
which may stabilise the distal benzoyl moiety through a π-cation interaction 
(Young et al. 2007). In Section 5.9 we report the use of in silico tools (docking) to 
suggest BzATP binding mode and an interpretation and contextualization of 
experimental data. 
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 YO-­‐PRO	  uptake	  assay	  	  5.5.2
As well as peculiar pharmacology, P2X7 presents also the distinctive characteristic 
of forming a large-conductance pore (also known as ‘macropore’) upon prolonged 
activation allowing the influx in the cytosol of large charged molecules (Di Virgilio 
et al. 2018). In normal conditions, living cells are non-permeable to YO-PRO – a 
fluorescent dye upon binding to DNA – therefore YO-PRO is commonly used to 
identify dead cells (Idziorek et al. 1995). The activation of P2X7 allows YO-PRO to 
enter directly through the large-conductance pore – as recently demonstrated by 
Karasawa et al. (Di Virgilio et al. 2018; Karasawa et al. 2017) - and thus the YO-
PRO assay relies on the measurement of the rate in fluorescence intensity 
increase as indirect measure of the channel activation (Virginio et al. 1999). 
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5.2  Generation of human and rat P2X7–
expressing cell lines 
1321N1 cells expressing human P2X7 (EE-tagged) and HEK293 cells rat P2X7-GFP 
were generated by transfection and selection of single foci as previously described 
(see Section 4.2 and Section 2.1.2).  Single-cell clone WB50 (human P2X7) and 
A3E10 (rat P2X7) showed high protein expression and strong ATP responses as 
measured by YO-PRO assay and were therefore used in the experiments described 
in the following sections. Appendix 3 contains more detailed information 
regarding selection of P2X7-expressing clones including protein expression level 
and ATP responses. 
5.3  Agonist EC50 at human and rat P2X7  
As observed by Surprenant et al. and Rassendren et al. (Surprenant et al. 1996) 
(Rassendren et al. 1997),  P2X7 receptor is inhibited by concentration of divalent 
cations, however magnesium and calcium display species-dependent potency 
being 10-fold more potent at human P2X7 compared to rat. For this reason all 
experiments were conducted in low-divalent extracellular solution (ECS-LD). 
Figure 5-1A presents ATP dose response curves for stable cell lines expressing 
human and rat P2X7 subtypes as calculated via YO-PRO assay. ATP concentration 
applied ranged from 1 μM to 3mM for human subtype (from 1 µM to 1 mM ATP for 
rat). Calculated EC50 values (reported in Table 5.1) for both rat P2X7 and human 
P2X7 were consistent with those previously reported when buffer with low-
divalent cation was used in the experiments (Young et al. 2007) (Stokes et al. 
2006). To further check the functionality of rat P2X7 stable cell line in preparation 
for the experiment described in Section 5.5.2, a dose-response curve for BzATP 
was also measured (Figure 5-1B). The calculated EC50 of 8.1 µM fell within the 
previously reported range (4-10 µM) (Young et al. 2007) (Donnelly‐Roberts et al. 
2009). 
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Figure 5-1: Agonist-induced YO-PRO uptake in cells expressing human 
(hP2X7) and rat P2X7 (rP2X7). A. Dose-dependent ATP responses expressed 
as dye uptake rate (gradient) measured by fluorescence increase and 
calculated over the first 10 cycles after addition of ATP (55 s/cycle) then 
normalized to the highest response values. Data merged from 2 or 3 
independent experiments for each species tested (3-5 repeats/plate). B. 
BzATP-induced responses in rat P2X7. Data pooled from 2 independent 
experiments and normalized to the highest response obtained for each. C. 
Representative traces obtained for ATP concentration responses curve 
measured YO-PRO dye uptake at human P2X7 (raw data). After 10 recording 
cycles of baseline, the ATP was manually added to the plate (black arrow) 
and increased in fluorescence intensity was recorded.  
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ATP  EC50 (µM) LogEC50 (± SEM) Hill slope 
Human P2X7  183.5  -3.736 (± 0.07) 1.563 
Rat P2X7  138.3 -3.859 (± 0.014) 1.785 
BzATP    
Rat P2X7 8.1 -5.089 (± 0.036) 1.633 
Table 5.1: ATP and BzATP EC50 values at human and rat P2X7. SEM: standard 
error of the mean. 
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5.4  Biological screening of compounds 1-42 
on human P2X7 
Due to the structural similarity and the high sequence identity between P2X4 and 
P2X7, the compounds from 1 to 42 (originally selected as potential candidate for 
P2X4) were also screened on human P2X7-expressing cells. Table 3.5 reports the 
complete list of molecular structures and Specs IDs. Figure 5-2 reports a single-
experiment screening to determine whether 30 μM of compounds (20 minutes 
incubation) were able to decrease the cell responses elicited by 300 μM ATP by 
more than 50%. 0.1 μM A740003 was used as positive control to obtain an almost 
complete blockage of dye uptake. Surprisingly, multiple compounds reduced 
responses by more than 25% at 30 μM, while Compound 25 reduced ATP responses 
by over 60% and therefore was selected for confirmation and further 
characterization. 
	  
Figure 5-2: Screening of compounds 1 to 42 on human P2X7 through YO-PRO 
uptake assay. Compounds were incubated 20 minutes before application of 
300 μM ATP (corresponding to approximately the concentration needed to 
elicit ~70% of the ATP maximal response). Responses were calculated as rate 
of fluorescence increase (gradient) over the first 10 cycles (55 
seconds/cycle) and normalized to the vehicle (0.1% DMSO). 0.1 μM A740003 
was used as positive control. Data represents a single experiment (n=3-4).  
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5.5  Compound 25 characterization  
 Compound	  25	  blocks	  YO-­‐PRO	  uptake	  in	  human	  and	  5.5.1
rat	  P2X7-­‐expressing	  cells	  
In 1321N1 cells stably expressing the cDNA encoding for human P2X7, Compound 
25 exhibited a dose-dependent ability to decrease YO-PRO uptake rate elicited by 
300 μM ATP, which approximately corresponded to the ATP EC70 value. The 
calculated IC50 value as result of 3 independent experiments was 8.7 μM (Figure 
5-3 and Table 5.2). The concentrations of Compound 25 used to determine the 
IC50 value ranged from 0.03 μM to 100 μM and the compound was pre-incubated for 
at least 20-30 minutes prior to the recording of the baseline. To assess any 
species-selectivity, Compound 25 was also tested on rat P2X7-expressing HEK-293 
cells. Compound 25 blocked ATP responses (300 μM ATP, corresponding to the 
concentration needed in order to obtain ~80% of the ATP maximal receptor 
activation) with an IC50 value of 24.4 μM (see Figure 5-3 and Table 5.2). The 
newly discovered antagonist displayed a ~3-fold higher potency at human receptor 
compared to the rat homologue however this difference in potency was not 
significant (p value = 0.0692, unpaired t test Welch-corrected for not assuming 
equal SDs, two-tailed P value). 
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Figure 5-3: Dose-dependent antagonist effect of Compound 25 on dye 
uptake in human P2X7 and rat P2X7-expressing cells.  
 IC50 (μM) LogIC50 (± SEM) Hill slope 
Human P2X7  8.7  -5.061 (± 0.167) -1.026 
Rat P2X7  24.4  -4.613 (± 0.082) -1.847 
Table 5.2: Compound 25 IC50 values at human and rat P2X7. Values 
calculated from 3 independent experiments. IC50 for human P2X7 was not 
significantly lower than rat P2X7 (p value = 0.0692, unpaired t test Welch-
corrected for not assuming equal SDs, two-tailed P value). SEM: standard 
error of the mean. 
5.5.1 Compound	  25	  blocks	  ion	  currents	  in	  rat	  P2X7-­‐
expressing	  cells	  
Whole cell patch clamp was employed to confirm the activity of the antagonist 
with an independent assay. Due to the intrinsic difficulties in patching 1321N1 cell 
due to their morphology, rat P2X7-GFP HEK-293 cells were used instead. Figure 
5-4A shows representative traces for responses obtained applying 300 μM ATP with 
or without co-application of two different concentrations of Compound 25 (5 μM 
and 25 μM). Applications of 25 μM of Compound 25 - corresponding to ~EC50 value 
calculated through YO-PRO assay - significantly blocked membrane currents in 
response to ATP (Figure 5-4B (Right), p<0.05, One-way ANOVA). These results 
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strongly confirmed the activity and the potency of Compound 25 as novel P2X7 
antagonist.  
 
Figure 5-4: Inhibition of ATP response by Compound 25 ('#25' in this figure) 
in rat P2X7-expressing cells confirmed by two independent assays. A. 
Inhibition of ATP-evoked current by #25 in whole-cell patch clamp 
experiments (representative traces). B. Data summary of the inhibition 
effect measured through two independent assays (YO-PRO uptake, left; 
whole-cell patch clamp, right). YO-PRO data reported in Section 5.5.1 is 
repurposed here for comparison. Whole-cell patch clamp experiments 
showed reduced currents with 5 μM #25 (n =7) and significant channel 
blockage with 25 μM #25 (n =5) compared with vehicle (0.1% DMSO, ctrl) 
with p<0.05 (One-way ANOVA followed by Dunnett’s multiple comparison 
test).  
5.5.2 Compound	  25:	  allosteric	  or	  competitive?	  
Initially, Compound 25 was one of the molecules selected as result of a virtual 
screening in the ATP-binding site of human P2X4 homology model. However, its 
biological testing on human P2X4-expressing cells did not display any activity up to 
100 μM - the highest concentration tested. This combined with the rather 
surprising antagonist activity of Compound 25 at human and rat P2X7 subtypes 
raised the question whether the binding site of Compound 25 is orthosteric or we 
made the serendipitous discovery of an allosteric modulator. To investigate in this 
direction, multiple concentration-response curves of BzATP for rat P2X7 in 
absence and in presence of increasing concentrations of compound 25 ranging 
from 10 μM to 100 μM were constructed, similarly to what has been described by 
Karasawa et al. (Karasawa and Kawate 2016). Each dose-response corresponding 
to a concentration of compound was measured through a single experiment (n=3). 
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These preliminary results were fitted with a competitive model as shown in Figure 
5-5A and subsequently the calculated BzATP EC50 were employed to generate a 
Schild plot (Figure 5-5B). Compound 25 appears to show a competitive action, 
according to the good linear regression fit (R=0.9875). However, on close 
inspection of Figure 5-5A it is possible to notice that when cells were incubated 
with the highest concentration of Compound 25 the responses tend to be lower 
than the maximal response obtained in absence of antagonist. Hence suggesting 
that at very high concentration the non-linear fit using a competitive model is less 
reliable. More accurate experiments, including the use of human P2X7, are 
required for a better understanding of the mode of action of the antagonist. 
Currently, the preliminary data suggests that an allosteric mode cannot be 
completely excluded due to (i) the micromolar potency – that allows only the test 
of one-Log range of Compound 25 concentrations - and (ii) the low solubility of 
Compound 25 at 100 μM, which did not permit the assessment of higher 
concentrations. 
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Figure 5-5: BzATP dose-response of rat P2X7-GFP in the presence of 
increasing concentrations of Compound 25 (#25). A. Percentage responses 
calculated as initial rates of YO-PRO uptake (first 10 cycles after agonist 
addition) and normalized to the maximal response obtained for the control 
(0.1% DMSO) were plotted and the dose-response curves were fitted with a 
competitive inhibition model (constraining top and bottom to 0% and 100% 
respectively, Hill Slope calculated collectively). Notably BzATP responses for 
cells incubated with 100 μM are notably lower than the maximal. Data 
obtained from a single-experiment (n=3). B. Schild plot obtained using EC50 
calculated from the BzATP dose-responses in presence of antagonist (A) 
suggesting a competitive inhibition mode. Y axis represents the logarithm of 
(r-1), where r=EC50’/EC50; EC50’ is the BzATP EC50 calculated in presence of 
the antagonist while EC50 is the BzATP EC50 calculated in absence of the 
antagonist. A linear regression fit was applied (R=0.9875). 
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5.6  Activity of analogues at human P2X7 
(compound 43-69) 
Aiming at the identification of the chemical features necessary for compound 
activity, the Specs.net library was searched for molecules with a similar structure 
to Compound 25.  The selection criteria included similar or same scaffold and 
presence of at least a functional group, which hypothetically contributed to 
Compound 25 activity (e.g. carboxylic acid, halogen substituent to the aromatic 
ring, ester, etc.). Table 5.3 lists the 27 compound analogues selected (named 
herein Compound 43 to Compound 69), purchased and tested. At 30 μM, several 
analogues were able to substantially decrease the dye uptake induce by 
application of 300 μM ATP (Figure 5-6A, pooled data from 2 or more independent 
experiments). More than 4 analogues showed a response reduction of 50% or over. 
Compound 47 and compound 68 were among the molecules with higher potency 
therefore a single-experiment (n=4) was conducted to determine whether the 
inhibition was dose-dependent (Figure 5-6B,C). This was the case for both 
compounds, which showed an IC50 (preliminary) of approximately 30 μM and 5.2 
μM, respectively.  
ID	   Structure	   Specs	  ID	   MW	   Chemical	  Name	  
25	  
	  
AH-­‐487/	  
14758206	  
484.30	  
(4-­‐bromo-­‐2-­‐(3-­‐
(methoxycarbonyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridin-­‐
4-­‐yl)phenoxy)acetic	  
acid	  
43	  
	  
AG-­‐690/	  
36535013	   385.46	  
methyl	  4-­‐(2,5-­‐
dimethoxyphenyl)-­‐
2,7,7-­‐trimethyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
O
O
O
N
O
O
O
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N
O
O
O
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44	  
	  
AG-­‐690/	  
36718061	  
413.51	  
isopropyl	  4-­‐(2,3-­‐
dimethoxyphenyl)-­‐
2,7,7-­‐trimethyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
45	  
	  
AK-­‐968/	  
15604330	  
423.51	  
(2-­‐(3,3,6,6-­‐
tetramethyl-­‐1,8-­‐dioxo-­‐
1,2,3,4,5,6,7,8,9,10-­‐
decahydro-­‐9-­‐
acridinyl)phenoxy)acet
ic	  acid	  
46	  
	  
AH-­‐487/	  
15150556	  
468.35	  
ethyl	  4-­‐(5-­‐bromo-­‐2-­‐
ethoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
47	  
	  
AH-­‐487/	  
14757970	  
439.85	  
(2-­‐chloro-­‐4-­‐(3-­‐
(methoxycarbonyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridin-­‐
4-­‐yl)phenoxy)acetic	  
acid	  
48	  
	  
AH-­‐487/	  
14758229	  
433.46	  
methyl	  4-­‐(4-­‐(2-­‐ethoxy-­‐
2-­‐oxoethoxy)phenyl)-­‐
2-­‐methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
N
O
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O
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49	  
	  
AN-­‐655/	  
14768403	  
445.31	  
methyl	  4-­‐(2-­‐
(benzyloxy)-­‐5-­‐
bromophenyl)-­‐1,6-­‐
dimethyl-­‐2-­‐oxo-­‐
1,2,3,4-­‐tetrahydro-­‐5-­‐
pyrimidinecarboxylate	  
50	  
	  
AG-­‐690/	  
40638872	  
476.87	  
methyl	  4-­‐(5-­‐(2-­‐chloro-­‐
5-­‐nitrophenyl)-­‐2-­‐
furyl)-­‐2-­‐methyl-­‐5-­‐oxo-­‐
4,5-­‐dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
51	  
	  
AG-­‐690/	  
40638873	  
442.43	  
methyl	  4-­‐(5-­‐(2-­‐
nitrophenyl)-­‐2-­‐furyl)-­‐
2-­‐methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
52	  
	  
AN-­‐988/	  
40667255	  
578.43	  
ethyl	  4-­‐(3-­‐bromo-­‐4-­‐
((4-­‐fluorobenzyl)oxy)-­‐
5-­‐methoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐4,5-­‐
dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
53	  
	  
AG-­‐205/	  
40649486	  
434.33	  
propyl	  4-­‐(5-­‐bromo-­‐2-­‐
methoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐
hexahydroquinoline-­‐3-­‐
carboxylate	  
N
N
O
O
O
Br
O
N
O
O
O O
N+
O
O-
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O O
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O
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54	  
	  
AG-­‐690/	  
10380042	  
429.51	  
ethyl	  2,7,7-­‐trimethyl-­‐
5-­‐oxo-­‐4-­‐(2,3,4-­‐
tris(methyloxy)phenyl)
-­‐1,4,5,6,7,8-­‐
hexahydroquinoline-­‐3-­‐
carboxylate	  
55	  
	  
AG-­‐690/	  
40749289	  
512.4	  
methyl	  4-­‐(2-­‐
bromophenyl)-­‐7-­‐(3,4-­‐
dimethoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
56	  
	  
AG-­‐690/	  
40751831	  
570.48	  
isopropyl	  4-­‐(5-­‐bromo-­‐
2-­‐methoxyphenyl)-­‐7-­‐
(3,4-­‐
dimethoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
57	  
	  
AM-­‐879/	  
42012121	  
415.87	  
(4-­‐chloro-­‐2-­‐(10-­‐
methyl-­‐1,8-­‐dioxo-­‐
1,2,3,4,5,6,7,8,9,10-­‐
decahydro-­‐9-­‐
acridinyl)phenoxy)acet
ic	  acid	  
58	  
	  
AM-­‐879/	  
42012369	  
446.3	  
(4-­‐bromo-­‐2-­‐(1,8-­‐
dioxo-­‐
1,2,3,4,5,6,7,8,9,10-­‐
decahydro-­‐9-­‐
acridinyl)phenoxy)	  
acetic	  acid	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59	  
	  
AM-­‐879/	  
42012458	  
401.84	  
(4-­‐chloro-­‐2-­‐(1,8-­‐dioxo-­‐
1,2,3,4,5,6,7,8,9,10-­‐
decahydro-­‐9-­‐
acridinyl)phenoxy)	  
acetic	  acid	  
60	  
	  
AE-­‐848/	  
42025036	  
426.51	  
4-­‐(3-­‐hydroxy-­‐4-­‐
methoxyphenyl)-­‐2,7,7-­‐
trimethyl-­‐3-­‐(4-­‐
morpholinylcarbonyl)-­‐
4,6,7,8-­‐tetrahydro-­‐
5(1H)-­‐quinolinone	  
61	  
	  
AJ-­‐292/	  
42032071	  
356.42	  
7,7-­‐dimethyl-­‐10-­‐(3-­‐
pyridinyl)-­‐6,7,8,10-­‐
tetrahydro-­‐5H-­‐
indeno(1,2-­‐
b)quinoline-­‐9,11-­‐
dione	  
62	  
	  
AK-­‐968/	  
11109126	  
489.35	  
(4-­‐bromo-­‐2-­‐(3-­‐
(ethylsulfanyl)-­‐6,7-­‐
dihydro(1,2,4)triazino(
5,6-­‐
d)(3,1)benzoxazepin-­‐
6-­‐yl)phenoxy)acetic	  
acid	  
63	  
	  
AG-­‐205/	  
11447043	  
389.83	  
ethyl	  4-­‐(6-­‐chloro-­‐1,3-­‐
benzodioxol-­‐5-­‐yl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
O
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O O
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O O
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64	  
	  
AJ-­‐292/	  
14827035	  
371.43	  
10-­‐(3-­‐hydroxyphenyl)-­‐
7,7-­‐dimethyl-­‐6,7,8,10-­‐
tetrahydro-­‐5H-­‐
indeno(1,2-­‐
b)quinoline-­‐9,11-­‐
dione	  
65	  
	  
AH-­‐487/	  
14758041	  
421.45	  
methyl	  2-­‐methyl-­‐5-­‐
oxo-­‐4-­‐(3,4,5-­‐
trimethoxyphenyl)-­‐
4,5-­‐dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
66	  
	  
AK-­‐454/	  
40961396	  
449.5	  
ethyl	  1,2-­‐dimethyl-­‐5-­‐
oxo-­‐4-­‐(3,4,5-­‐
trimethoxyphenyl)-­‐
4,5-­‐dihydro-­‐1H-­‐
indeno(1,2-­‐b)pyridine-­‐
3-­‐carboxylate	  
67	  
	  
AN-­‐655/	  
41064474	  
399.27	  
(2-­‐(5-­‐acetyl-­‐6-­‐methyl-­‐
2-­‐thioxo-­‐1,2,3,4-­‐
tetrahydro-­‐4-­‐
pyrimidinyl)-­‐4-­‐
bromophenoxy)acetic	  
acid	  
68	  
	  
AG-­‐690/	  
12892844	  
477.56	  
2-­‐methoxyethyl	  4-­‐
(2,5-­‐
dimethoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐7-­‐
phenyl-­‐1,4,5,6,7,8-­‐
hexahydro-­‐3-­‐
quinolinecarboxylate	  
N
OO
O
N
O
O
O O
O
O
N
O
O
O O
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O
O
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O
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69	  
	  
AG-­‐205/	  
15156184	  
476.36	  
tetrahydro-­‐2-­‐
furanylmethyl	  4-­‐(5-­‐
bromo-­‐2-­‐
methoxyphenyl)-­‐2-­‐
methyl-­‐5-­‐oxo-­‐
1,4,5,6,7,8-­‐hexahydro-­‐
3-­‐
quinolinecarboxylate	  
Table 5.3: Compound 25 analogues (Compound 43 to 69). Compound 25 is 
also included for reference.  
N
O
O
O
O
Br
O
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Figure 5-6: Antagonist activity of Compound 43-69 at human P2X7. A. 
Inhibition of ATP-induced (300 μM) cell response by 30 μM compound. 0.1 μM 
A74000s and  0.1% DMSO functioned as controls. Responses correspond to the 
gradient over the first 10 cycles after ATP addition (55 s/cycle) and are 
normalized to the DMSO (100% response). Compounds are in decreasing order 
(from left to right) according to their potency at 30 μM. and were considered 
weakly active if able to reduce responses by at least 25% (dashed line) and 
active if their inhibition was 50% or over (dotted). Data represents 2 or more 
independent experiments (n=3-4/each).  B, C. Dose-inhibition curves for 
Compound 47 (B) and Compound 68 (C) (single experiment, n=4) with an 
approximated IC50 of 30 μM and 5.2	  μM. 
  
A 
B C 
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Overall - although the number of analogues tested was relatively low and only few 
of the desired substituents were available or present in the SPECS library - it was 
possible to build a basic Structure-Activity relationship (SAR) to identify some of 
the molecular features important for activity. 24 of the 27 analogues shared 
similar scaffolds, whose common structures are depicted in Figure 5-7. Scaffold IB 
is substantially similar to Scaffold IA differing only for the presence of a furanyl 
linker and it is presented separately for clarity purpose of the description. Most of 
the compounds that showed moderate or good activity shared a common scaffold 
(Figure 5-7 IA-B or IV). The presence of the methoxyl acetate as substituent  (R1) 
on the phenyl ring (Scaffold IA) seems important for compound activity as the 
substitution with a methoxyl (as for Compound 46, Table 5.3) completely 
abolished the activity. According to the IC50 calculated for Compound 25 (8.7 μM) 
and Compound 47 (~30 μM, single-experiment), the presence of the methoxyl 
acetate in para- was tolerated but the ortho-substituent was favoured. Halogen 
substituents in meta- position of the phenyl ring (Scaffold IA and IB) seem to 
improve activity and their absence (Compound 50 compared to Compound 51) may 
contribute to a reduced activity although the presence of a Bromine in Compound 
46 was not sufficient to obtain an IC50 below 30 μM. The introduction of a furan 
linker between the dihydro-1H-indeno(1,2-b)pyridine-3-carboxylate and the 
phenyl moiety (Scaffold IB) was quite well tolerated provided the presence of an 
halogen in ortho- and a nitro-group in para-position (Compound 50). 
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Figure 5-7: Common scaffold shared by 24 of the 27 analogues of Compound 
25. Structure Ia and Ib differs only from the aromatic substituent (phenyl in 
Ia, or furanyl-phenyl in Ib) to the dihydro-1H-indeno(1,2-b)pyridine-3-
carboxylate. R1: (1 or more) halogen, metoxyl, methoxyl acetate, etc. R2: 
methyl, ethyl, propyl, iso-propyl, methoxyethyl, tetrahydro-2-
furanylmethyl, etc. R3: (1 or more) halogen, nitro. R4: H, methyl. R5: H, (2) 
methyl. R6: methyl, phenyl, dimethoxy-phenyl. A: C or N. Q: O or N. 
No inhibition over ~25% was observed at 30 uM for compounds bearing the Scaffold 
II or Scaffold III, which may indicate that the substitution of the carboxylate to a 
cyclic ketone is not favoured. Interestingly, Compound 68 - that presents Scaffold 
IV – blocked YO-PRO uptake with a measured IC50 (preliminary) comparable to 
Compound 25. According to its structure, a metoxyethyl substituent at R2 is well 
tolerated and the presence of a phenyl substituent in R6 may be significant to the 
activity at human P2X7 (in comparison with Compound 43). Compound 68  -
presenting 2 chiral centres - was purchased as racemic mixture with no knowledge 
of the enantiomers ratio and composition. It is possible that not all the 
enantiomers share the same activity and potentially, the isolation and test of each 
one of them alone could lead to the observation of a much higher potency. 
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5.7  Activity of analogues at rat P2X7 
(compound 43-69) 
In parallel to what described in Section 5.5.1 for compound 17 to 42, the 27 
analogues of compound 25 were also tested on cells expressing rat P2X7-GFP at 
the same concentration tested against human P2X7 (30 μM). Overall, compounds 
showed lower potency in reducing cell responses induced by 300 μM ATP, which 
might be partially attributed to a lower ATP EC50 at rat P2X7 receptor, therefore 
300 μM approximately corresponded to EC80 rather than EC70. However, as 
presented in Figure 5-8, the overall trend in compound activity was remarkably 
different and most of the compounds found active against human P2X7 showed 
almost no activity against rat homologue (exception made for Compound 68) 
whereas molecules such as Compound 69 showed selectivity towards rat over 
human receptor. Compared to compounds with which it shares the same scaffold 
(Scaffold IV, Figure 5-7. e.g Compound 68), Compound 69 does not bear a phenyl 
substituent in R6 position and presents at R2 the inclusion of the distal methoxyl 
group of the methyl-carboxylate in a 5-membered ring constituting a more 
hindered functional group with an additional chiral centre and a reduction in the 
number of rotable bonds. According to the biological tests, this is more tolerated 
by the rat P2X7 pocket. Conversely, the >50% inhibition of Compound 47 and 
Compound 50 (scaffold IA and IB, respectively) observed in human but not rat 
suggests that a difference in one or more amino acid residues in the pocket, lining 
nearby the phenyl (scaffold IA) or the furanyl-phenyl (Scaffold IB) may be 
responsible for species-selectivity. For the human receptor, large substituents in 
para- position or the furanyl linker are quite well tolerated whereas for rat 
homologues they are not.  
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Figure 5-8: Screening of Compound 25 analogue on rat P2X7-GFP expressing 
cells. Data represents 2 or more independent experiments (n=3-4/each). 
Cells were pre-incubated 20-30 minutes with 30 μM compound before 
baseline measurement and following addition of 300 μM ATP. 0.1 μM 
A740003 and 0.1% DMSO served as controls. Responses were calculated as 
gradient for the first 10 cycles (55 s/cycle) and are presented as percentage 
response compared to the vehicle (DMSO). The compound order presented is 
the same as in Figure 5-6A to simplify the comparison of compound activity 
at human and rat receptor. As in Figure 5-6A, thresholds for active 
compounds (50% inhibition or over) and weakly active compounds (response 
reduction by 25% or over) are marked by dotted and dashed lines 
respectively. 
Compound 68 was confirmed to be a hit both at human and rat homologues 
although as previously discussed it was tested as racemic mixture and no 
knowledge of which enantiomer(s) is responsible for activity and whether 
different enantioners show different specie-selectivity. In the attempt to suggest 
which enantiomer may interact more favourably with human P2X7 a number of in 
silico simulations were conducted and described in the following section. 
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5.8  In silico studies of Compound 25 and 68 
in human P2X7 models 
A ‘blind docking’ is usually employed to investigate potential binding pockets for a 
ligand when little or no biological data is known regarding its interaction site with 
the target. In this work, the blind docking has been employed as a less biased 
method to investigate potential binding sites for compound 25 and Compound 68, 
which were found active at human P2X7 however their binding site has not been 
confirmed by mutagenesis or extensive competitive binding assay (due to time 
limitations).  
Homology models of human P2X7 were built with MOE aligning the amino acid 
sequence (Uniprot ID: Q99572) to either the panda P2X7 crystal structure in the 
closed state (PDB ID: 5U1L) or to Chain B of the ATP-bound panda P2X7 structure 
(PDB ID: 5U2H.B), then checked for gross geometry errors and finally prepared 
through Protein Preparation Wizard (Schrödinger Suite 2015-1 Protein Preparation 
Wizard; Epik, Schrödinger, LLC, New York, NY, 2018; Impact, Schrödinger, LLC, 
New York, NY, 2018; Prime, Schrödinger, LLC, New York, NY, 2018). Prior to 
protein preparation the two models were superposed in order to have comparable 
coordinates in the virtual molecular space. The structures of Compound 25 and 68 
were prepared using LigPrep (LigPrep, Schrödinger, LLC, New York, NY, 2018) 
following the general procedure described in Section 2.4.7. As Glide does not 
support a specific and automated workflow for blind docking, a total of 122 
receptor grids (32 Å3) were manually created for each ecto-domain of the two 
models (apo state or ATP-bound) allowing overlapping between adjacent grids and 
having pair-wise identical centroids coordinates between the 2 models. Instead 
the Virtual Screening workflow (vsw) was employed as it allows multiple grids as 
input. As in this case the use of the vsw workflow was not to screen large library 
of compounds but rather semi-automate the docking on a large number of grids, 
the docking settings applied were quite conservative. The first HTVS step included 
the generation of 3 docked poses and retention of best 34% poses for the 
subsequent step - ideally obtaining the same number of poses as the number of 
confomers entered (both compounds presenting chiral centres and potential 
tautomers). The Standard Precision (SP) and the Extra precision (XP) steps aimed 
at re-docking and rescoring the poses with more accuracy maintaining all the 
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poses with good scores. 122 docking simulations (using reiteratively increasing 
precision from HTVS to XP) were conducted for each receptor state and results 
were merged, ranked according to the docking score and clustered for further 
comparison. Top ranked poses for Compound 25 could be grouped roughly in 2 sets 
according to the two most populated regions of binding with top ranked 
conformations. Figure 5-9A depicts the approximate location of these two regions 
showing Compound 25 in yellow or gold spheres, ATP (in black wires) and 
JNJ47965567 (in blue wires) were superposed as reference. The two regions 
correspond to the upper vestibule in direct communication with the pocket 
corresponding to the allosteric site identified by Karasawa et al. (Karasawa and 
Kawate 2016) and the ATP-binding site. In the first case, the poses – either 
located entirely within the vestibule or partially in the vestibule and partially 
protruding in the allosteric site - were mainly obtained by docking in the apo-form 
of the receptor while in the second instance the poses were obtained from 
docking simulations in the open state model. Notably, Figure 5-9C shows that 
multiple poses of Compound 25 docked in the ATP-binding pocket occupying the 
cavity roof defined by the head domain (pose in yellow) rather than the site that 
interacts with the ribose and the adenine moieties of the ATP (pose in gold, 
superposed ATP in black for reference). 
Interestingly the top-scored poses for Compound 68 were strongly clustered in one 
single group, which included poses (i) entirely within the upper vestibule of the 
receptor and (ii) poses located in the allosteric binding site (Karasawa and Kawate 
2016) and partially protruding towards the upper vestibule (Figure 5-9B). Figure 
5-9D shows an example of high scored docked pose of Compound 68 fitting the 
allosteric binding site. Strikingly, no high scored poses - obtained neither from the 
apo nor from the open state - were found in the ATP-binding site.  
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Figure 5-9: Blind docking of Compound 25 and Compound 68 in human P2X7 
homology model. Top-ranked poses obtained from docking simulations 
conducted on 122 receptor grids (generated for the open and closed human 
P2X7 models) were clustered into different populations according to the 
region of binding. Representative of these populations are depicted in 
spheres in yellow and gold (A and C, Compound 25) and in orange (B and D, 
Compound 68). Superposed ATP (in black wires) and JNJ47965567 (in blue 
wires) in A-D are employed as reference for the location of the ATP-binding 
site and the allosteric binding pocket, respectively. C. Pocket view (ATP-
binding site) with two docked conformations of Compound 25. D. Docked 
Compound 68 in the allosteric binding site (Karasawa and Kawate 2016) in 
comparison with superposed JNJ47965567 and A740003 (in blue and green  
wires, respectively). 
A 
Compound	  25 
C 
Compound	  68 
D B 
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As the dock of Compound 68 surprisingly showed strong preference for the 
allosteric site identified by Karasawa et al. (Karasawa and Kawate 2016) (Figure 
5-9D), the next hypothesis was that a superposition between the structures of the 
5 allosteric antagonists co-crystallised in the panda P2X7 receptor (A740003, 
A804598, AZ10606120, JNJ47965567 and GW791343) and Compound 68 may reveal 
important shared features. Structures of panda P2X7 bound to each of the 5 
antagonists were superposed, the receptor structures were removed and the 5 
superposed antagonist molecules were analysed with the Pharmaphore Consensus 
tool (MOE) generating pharmacophore descriptors for features present in at least 2 
of the 5 structures. Figure 5-10 presents the pharmacophore features (depicted 
as green and cyan spheres and labelled F1 to F6) superposed to Compounds 68 
structure. Some spheres include functional groups of Compound 68 with the same 
properties of the corresponding pharmacophore features. For example, F3 and F4 
denote areas occupied by hydrophobic groups (Hyd) of at least 3 of the panda 
P2X7 antagonists and overlap with a phenyl and a methyl group of Compound 68, 
respectively. F5 and F6 (partially), both indicating an H-bond acceptor group 
(Acc), is also a common feature shared with Compound 68 (or located within ~2 
Å). According to the pharmacophore model reported in Figure 5-10, the activity 
of Compound 68 might be increased by the introduction of a H-bond acceptor 
substituent to the phenyl group to satisfy Feature F2 (currently not satisfied).  
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Figure 5-10: Ligand-based pharmacophore highlighting common features 
among P2X7 antagonists co-crystallised in panda P2X7 and comparison with 
Compound 68. Pharmacophore features in common among 2 or more 
structures (named F1 to F6). Acc: H-bond acceptor feature. Hyd: 
hydrophobic centre. 
  
F1:Hyd F2:Acc 
F3:Hyd 
F4:Hyd 
F5:Acc 
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Chapter 5 – Results: Identification of a novel P2X7 antagonist 
 201 
5.9  Dock of BzATP in mouse P2X7 mutant 
A127K 
Docking was employed to investigate a molecular justification for the large 
difference in BzATP potency at rat and mouse P2X7 in line with the experimental 
data and the hypothesis proposed by Young et al. (Young et al. 2007). A model of 
mouse P2X7 (Uniprot sequence: Q9Z1M0, modified) bearing the A127K mutation 
was built with MOE (MOE 2014.10; Chemical Computing Group ULC, 1010 
Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018) employing 
the panda P2X7 crystal structure bound to ATP as a template (PDB ID: 5U2H, chain 
B) and following the general procedure described in Section 2.4.2. The model was 
assessed then prepared for docking using protein preparation Wizard (Schrödinger 
Suite 2015-1, Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY; 
Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY), 
while both isomers where are you using MOE Builder tool and parameterized with 
LigPrep (Schrödinger, LLC, New York, NY). Ligands were docked with Glide XP in 
the orthosteric binding site within a receptor grid of 38 Å3 centred on superposed 
ATP from the crystal (in dark grey wires in Figure 5-11). Conformations obtained – 
for both isomers – showed the distal aromatic ring of the benzoylbenzoyl moiety in 
proximity of Lys-127 suggesting that a pi-cation interaction is possible (colored in 
blue in Figure 5-11). The dock of isomer 2’ resulted in a confirmation extremely 
similar to ATP including the position of the gamma phosphate and entertaining 
strikingly similar interaction to ATP (Figure 5-11A). In the case of isomer 3’ the 
particular U-shape was not retained (Figure 5-11B). 
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Figure 5-11: dock of BZ ATP into mouse P2X7 A127K mutant model. 
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5.10  Chapter discussion 
Compounds from 1 to 42 were originally discussed in Chapter 3 as results from 
two virtual screenings on human P2X4 orthosteric binding pocket, which 
unfortunately provided no active hits. These same compounds were tested on 
human P2X7 resulting in the identification of multiple active compounds at 30 μM. 
Compound 25 was selected for further characterization being the most active with 
an IC50 of 8.7 μM in subsequent experiments. Its activity was also observed at rat 
P2X7 although the IC50 resulted 3-fold higher (24.4 μM). ATP-induced membrane 
currents were blocked by co-application of 25 uM Compound 25 in rat P2X7-GFP 
expressing cells strongly confirming the antagonist activity observed in YO-PRO 
assay. From preliminary investigation, Compound 25 appears to inhibit BzATP 
responses in a competitive manner although at high concentrations the maximal 
responses is never reached. More thorough experiments are needed although the 
solubility of the compound (<100 μM) combined with an IC50 in the low micromolar 
range may limit to test of a wide range of concentrations. 27 analogues were 
selected based on similarity with Compound 25 structure helping in the study of 
the structure-activity relationship (SAR). Although relying on the purchase of 
compounds as source of analogues does limit the number and the choice of 
structures to be tested, it was possible to determine some of the features that 
may contribute to the antagonist activity of Compound 25, 47, 50 and 68. Aiming 
at increasing activity and compound drug-likeness, we also suggest the test of very 
similar scaffolds (to Scaffold I and IV, Figure 5-7) with either completely 
saturated bonds or entirely heteroaromatic to reduce the potential reactivity 
ought to the presence of an α,β-unsaturated carbonyl group.  
Compound 25 inactivity at human P2X4 (as shown in Chapter 3) and conversely 
the activity at human p2x7 was particularly interesting in terms of structure-
activity relationship given the fact that Compound 25 scaffolds shows similarity to 
a series of compounds patented by Sunovion Pharmaceuticals Inc. and described 
as P2X4 anatgonist with nanomolar potency (Newcom and Spear 2015). Most 
structures reported by Newcom et al. present substituents at the phenyl in ortho-
position and lack of chiral centre (therefore enhanced planarity) due to the 
hetero-aromatic scaffold.  It may be interesting to test Compound 25 analogues on 
human P2X4 to investigate the presence of features that may confer subtype-
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selectivity. To our knowledge the compounds presented by Newcom et al. have 
never been reported in any scientific journal and their binding site is currently 
unknown although the patent briefly alludes to an allosteric mechanism of 
inhibition (Newcom and Spear 2015).  
A preliminary assessment of mechanism of action conducted on Compound 25 has 
not resolutely ruled out an allosteric mode of action. A thorough mutagenesis 
study would be needed for this purpose, although due to time limitations a blind 
docking has been used as initial tool to probe potential binding sites. An example 
of blind docking use in the purinergic field was presented by Allsopp et al. as 
preliminary and less biased tool to probe where the antagonist was more likely to 
interact (Allsopp et al. 2017). In this work, a blind docking was conducted for 
Compound 25 and Compound 68 on both the apo and the ATP-bound state of the 
human P2X7 model and the top-ranked poses were analysed. Intriguingly, while 
multiple potential binding sites were found for Compound 25, Compound 68 
preference for the allosteric binding site corresponding to the site identified by 
Karasawa et al. in panda P2X7 (Karasawa and Kawate 2016) was striking. A ligand-
based pharmacophore based on the superposition of the 5 antagonists co-
crystalised with panda P2X7 (Karasawa and Kawate 2016) was then superposed to 
the docked pose of Compound 68. This highlighted the presence of common 
features between the published antagonists and Compound 68 and could be a 
useful tool to further suggest scaffold modifications and or functional groups 
substitutions/additions to Compound 68 structure aiming at potency increase.  
Contrary to the compounds tested in this Chapter – where still little is clear 
regarding their binding site, plenty of experiments have been conducted with 
BzATP to determine the binding site. Here we presented the dock of BzATP for 
both isomers observing conformation that supports the hypothesis of the 
formation of a π-cation interaction with Lys-127 (Young et al. 2007). Lys-127 was 
previously found by Young et al. to be responsible for the increased potency of 
BzATP at rat P2X7 (Young et al. 2007). To our knowledge it is not known which 
isomer is more potent. According to our docking, isomer 2’ seems the one capable 
of better retaining ATP conformation and interaction seen in the crystal (Hattori 
and Gouaux 2012) and therefore we suggest it might be the most potent between 
the two isomers. Testing each of the purified isomer is needed to validate this 
hypothesis. In 2015, an in silico study of BzATP binding mode was presented by 
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Dal Ben et al. (Dal Ben et al. 2015). In comparison, our BzATP poses show similar 
location of the adenine and of the triphosphate (in the case of the 2’ isomer) but 
substantial differences in the conformation of the benzoyl-benzoyl moiety. 
According to Dal Ben et al. (Dal Ben et al. 2015), the benzoyl-benzoyl moiety is 
plausibly stabilized by aromatic and hydrophobic residues including Phe-288 (Tyr-
288 in human), Phe-218 and Ile-214. However their dock does not show any 
involvement of Lys-127, which has instead been strongly and elegantly supported 
by experimental data (Young et al. 2007). 	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6 CONCLUSIONS	  AND	  FUTURE	  DIRECTIONS	  
During the course of this work, the activity of potential P2X4 and P2X7 antagonist 
candidates has been evaluated and the pharmacological properties of a known 
P2X4 antagonist and a novel P2X7 antagonist were investigated. The most 
important findings and achievements of this work are summarized below: 
• The differential potency of BX-430 at rat and human P2X4 was confirmed 
and provided the basis for the discovery of the BX-430 allosteric binding 
pocket via mutagenesis and functional assay. 
• A virtual screening was conducted in the identified BX-430 pocket and a 
list of hit candidates has been selected for future biological evaluation. 
• Multiple compounds, initially selected as ‘hits’ from virtual screening in 
human P2X4, were found to be active at human P2X7 with micromolar 
potency, leading to the characterisation of Compound 25, a novel P2X7 
antagonist. 
• in silico docking simulations were used to (i) provide a molecular basis for 
differential BzATP potency at rat and mouse P2X7 from a structural 
analysis of the mouse P2X7 A127K mutant and (ii) provide a plausible 
binding mode for ivermectin at rat P2X4 which was in good agreement with 
published pharmacological data. 
This chapter gives a synopsis of the work conducted and − at the end of each of 
the following sections – proposes directions for future experiments and outlines 
hypotheses that have arisen during the course of this work. 
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6.1  Attempts to identify a novel competitive P2X4 
antagonist 
Efforts to identify a novel P2X4 competitive antagonist were unsuccessful. Indeed, 
none of the 42 compounds identified through two rounds of virtual screening were 
significantly active at 10 µM (Compound 23 was tested at 2 µM, due to low 
solubility). The negative results could be explained by a number of factors varying 
from inaccuracies in the homology model or hit selection, to not having tested a 
sufficient number of compounds. However the ‘hit’ candidates were selected 
independently in two rounds of screening (carried out by Dr Marcella Bassetto and 
the author of this thesis) and two different homology modelling softwares were 
employed to generate the models, reducing the margin for human error. 
Additionally, the group of LinHua Jiang demonstrated the effectiveness of a 
structure-based approach by identifying hit compounds active against human P2X7 
(Caseley, Muench, Fishwick, & Jiang, 2016) and highlighted the direct application 
of in silico tools to the drug discovery of P2X antagonists. The absence of reported 
P2X4 competitive antagonists (compared to antagonists selective for other 
subtypes (Mansoor et al., 2016)) may suggest a structural reason peculiar to this 
subtype for the increased difficulty in finding ligands that ‘fit’ the ATP-binding 
site. 
However, while initially discouraging, this result sparked a series of new 
experiments which led to: (i) the exploration of alternative (allosteric) binding 
sites and (ii) the assay of the same 42 compounds (and more) at human P2X7, 
which led to the identification of a novel P2X7 antagonist with micromolar 
potency. 
6.2  Exploring allosteric binding sites in human 
P2X4 
The design of novel human P2X4 antagonists was approached from a different 
angle. Rather than searching for a competitive ligand, the focus moved to P2X4 
allosteric pockets, which led to a complication: although most P2X4 antagonists 
show an allosteric mechanism of action (Ase, Honson, Zaghdane, Pfeifer, & 
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Séguéla, 2015; Hernandez-Olmos et al., 2012; Matsumura et al., 2016; M. Wang et 
al., 2017), no allosteric pocket had been reported before besides the ivermectin 
binding site. The ivermectin binding site has been identified through mutagenesis 
to lie between transmembrane domains, which (due to the large size of the 
pocket, the lack of resolution in the crystal structures, and the lack of information 
about the lipid conformation in this region of the protein) precludes its use in 
structure-based drug design. Therefore the identification of a second allosteric 
binding site at human P2X4 had become pivotal to the project. The recent report 
of the allosteric pocket in panda P2X7 using direct structural data (Karasawa & 
Kawate, 2016), combined with the pharmacological data for the commercially 
available allosteric P2X4 antagonist BX430 (Ase et al., 2015), suggested the 
potential presence in human P2X4 of a binding pocket corresponding to the one 
identified by Karasawa et al. This hypothesis was confirmed by analyzing the 
difference in pharmacology of the single point mutant I312T at human P2X4, 
which revealed to be responsible for a greater than 40-fold reduction in BX430 
activity with a calculated IC50 >100 μM compared to an IC50 of 2.2	  μM measured for 
human P2X4 wild-type. The ‘mirror’ point mutation (T312I) in rat P2X4 decreased 
the IC50 to 1.4 μM, a value comparable to human P2X4 (over 40-fold more potent 
than at rat P2X4 wild-type), further supporting the hypothesis that BX430 binds in 
proximity of Ile-312. This important discovery led to a new virtual screen and a 
selection of 20 potential ‘hits’, whose biological activity can be assayed in future 
work.  
The latest solved crystal structures reporting the allosteric binding site at P2X3 
raised a similar hypothesis of a third potential pocket present in human P2X4 and 
corresponding to the AF-219 binding site (J. Wang et al., 2018). This was briefly 
explored but has not been included in this thesis and may constitute the basis for 
further future work. More modulator-binding pockets may be potentially present 
(i) at the interface of 2 different subunits or (ii) in a very flexible domain whose 
conformational changes are crucial for channel activation (e.g. head domain). An 
intriguing hypothesis is that NP-1815-XP and molecules with similar scaffolds may 
bind to the apo-state in the head domain near the residues involved in the ATP-
binding site. Circumstantial evidence arises from the publication of the NMR 
structure of rat P2X4 head domain with direct reference to a potential use in 
structure-based drug design (Igawa, Abe, Tsuda, Inoue, & Ueda, 2015) and 
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authored by the same research group that – years later - has developed NP-1815-
XP and numerous analogues mentioned in multiple patents (Inoue, Tsuda, 
Koizumi, & Kohsaka, 2005; Matsumura et al., 2016; Sakuma, Takahashi, Ushioda, 
Imai, & Inoue, 2013). A binding site in a similar location in human P2X1 has been 
very recently reported by Huo et al. (Huo, Fryatt, Farmer, Schmid, & Evans, 
2018), which confirmed the involvement of Lys-249 and identified 3 further 
residues important in PPADS binding through an exhaustive cysteine mutagenesis 
study.  
6.3  Compounds with antagonist activity at human 
P2X7 
Novel P2X7 antagonists were discovered among the molecules selected after two 
rounds of virtual screening as human P2X4 ‘hit’ candidates, which were yet 
inactive at human P2X4 in calcium influx assay. In particular, Compound 25 
blocked YO-PRO uptake (induced by 300 µM ATP) in human P2X7 and rat P2X7 cell 
lines with an IC50 value of 8.7 µM and 24.4 µM, respectively. The antagonist effect 
was confirmed through whole-cell patch clamp on rat P2X7 cells, however, more 
experiments are needed for a correct determination of the mechanism of 
inhibition, which from initial data appears to be competitive at concentrations 
lower than the maximal concentration tested (100 µM). 27 analogues were then 
purchased and tested on human P2X7. Compounds 47, 50 and 68 showed activity 
at <30 µM, helping in the identification of important moieties, which may be 
exploited in future to synthesise analogues with improved drug-likeness and 
activity profile. 
According to the sequence alignment, human P2X4 and human P2X7 share 46% 
identity at the amino acid level. The reason underlining the unexpected finding of 
multiple active compounds with selectivity towards P2X7 − while originally 
selected after screen in the orthosteric site of a different receptor subtype − still 
needs further investigation although one could be the difficulty in modelling 
intrinsically similar − yet sufficiently different − pockets for the two distinctive 
receptor subtypes. A comparison between Compound 25 and a series of potent 
anti-P2X4 patented compounds sharing a similar scaffold reported by Newcom et 
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al. (Newcom & Spear, 2015) may shed more insight regarding the features that 
confer subtype selectivity between P2X4 and P2X7. 
6.4  In silico studies of well-known P2X4 and P2X7 
ligands  
This work also applied in silico simulations in order to correlate structural and 
mutagenesis data regarding two P2X ligands − BzATP and ivermectin − that have 
been intensively studied as important pharmacological tools to investigate the 
properties of P2X subtypes (North, 2002). Although no crystal structure of any P2X 
receptor has been solved in presence of BzATP or IVM, substantial mutagenesis 
analysis has identified the binding site for each of the ligands (Silberberg, Li, & 
Swartz, 2007; Young, Pelegrin, & Surprenant, 2007), the first corresponding to the 
ATP-binding site while the second was identified in transmembrane domain.  
Docking simulations of BzATP (both 2’ and 3’-isomer) sustains the hypothesis of 
the formation of a π-cation interaction between the benzoyl-benzoyl moiety and 
Lys-127 (in mouse P2X7) − a pivotal residue responsible for the increased BzATP 
potency at rat P2X7 (Young et al., 2007). Furthermore, our dock indicates that 
isomer 2’ may retain a conformation and interactions that are more similar to 
those observed for ATP observed in the crystal structure of zfP2X4 (Hattori & 
Gouaux, 2012). 
Docking simulations of ivermectin showed a good correlation with experimental 
data fitting the ligand in close proximity to 7 of the 9 rat P2X4 residues that are 
important in ivermectin response potentiation action (Silberberg et al., 2007). 
Based on our docking, we hypothesize that the mutation of Asn-338 − forming a H-
bonds with the disaccharide moiety of ivermectin − to a residue unable to form H-
bonds or H-arene bond would significantly affect the ivermectin ability to 
potentiate ATP –induced responses at rat P2X4.  
Both in silico studies conducted on BzATP and ivermectin were the focus of 
recently published work (Pasqualetto, Brancale, & Young, 2018). 
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APPENDIX	  1:	  	  
Generation	  of	  P2X4-­‐expressing	  stable	  cell	  lines	  
A1.1	   Human	  P2X4	  stable	  cell	  line	  (G34)	  
 
Figure A-1: A. Immunoblot of 1321N1 stable cell line clones expressing 
human P2X4 receptor detected with anti-P2X4 antibody. Cell transfected 
with 1 µg DNA and grown with G418 from single cell colonies. Cells were 
lysed from confluent 6-wells plates. Samples from each clone were resolved 
by SDS-PAGE and blotted with polyclonal anti-P2X4 (1:2000 dilution) 
followed by HRP-conjugated anti-rabbit IgG. B. Functional assessment of the 
clones after antibiotic selection. 100 µM ATP was used to elicit responses 
measured via calcium influx assay. 
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A1.2	   Rat	  P2X4	  stable	  cell	  line	  (RML2)	  
	  
Figure A-2: Expression and functional characterization of rat P2X4 receptor 
in clones of 1321N1 post-selection. Rat P2X4 construct was gifted by Murriel-
Legnardo (construct named RML2 hereafter). Clones were transfected with 
1µg RML2, selected with G418 and single foci were isolated and expanded. 
28 clones were checked for wild-type rat P2X4 expression with 26 clones. (A) 
Following transfection with 1µg DNA (RML2 plasmid), single-cell colonies 
were grown in presence of G418. Cells aliquot from each colony were lysed 
and samples with 4 µg of total protein were resolved by SDS-PAGE and 
immuno-blotted with polyclonal anti-P2X4 (1:2000 dilution). G34, the stable 
cell line expressing human P2X4, was used as positive control. Expression 
levels were notably variable across the clones. 8 of the clones with high 
expression levels were assessed for functionality (B). Clone 13 (name 
hereafter ‘RML2 13’) showed a pronounced response to 100µM ATP in the 
calcium influx assay and was chosen for further characterization. Not all the 
assessed clones were included in the present figure. 
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A1.3	   Rat	  P2X4	  T312I	  (RTI	  13)	  and	  human	  P2X4	  I312T	  (HIT	  08)	  cell	  lines	  
	  
	  
	  
Figure A-3: Expression and functionality of 1321N1 cell expressing human 
P2X4 Ile-312 to Thr (A, B) and rat P2X4 Thr-312 to Ile (C, D) receptors. The 
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DNA constructs of human P2X4 I312T mutant and rat P2X4 T312I were 
generated by Dr Mark T. Young using Quikchange according to the supplier 
protocol (A), (C) Immunoblot showing expression level of human and rat 
P2X4 mutants in single-cell colonies. Transfection with 1µg DNA was 
followed by selection with G418. Samples from each colony were lysed and 
aliquots containing 4.2 µg of total protein were resolved by SDS-PAGE and 
immunoblotted with polyclonal anti-P2X4 (1:2000 dilution) followed by 
treatment with anti-rabbit HRP conjugated secondary antibody detected by 
chemilunminescence method. Not all the assessed clones were included in 
the present figure. (B), (D) ATP response (at 100 µM concentration) of 
selected clones. Stable cell lines expressing human P2X4 wild-type (G34) and 
rat P2X4 wild-type (RML2 13) were taken as positive reference (data 
normalized to the positive control). Sequencing of the genomic DNA 
extracted from of RTI 13 and HIT 08 confirmed the presence of the correct 
mutation in each corresponding stable cell line. 
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APPENDIX	  2:	  	  
BX-­‐430	  inhibition	  at	  rP2X4	  WT,	  rP2X4	  T312I,	  
hP2X4	  WT	  and	  hP2X4	  I312T	  (independent	  
experiments)	  
A2.1	   BX-­‐430	  inhibitory	  effect	  at	  human	  P2X4	  WT	  
 
	   IC50	  (μM)	   LogIC50	   Hill	  Coeficient	  
Curve-­‐fit	  experiment	  A	   1.7	  	  (n=2-­‐4)	   -­‐5.765	   -­‐2.641	  
Curve-­‐fit	  experiment	  B	   2.4	  	  (n=4-­‐5)	   -­‐5.627	   -­‐3.521	  
Curve-­‐fit	  experiment	  C	   2.1	  (n=3-­‐5)	   -­‐5.681	   -­‐2.498	  
Figure A-4: BX-430 inhibitory effect at human P2X4 WT. An inhibition curve 
was fit for each independent experiment. 
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A2.2	   BX-­‐430	  inhibitory	  effect	  at	  human	  P2X4	  I312T	  
 
	   IC50	  (μM)	   LogIC50	   Hill	  Coeficient	  
Curve-­‐fit	  experiment	  A	   (Interrupted	  curve)	  
(n=4-­‐5)	  
-­‐	   -­‐	  
Curve-­‐fit	  experiment	  B	  
~41	  
(Ambiguous	  fit)	  
(n=4-­‐5)	  
~-­‐4.387	   ~-­‐2060	  
Figure A-5: BX-430 inhibitory effect at human P2X4 I312T. An inhibition 
curve was fit for each independent experiment. 
 
  
A B 
Appendixes 
 248 
A2.3	   BX-­‐430	  inhibitory	  effect	  at	  rat	  P2X4	  WT	  
 
 
	   IC50	  (μM)	   LogIC50	   Hill	  Coeficient	  
Curve-­‐fit	  experiment	  A	   27.1	  (n=4)	   -­‐4.567	   -­‐1.369	  
Curve-­‐fit	  experiment	  B	  
~230	  (n=3-­‐4)	  
(Ambiguous	  fit)	  
~-­‐1.637	   ~-­‐0.8433	  
Curve-­‐fit	  experiment	  C	  
~32	  (n=3-­‐4)	  
(Ambiguous	  fit)	  
-­‐4.492	   -­‐18.54	  
Curve-­‐fit	  experiment	  D	   52.6	  (n=5)	   -­‐4.279	   -­‐5.315	  
 
Figure A-6: BX-430 inhibitory effect at rat P2X4 WT. An inhibition curve was 
fit for each independent experiment. 
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A2.4	   BX-­‐430	  inhibitory	  effect	  at	  rat	  P2X4	  T312I	  
 
 
	   IC50	  (μM)	   LogIC50	   Hill	  Coeficient	  
Curve-­‐fit	  experiment	  A	   0.88	  (n=4)	   -­‐6.056	   -­‐1.004	  
Curve-­‐fit	  experiment	  B	   2.38	  (n=4-­‐5)	   -­‐5.623	   -­‐1.266	  
Curve-­‐fit	  experiment	  C	   1.6	  (n=4-­‐5)	   -­‐5.794	   -­‐1.744	  
 
Figure A-7: BX-430 inhibitory effect at rat P2X4 T312I. An inhibition curve 
was fit for each independent experiment. 
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APPENDIX	  3:	  	  
Generation	  of	  P2X7-­‐expressing	  stable	  cell	  lines	  
A3.1	   Human	  P2X7	  cell	  lines	  (WB50)	  
 
Figure A-8: Expression and functional assessment of human P2X7-expressing 
clones (1321N1 cells). A. Immunoblot of clones stably transfected with 
human P2X7 receptor and detected with anti-P2X7 antibody. Stable cells 
from single cell colonies were obtained through transfected with 1 μg	  DNA 
and selected with G418. Clones were grown to confluence and subsequently 
lysed. Samples were blotted with polyclonal anti-P2X7 (1:2000 dilution) 
followed by HRP-conjugated anti-rabbit IgG. B. ATP-dependent YO-PRO dye 
uptake in for clone WB50, employed in all the experiments described in 
Chapter 5. HNFL2, a mouse P2X7 (M283) stable cell line, was used as positive 
control while 1321N1 WT and HEK293 WT as negative controls. 
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A3.2	   Human	  P2X7	  cell	  lines	  (WB50)	  
	  
Figure A-9: Expression and functional assessment of HEK293 stable cell line 
clones expressing rat P2X7-GFP. A. Immunoblot of HEK-293 stable clones 
expressing rat P2X7-GFP receptor detected with anti-P2X7 antibody. 
Stable cells from single cell colonies were obtained through transfected with 
1 μg	   DNA and selected with G418 in presence of 0.1 μM A740003. Clones 
were grown to confluency in 6-wells plates, then lysed. Samples were 
blotted with polyclonal anti-P2X7 (1:2000 dilution) followed by HRP-
conjugated anti-rabbit IgG. B. ATP-dependent YO-PRO dye uptake in 5 
clones incubated with +/- 0.1 μM A740003 and and stimulated with 300 μM 
ATP. Clone A3E10 was selected and use for all the subsequent experiments 
reported in Chapter 5. 
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APPENDIX	  4:	  	  
Publications	  
 
1. Pasqualetto, G. et al. 2018. The molecular determinants of small-molecule 
ligand binding at P2X receptors. Frontiers in Pharmacology 9: 58.	  
 
